ATF6 inhibitors and uses thereof
Through the combination of ATF6 inhibitors and other drugs, the endoplasmic reticulum stress response pathway is regulated, which solves the problem of resistance of multiple myeloma to existing treatment methods, improves the therapeutic effect, and provides a new therapeutic approach for diseases involving ATF6.
Patent Information
- Application Number
- CN202411011046.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-04-06
- Filing Date
- 2019-04-06
- Publication Date
- 2024-12-03
AI Technical Summary
Multiple myeloma (MM) is resistant to existing therapeutic methods such as bortezomib, and ATF6 signaling of the endoplasmic reticulum stress response pathway is not effectively inhibited in MM cells, resulting in increased treatment difficulty.
Develop an ATF6 inhibitor that inhibits the activity of transcriptional activator 6 (ATF6) through specific compounds, combined with other drugs such as IRE1/XBP1 pathway inhibitors, modulates unfolded protein responses and stress responses to enhance therapeutic effects on MM cells .
Effectively improve the sensitivity of multiple myeloma cells to bortezomib, extend patient survival, and provide new therapeutic strategies for other diseases involving ATF6.
Smart Images

Figure BDA0004964358700000031 
Figure BDA0004964358700000032 
Figure BDA0004964358700000091
Abstract
Description
[0001] This application is a divisional application of the invention patent application with the application date of April 6, 2019, application number 201980037115.9 (international application number PCT / US2019 / 026198), and name “ATF6 inhibitors and their uses”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 654,263, filed April 6, 2018, the disclosure of which is hereby incorporated by reference in its entirety. Technical Field
[0004] The present disclosure generally relates to therapeutic agents useful as inhibitors of activator of transcription 6 (ATF6). Background Art
[0005] Despite high-dose chemotherapy, autologous stem cell transplantation, and novel agents, multiple myeloma (MM) remains a largely incurable malignancy. Proteasome inhibitors (PIs), such as bortezomib, have improved the response rate and survival of MM patients. The overall patient response rate for newly diagnosed MM to bortezomib and dexamethasone is approximately 67%. In relapsed, refractory MM, the response rate is reduced to approximately 40-60%. Therefore, there are a considerable number of MM patients who are resistant to bortezomib. MM cells themselves are sensitive to PIs because their large immunoglobulin production requires constitutive expression of physiological unfolded protein response (UPR) genes. This appears to lower the threshold for inducing pro-apoptosis / terminal UPR in response to PI-induced endoplasmic reticulum (ER) stress. One of the hallmarks of UPR induction is increased transcription and translation of ER chaperone proteins. These genes are induced by the UPR transcription factors XBP1 and ATF6. Although XBP1 splicing and its resulting activation have been shown to be inhibited in MM cells treated with PIs, our results show that the high constitutive expression of two XBP1 target gene products, GRP78 and GRP94, is not reduced by PI treatment, and the observation that the XBP1-dependent UPR target gene ERdj4 is normally induced by PIs suggests that the UPR remains functional in MM cells treated with PIs. Because both XBP1 and ATF6 can bind to ER stress response elements in the promoters of UPR target genes, it is proposed that ATF6 can compensate for the reduction in XBP1 activity in MM cells treated with PIs. Consistent with this, it has been shown that XBP1 - / -Induction of GRP78 and GRP94 in B cells was only slightly impaired, and GRP94 expression required either ATF6 or XBP1, but not both. Interestingly, previous studies have shown that XBP1 predicts sensitivity to bortezomib and that its expression correlates proportionally with bortezomib sensitivity. Recently, Harnoss JM et al. demonstrated that genetic and pharmacological disruption of the IRE1a-XBP1s pathway plays a key role in MM growth in vitro and in vivo. Indeed, inhibition of IRE1α kinase activity using small molecules has been shown to be a potentially effective and safe clinical therapy for MM.
[0006] In addition to amount, PI sensitivity also seems to be related to the effectiveness of immunoglobulin folding in MM cells. The highly constitutive expression of ER resident chaperones GRP78 and GRP94 in MM cell lines is consistent with reports that professional secretory cell function requires physiological UPR gene expression. Elevated levels of ER chaperones are characteristics of plasma cells, and their expression is crucial for appropriate antibody assembly and secretion. GRP78 has been shown to stably bind to immunoglobulin heavy chains that have not yet associated with immunoglobulin light chains and help immunoglobulin assembly. In addition, GRP78 and GRP94 are important for immunoglobulin light chain folding and targeting unassembled subunits for degradation. The fact that the expression of GRP78 and GRP94 is only slightly increased in MM cells treated with PI and classical ER stress agents shows that it has expressed cell protective UPR proteins close to the maximum level to serve as secretory cells. Therefore, these cells can have a lower threshold value (compared to non-secretory cells) of inducing the terminal UPR after any additional stress on ER. Therefore, more resistant myeloma clones, as well as other non-secretory malignancies, could be sensitized to bortezomib by combining bortezomib with agents that interfere with the UPR, such as modulators of the ATF6 signaling pathway.
[0007] The accumulation of misfolded proteins in the ER of mammalian cells causes the folding machinery to become overwhelmed and triggers a stress response. The cell attempts to reduce the ER protein load by sending signals from the ER to the nucleus, activating a vast gene expression program that increases the protein folding capacity in the ER. However, if this system breaks down and homeostasis can no longer be established, the cell will die by engaging in apoptosis. The UPR is an evolutionarily conserved signaling pathway that maintains protein homeostasis in response to ER stress.
[0008] Three intertwined signaling pathways comprise the UPR: (1) PERK (protein kinase RNA-like ER kinase); (2) IRE1 (inositol-requiring enzyme 1α); and (3) ATF6 (transcription activator 6) (McKimpson, WM et al., Circ Res, 2017, 120(5):759-761). Activation of the ATF6 pathway leads to upregulation of genes such as BIP (Grp78), CHOP, or XBP-1, which enhance the ability of the endoplasmic reticulum to fold proteins or mediate quality control. ATF6 works in conjunction with IRE1 because one of ATF6's target genes is a key substrate of XBP1-IRE1 (Yoshida, H. et al., Cell, 2001, 107(7):881-891). PERK plays several other roles, including pausing the production of new proteins to temporarily reduce the protein folding burden.
[0009] ATF6 is a type II transmembrane protein located in the ER that acts as an ER stress sensor and transcription factor (Adachi, Y. et al., Cell Struct Funct, 2008, 33(1):75-89; Wu, J. et al., Dev Cell, 2007, 13(3):351-64). When demand exceeds the folding capacity of the ER, ATF6 is transported from the ER to the Golgi apparatus, where two proteases present in the two Golgi apparatuses, site-1 and site-2 proteases (S1P and S2P), sequentially cleave its N-terminal domain (ATF6N) from the Golgi membrane and are introduced into the nucleus, where it activates the transcription of its target genes (Ye, J. et al., Mol Cell, 2000, 6(6):1355-64). This activation involves the binding of ATF6 to a common sequence called the ER stress response element (ERSE). The consensus sequence of ERSE is CCAATCGGCGGCGGCCACG (SEQ ID NO. 1).
[0010] ATF6-activated transcriptional targets play a role in the pathogenesis and development of a variety of diseases, including viral infection, cancer, neurodegeneration, Alzheimer's disease, cerebral ischemia, hereditary cerebellar atrophy and ataxia, type 2 diabetes and diabetic nephropathy, as well as cardiovascular diseases such as myocardial atrophy, heart failure, ischemic heart disease and atherosclerosis (Chu, WS et al., Diabetes, 2007, 56(3):856-62; Vekich, JA et al., J Mol Cell Cardiol, 2012, 53(2):259-67; Liu, CL et al., Int J Mol Med, 2016, 37(2):407-14). Therefore, inhibition of ATF6-mediated transcription may provide a therapeutic strategy for these and other diseases involving ATF6 regulation. Summary of the Invention
[0011] In one aspect, there is provided a compound of formula (A):
[0012]
[0013] or a pharmaceutically acceptable salt thereof, wherein A, R 1 ,n,L,R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 , G1 and G2 are as described in detail herein.
[0014] In some embodiments, a compound of formula (I) is provided:
[0015]
[0016] or a pharmaceutically acceptable salt thereof, wherein A, R 1 ,n,L,R 2 、R 3 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as described in detail herein.
[0017] In some embodiments, the compound of Formula (A), (I), or a pharmaceutically acceptable salt thereof has Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), as described in detail herein.
[0018] In another aspect, a method of treating a disease or condition mediated by activator of transcription 6 (ATF6) in a subject in need thereof is provided, wherein the method comprises administering to the subject an effective amount of a compound of formula (A) or (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound. In another aspect of the method, the compound of formula (A) or (I) or a salt thereof is a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or a pharmaceutically acceptable salt of any of the foregoing compounds, or a pharmaceutical composition comprising the compound. In some embodiments, the disease or condition mediated by activator of transcription 6 (ATF6) is a viral infection, cancer, a neurodegenerative disease, or a vascular disease. In certain embodiments, the disease or condition is a viral infection, hereditary cerebellar atrophy and ataxia, Alzheimer's disease, type 2 diabetes, diabetic nephropathy, myocardial atrophy, heart failure, atherosclerosis, ischemia, ischemic heart disease, or cerebral ischemia. In some embodiments, the disease or disorder characterized by activator of transcription 6 (ATF6) is cancer. In some embodiments, ATF6 is ATF6α.
[0019] In another aspect, a method of treating a disease or condition characterized by activation of transcription factor 6 (ATF6) in an individual in need thereof is provided, wherein the method comprises administering to the individual an effective amount of a compound of Formula (A) or (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound. In another aspect of the method, the compound of Formula (A) or (I) or a salt thereof is a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or a pharmaceutically acceptable salt of any of the foregoing compounds, or a pharmaceutical composition comprising the compound. In some embodiments, the disease or condition characterized by activation of ATF6 is a viral infection, cancer, a neurodegenerative disease, or a vascular disease. In certain embodiments, the disease or condition is a viral infection, hereditary cerebellar atrophy and ataxia, Alzheimer's disease, type 2 diabetes, diabetic nephropathy, myocardial atrophy, heart failure, atherosclerosis, ischemia, ischemic heart disease, or cerebral ischemia. In some embodiments, the disease or disorder characterized by activator of transcription 6 (ATF6) is cancer. In some embodiments, ATF6 is ATF6α.
[0020] In another aspect, a method of treating cancer in an individual in need thereof is provided, the method comprising administering to the individual a therapeutically effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound. In another aspect of the method, the compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof, is a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or a pharmaceutically acceptable salt of any of the foregoing compounds, or a pharmaceutical composition comprising the compound.
[0021] In some embodiments, the cancer is breast cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer, kidney cancer, lung cancer, melanoma, fibrosarcoma, osteosarcoma, connective tissue sarcoma, renal cell carcinoma, giant cell carcinoma, squamous cell carcinoma, leukemia, skin cancer, soft tissue cancer, liver cancer, gastrointestinal cancer, or adenocarcinoma. In some embodiments, the one or more cancer cells in the individual are dormant cancer cells.
[0022] In some embodiments, the individual has undergone prior treatment. In some embodiments, the cancer is resistant to or refractory to prior treatment. In some embodiments, the cancer is resistant to treatment with a ubiquitin-proteasome pathway inhibitor, a taxane, a Cox-2 inhibitor, a platinum-based anti-tumor drug, an anthracycline, a pyrimidine analog, a topoisomerase inhibitor, an mTOR inhibitor, an immune checkpoint inhibitor, or an agent used in immuno-oncology.
[0023] In some embodiments, the method further comprises administering radiation. In some embodiments, the method further comprises administering a second anticancer agent. In some embodiments, the second anticancer agent targets an immune checkpoint protein.
[0024] In another aspect, a method of treating an angiogenesis-related disease or condition in a subject in need thereof is provided, wherein the method comprises administering to the subject an effective amount of a compound of Formula (A), (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound. In another aspect of the method, the compound of Formula (I) or a salt thereof is a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or a pharmaceutically acceptable salt of any of the foregoing compounds, or a pharmaceutical composition comprising the compound. In some embodiments, the method further comprises administering a second anti-angiogenic agent.
[0025] In some embodiments of the methods disclosed herein, the methods further comprise administering a second agent that modulates the unfolded protein response or the integrated stress response. In some embodiments, the second agent inhibits the IRE1 / XBP1 pathway.
[0026] In another aspect, a method of inhibiting ATF6 in a subject is provided, the method comprising administering to the subject a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound. In another aspect of the method, the compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof, is a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or a pharmaceutically acceptable salt of any of the foregoing compounds, or a pharmaceutical composition comprising the same.
[0027] In another aspect, a method of inhibiting ATF6 in a cell is provided, the method comprising delivering a compound of formula (A) or (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound, to the cell. In another aspect of the method, the compound of formula (A) or (I) or a salt thereof is a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or a pharmaceutically acceptable salt of any of the foregoing compounds, or a pharmaceutical composition comprising the compound.
[0028] Also provided are pharmaceutical compositions comprising: (A) a compound as described in detail herein, such as a compound of Formula (A), (I), or a pharmaceutically acceptable salt thereof, or a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or a pharmaceutically acceptable salt thereof; and (B) a pharmaceutically acceptable carrier or excipient. Also provided are kits comprising a compound as described in detail herein, or a salt thereof, and optionally instructions for use. Also provided are compounds as described in detail herein, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treating a disease or condition characterized by ATF6 activation. In some embodiments, the disease or condition is cancer, a neurodegenerative disease, or a vascular disease. In certain embodiments, the disease or condition is a viral infection, hereditary cerebellar atrophy and ataxia, Alzheimer's disease, type 2 diabetes, diabetic nephropathy, myocardial atrophy, heart failure, atherosclerosis, ischemia, ischemic heart disease, or cerebral ischemia. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1We delineate the regulation of ATF6-dependent molecular mechanisms of the endoplasmic reticulum (ER) proteostasis network in multiple myeloma (MM) cell lines.
[0030] Figure 2A 、 2B and 2C show how modulation of the ER proteostasis network using three exemplary compounds affects cell viability in MM cell lines. DETAILED DESCRIPTION
[0031] definition
[0032] As used herein, use of the terms "a", "an", "an", etc. refers to one or more unless specifically indicated otherwise.
[0033] Reference herein to "about" a value or parameter includes (and describes) embodiments for that value or parameter itself. For example, description referring to "about X" includes description of "X."
[0034] As used herein, unless otherwise indicated, "alkyl" refers to and includes groups having the specified number of carbon atoms (i.e., C1-C 10 A saturated straight chain (i.e., unbranched) or branched monovalent hydrocarbon chain or a combination thereof having from 1 to 20 carbon atoms ("C1-C 20 alkyl”), having 1 to 10 carbon atoms (“C1-C 10 alkyl”), having 6 to 10 carbon atoms (“C6-C 10 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.
[0035] "Alkoxy" refers to the group RO-, where R is alkyl; and includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.
[0036] As used herein, "aryl" or "Ar" refers to an unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple fused rings (e.g., naphthyl or anthracenyl), which may or may not be aromatic. Particular aryl groups are those having 6 to 14 ring carbon atoms ("C6-C 14An aryl group having more than one ring at least one of which is non-aromatic may be attached to the parent structure at an aromatic ring position or at a non-aromatic ring position. In one variation, an aryl group having more than one ring at least one of which is non-aromatic is attached to the parent structure at an aromatic ring position.
[0037] As used herein, unless otherwise indicated, "cycloalkyl" refers to and includes alkyl groups having the specified number of carbon atoms (i.e., C3-C 10 "Cycloalkyl" refers to a saturated cyclic monovalent hydrocarbon structure having three to ten carbon atoms. Cycloalkyl can be composed of one ring, such as cyclohexyl, or composed of multiple rings, such as adamantyl. Cycloalkyl comprising more than one ring can be a fused cycloalkyl, a spirocycloalkyl or a bridged cycloalkyl, or a combination thereof. Specific cycloalkyl is a cycloalkyl with 3 to 12 ring carbon atoms. Preferred cycloalkyls are cyclohydrocarbons with 3 to 8 ring carbon atoms ("C3-C8 cycloalkyl"), with 3 to 6 carbon atoms ("C3-C6 cycloalkyl") or with 3 to 4 ring carbon atoms ("C3-C4 cycloalkyl"). Examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, etc.
[0038] "Halo" or "halogen" refers to an element of the 17th group having an atomic number of 9 to 85. Preferred halogen groups include groups of fluorine, chlorine, bromine and iodine. If a residue is substituted with more than one halogen, it can be referred to by using a prefix corresponding to the number of attached halogen moieties, for example, dihaloaryl, dihaloalkyl, trihaloaryl, etc. refer to aryl and alkyl substituted with two ("di") or three ("tri") halogen groups, which may be identical halogens but not necessarily identical halogens; thus, 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. An alkyl group in which each hydrogen is replaced by a halo is referred to as a "perhaloalkyl". A preferred perhaloalkyl group is trifluoromethyl (-CF3). Similarly, a "perhaloalkoxy" group refers to an alkoxy group in which a halogen replaces each H of the alkyl portion constituting the alkoxy group in a hydrocarbon. An example of a perhaloalkoxy group is trifluoromethoxy (-OCF3).
[0039] The term "haloalkyl" refers to an alkyl group having one or more halo substituents or one, two or three halo substituents. Examples of haloalkyl groups include -CF3, -(CH2)F, -CHF2, CH2Br, -CH2CF3 and -CH2CH2F.
[0040] As used herein, "heteroaryl" refers to an unsaturated aromatic cyclic group having 1 to 14 ring carbon atoms and at least one ring heteroatom, the ring heteroatoms including but not limited to heteroatoms such as nitrogen, oxygen and sulfur. A heteroaryl group can have a single ring (e.g., pyridyl, furyl) or multiple fused rings (e.g., indolizinyl, benzothienyl), which may or may not be aromatic rings. A specific heteroaryl group is a 5- to 14-membered ring having 1 to 12 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; a 5- to 10-membered ring having 1 to 8 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; or a 5-, 6- or 7-membered ring having 1 to 5 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, specific heteroaryl is a monocyclic aromatic 5, 6 or 7-membered ring with 1 to 6 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur. In another variation, specific heteroaryl is a polycyclic aromatic ring with 1 to 12 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from nitrogen, oxygen and sulphur. Heteroaryl having more than one ring and at least one ring being a non-aromatic ring can be connected to the parent structure at the aromatic ring position or at the non-aromatic ring position. In one variation, heteroaryl having more than one ring and at least one ring being a non-aromatic ring is connected to the parent structure at the aromatic ring position. Heteroaryl can be connected to the parent structure at the ring carbon atoms or at the ring heteroatoms.
[0041] As used herein, "heterocycle," "heterocyclic," or "heterocyclyl" refers to a saturated or unsaturated non-aromatic cyclic group having a single ring or multiple fused rings and having 1 to 14 ring carbon atoms and 1 to 6 ring heteroatoms such as nitrogen, sulfur, or oxygen. Heterocycles containing more than one ring may be fused, bridged, or spirocyclic, or any combination thereof, but do not include heteroaryl groups. Heterocyclyl groups may be optionally substituted independently with one or more substituents described herein. Particular heterocyclyl groups are 3- to 14-membered rings having 1 to 13 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3- to 12-membered rings having 1 to 11 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3- to 10-membered rings having 1 to 9 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3- to 8-membered rings having 1 to 7 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 3- to 6-membered rings having 1 to 5 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In one variation, heterocyclyl includes monocyclic 3-, 4-, 5-, 6-, or 7-membered rings having 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 ring carbon atoms and 1 to 2, 1 to 3, or 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In another variation, heterocyclyl includes polycyclic non-aromatic rings having 1 to 12 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0042] "Pharmaceutically acceptable carrier" refers to a component of a pharmaceutical formulation other than the active ingredient that is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0043] As used herein, "treatment" or "treating" is an approach for obtaining beneficial or desired results, including clinical results. For example, beneficial or desired results include, but are not limited to, one or more of the following: reducing symptoms caused by the disease, improving the quality of life of a person suffering from the disease, reducing the dosage of other drugs required to treat the disease, delaying the progression of the disease, and / or prolonging the survival of an individual. When referring to cancer or other undesirable cell proliferation, beneficial or desired results include: shrinking the tumor (reducing the size of the tumor); reducing the growth rate of the tumor (so as to inhibit tumor growth); reducing the number of cancer cells; inhibiting, delaying or slowing down to some extent and preferably stopping the infiltration of cancer cells into surrounding organs; inhibiting (slowing down to some extent and preferably stopping) tumor metastasis; inhibiting tumor growth; preventing or delaying the occurrence and / or recurrence of tumors; and / or alleviating to some extent one or more symptoms associated with cancer. In some embodiments, beneficial or desired results include preventing or delaying the recurrence of, for example, undesirable cell proliferation.
[0044] As used herein, an "effective dose" or "effective amount" of a compound or salt thereof or pharmaceutical composition is an amount sufficient to achieve a beneficial or desired result. For preventive uses, beneficial or desired results include results such as eliminating or reducing the risk of disease; reducing the severity of the disease; or delaying the onset of the disease, including the biochemical, histological and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes presented during the development of the disease. For therapeutic uses, beneficial or desired results include improving, alleviating, alleviating, delaying or reducing one or more symptoms caused by the disease; improving the quality of life of people with the disease; reducing the dose of other drugs required to treat the disease; for example, enhancing the effect of another drug via targeting; delaying the progression of the disease; and / or prolonging survival. When referring to cancer or other undesirable cell proliferation, an effective amount includes an amount sufficient to shrink the tumor and / or reduce the tumor growth rate (so as to inhibit tumor growth), or prevent or delay other undesirable cell proliferation. In some embodiments, the effective amount is an amount sufficient to delay development. In some embodiments, the effective amount is an amount sufficient to prevent or delay recurrence. An effective amount can be administered in one or more administrations. In the case of cancer, an effective amount of a drug or composition can: (i) reduce the number of cancer cells; (ii) reduce the size of the tumor; (iii) inhibit, delay, slow down to some extent, and preferably stop the infiltration of cancer cells into surrounding organs; (iv) inhibit (i.e., slow down to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay tumor recurrence; and / or (vii) alleviate one or more symptoms associated with cancer to some extent. An effective dose can be administered in one or more administrations. For the purposes of this disclosure, an effective dose of a compound or salt thereof or a pharmaceutical composition is an amount sufficient to directly or indirectly achieve a preventive or therapeutic treatment. It is contemplated and understood that an effective dose of a compound or salt thereof or a pharmaceutical composition may or may not be achieved in combination with another drug, compound, or pharmaceutical composition. Thus, an "effective dose" can be considered in the context of administering one or more therapeutic agents, and a single agent can be considered to be given in an effective amount if, in combination with one or more other agents, the desired result can be achieved or has been achieved.
[0045] As used herein, the term "subject" refers to a mammal, including humans. Subjects include, but are not limited to, humans, bovines, horses, felines, canines, rodents, or primates. In some embodiments, the subject is a human. The subject (e.g., a human) may have advanced disease or a less advanced disease, such as a low tumor burden. In some embodiments, the subject is in the early stages of a proliferative disease (e.g., cancer). In some embodiments, the subject is in the late stages of a proliferative disease (e.g., late-stage cancer).
[0046] It should be understood that the aspects and variations described herein also include "consisting of" and / or "consisting essentially of" the aspects and variations.
[0047] All references throughout, such as publications, patents, patent applications, and published patent applications, are incorporated herein by reference in their entirety.
[0048] Compound
[0049] In one aspect, there is provided a compound of formula (A):
[0050]
[0051] or a pharmaceutically acceptable salt thereof, wherein:
[0052] One of G1 and G2 is N and one of G1 and G2 is CR d ,
[0053] where R d is H or C1-C6 alkyl;
[0054] R 1 is H, C1-C6 alkyl, C3-C8 cycloalkyl or C1-C6 haloalkyl;
[0055] R 8 is H or C1-C6 alkyl,
[0056] n is 0 or 1;
[0057] L is -CH2- or absent;
[0058] R 2 、R 3 、R 4 、R 5 and R 6 Each is independently H, halo, CN, C1-C6 alkyl or C1-C6 haloalkyl;
[0059] or R 2 、R 4 、R 5 and R 6 are each independently H, halo, CN, C1-C6 alkyl or C1-C6 haloalkyl and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring, wherein the 5- or 6-membered ring is unsubstituted or substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl;
[0060] The conditions are:
[0061] R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring; or
[0062] R 2 、R 3 、R 4 、R 5 and R 6 At least two of them are not H; or
[0063] R 2 、R 3 、R 4 、R 5 and R 6 One of them is cyano;
[0064] A is
[0065] Among them --- instructions connected in E or Z configuration;
[0066] R a and R b Each is independently H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl, wherein R a and R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from OH, halo, C1-C6 alkyl, and C1-C6 alkoxy;
[0067] R c is C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl, wherein R c Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl group is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl;
[0068] R e is H, C1-C6 alkyl or C1-C6 haloalkyl;
[0069] The condition is that when A is And R a When it is H, methyl, ethyl, n-Pr, i-Pr, i-Bu, 2-thiofuryl, 2-furyl, unsubstituted phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3,4-dimethoxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-fluorophenyl or 2,4-dichlorophenyl, at least one of (i.) to (ix.) applies:
[0070] (i.) G2 is N;
[0071] (ii.) n is 1, L does not exist, and R 1 is a C1-C6 alkyl group;
[0072] (iii.) n is 0, L does not exist, and R 2 、R 3 、R 4 、R 5 and R 6 At least one of them is halo, CN or C1-C6 haloalkyl;
[0073] (iv.) n is 1, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring;
[0074] (v.)R 2 、R 3 、R 4 、R 5 and R 6 One of them is CN; and
[0075] (vi.)R 4 and R 5 Each is independently Cl, Br, I, CN, C1-C6 alkyl or C1-C6 haloalkyl;
[0076] (vii.) R d and R 7 One of them is a C1-C6 alkyl group;
[0077] (viii.)R 2 and R 3 Each is Cl;
[0078] (ix.)R 2 、R 3 、R 4 、R 5 and R 6 At least one of them is F, Br, I, CN or C1-C6 haloalkyl and R a is H or 2-thiofuryl;
[0079] The condition is that when A is When n is 1, R 1 Not for H;
[0080] The condition is that when A is When n is 0 and L does not exist, R a Not for H;
[0081] The condition is that when A is And R e When it is methyl, R ais not an unsubstituted phenyl group;
[0082] The condition is that when A is When n is 1 and L does not exist, R 1 Not for H;
[0083] and
[0084] R 7 is H or C1-C6 alkyl,
[0085] The condition is that when R d is a C1-C6 alkyl group, R 7 When H, and when R 7 is a C1-C6 alkyl group, R d For H.
[0086] In one variation, there is provided a compound of formula (A) or a salt thereof, wherein when R 1 When R is not H (i.e., C1-C6 alkyl, C3-C8 cycloalkyl or C1-C6 haloalkyl) 1 In another variation, there is provided a compound of formula (A) or a salt thereof, wherein when R 1 When R is not H (i.e., C1-C6 alkyl, C3-C8 cycloalkyl or C1-C6 haloalkyl) 1 Also contemplated are mixtures of compounds of formula (A), including racemic or non-racemic mixtures of a given compound, as well as mixtures of two or more compounds having different chemical formulae.
[0087] In the description herein, it should be understood that each description, variation, embodiment or aspect of one part can be combined with each description, variation, embodiment or aspect of other parts, just as if each description combination was specifically and individually listed. 1 Each description, variation, embodiment, or aspect provided may be combined with each description, variation, embodiment, or aspect of A, just as if each description combination were specifically and individually listed. 1 Each description of can be combined with each description for A and G1 and G2 as if each description were specifically and individually listed.
[0088] In some embodiments, compounds of formula (A) are provided, wherein A is
[0089] In some embodiments, compounds of formula (A) are provided, wherein A is
[0090] In some embodiments, compounds of formula (I) are provided:
[0091]
[0092] or a pharmaceutically acceptable salt thereof, wherein:
[0093] One of G1 and G2 is N and one of G1 and G2 is CR d ,
[0094] where R d is H or C1-C6 alkyl;
[0095] R 1 is H, C1-C6 alkyl or C3-C8 cycloalkyl;
[0096] n is 0 or 1;
[0097] L is -CH2- or absent;
[0098] R 2 、R 3 、R 4 、R 5 and R 6 Each is independently H, halo, CN, C1-C6 alkyl or C1-C6 haloalkyl;
[0099] or R 2 、R 4 、R 5 and R 6 are each independently H, halo, CN, C1-C6 alkyl or C1-C6 haloalkyl and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring, wherein the 5- or 6-membered ring is unsubstituted or substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl;
[0100] The conditions are:
[0101] R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring; or
[0102] R 2 、R 3 、R 4 、R 5 and R 6 At least two of them are not H; or
[0103] R 2 、R 3 、R 4 、R5 and R 6 One of them is cyano;
[0104] A is
[0105] Among them --- instructions connected in E or Z configuration;
[0106] R a and R b Each is independently H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl, wherein R a and R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl group is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl;
[0107] R c is C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl, wherein R c Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl group is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl;
[0108] The condition is that when A is And R a When it is H, methyl, ethyl, n-Pr, i-Pr, i-Bu, 2-thiofuryl, 2-furyl, unsubstituted phenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-fluorophenyl or 2,4-dichlorophenyl, at least one of (i.) to (ix.) applies:
[0109] (i.) G2 is N;
[0110] (ii.) n is 1, L does not exist, and R 1 is a C1-C6 alkyl group;
[0111] (iii.) n is 0, L does not exist, and R 2 、R 3 、R 4 、R 5 and R 6 At least one of them is halo, CN or C1-C6 haloalkyl;
[0112] (iv.) n is 1, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring;
[0113] (v.)R 2 、R 3 、R 4 、R 5 and R 6 One of them is CN; and
[0114] (vi.)R 4 and R 5 Each is independently Cl, Br, I, CN, C1-C6 alkyl or C1-C6 haloalkyl;
[0115] (vii.) R d or R 7 One of them is a C1-C6 alkyl group;
[0116] (viii.)R 2 and R 3 Each is Cl;
[0117] (ix.)R 2 、R 3 、R 4 、R 5 and R 6 At least one of them is F, Br, I, CN or C1-C6 haloalkyl and R a is H or 2-thiofuryl; and
[0118] R 7 is H or C1-C6 alkyl,
[0119] The condition is that when R d is a C1-C6 alkyl group, R 7 When H, and when R 7 When it is C1-C6 alkyl, R d For H.
[0120] In some embodiments of formula (I), when A is And R a When it is 2-methoxyphenyl, 3-methoxyphenyl or 3,4-dimethoxyphenyl, at least one of (i.) to (ix.) applies.
[0121] In some embodiments, compounds of formula (Ia) are provided:
[0122]
[0123] or a pharmaceutically acceptable salt thereof, wherein: A, R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R7 , G1 and G2 are as defined for formula (I).
[0124] In some embodiments, compounds of formula (Ib) are provided:
[0125]
[0126] or a pharmaceutically acceptable salt thereof, wherein: A, R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as defined for formula (I).
[0127] In some embodiments, compounds of formula (Ic) are provided:
[0128]
[0129] or a pharmaceutically acceptable salt thereof, wherein: A, R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as defined for formula (I).
[0130] In some embodiments, compounds of formula (Id) are provided:
[0131]
[0132] or a pharmaceutically acceptable salt thereof, wherein: A, R d ,n,L,R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and R 7 As defined for formula (I).
[0133] In one embodiment of Formula (Id), L is absent. In one embodiment of Formula (Id), L is absent and n is 0. In one embodiment of Formula (Id), L is absent, n is 1 and R 1 is H, C1-C6 alkyl or C3-C8 cycloalkyl. In one embodiment of formula (Id), L is absent, n is 1 and R 1 is C1-C6 alkyl or C3-C8 cycloalkyl. In one such embodiment, R 1In another such embodiment, the carbon of R 1 The carbon is in R-configuration.
[0134] In some embodiments, compounds of formula (Ie) are provided:
[0135]
[0136] or a pharmaceutically acceptable salt thereof, wherein: A, R d ,n,L,R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and R 7 As defined for formula (I). In one embodiment of formula (Ie), L is absent.
[0137] In one embodiment of Formula (Ie), L is absent and n is 0. In one embodiment of Formula (Ie), L is absent, n is 1 and R 1 is H, C1-C6 alkyl or C3-C8 cycloalkyl. In one embodiment of formula (Ie), L is absent, n is 1 and R 1 is C1-C6 alkyl or C3-C8 cycloalkyl. In one such embodiment, R 1 In another such embodiment, the carbon of R 1 The carbon is in R-configuration.
[0138] In some embodiments, compounds of formula (If) are provided:
[0139]
[0140] or a pharmaceutically acceptable salt thereof, wherein: A, R 2 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as defined for formula (I).
[0141] In some embodiments, compounds of formula (Ig) are provided:
[0142]
[0143] or a pharmaceutically acceptable salt thereof, wherein: A, R 2 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as defined for formula (I).
[0144] In some embodiments, compounds of formula (Ih) are provided:
[0145]
[0146] or a pharmaceutically acceptable salt thereof, wherein: A, R 2 、R 3 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as defined for formula (I).
[0147] In some embodiments, compounds of formula (Ii) are provided:
[0148]
[0149] or a pharmaceutically acceptable salt thereof, wherein: A, n, R 1 、R 2 、R 6 、R 7 , G1 and G2 are as defined for formula (I).
[0150] In some embodiments, compounds of formula (Ij) are provided:
[0151]
[0152] or a pharmaceutically acceptable salt thereof, wherein: A, n, R 1 、R 2 、R 3 、R 7 , G1 and G2 are as defined for formula (I).
[0153] In some embodiments, compounds of formula (Ik) are provided:
[0154]
[0155] or a pharmaceutically acceptable salt thereof, wherein: A, n, R 1 、R 4 、R 5 、R 7 , G1 and G2 are as defined for formula (I).
[0156] Any embodiment detailed herein with respect to Formula (A) or (I) applies equally to Formulas (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), and (Ik), where applicable. It is also understood that the description of any variable of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), where applicable, can be combined with one or more descriptions of any other variable, as if each combination of variables were specifically and individually listed. For example, the description of R 1 Each description of may be combined with each description of A, just as if each combination were specifically and individually listed. 1 Each description of can be combined with each description for A and G1 and G2 as if each description were specifically and individually listed.
[0157] In some embodiments of compounds of Formula (A), R 8 In some embodiments of the compound of formula (A), R 8 In some embodiments of compounds of formula (A), R 8 For H.
[0158] In some embodiments of compounds of Formula (A), (I), (Id), (Ie), (Ii), (Ij), or (Ik), n is 1 and R 1 is H. In some embodiments, n is 1 and R 1 is a C1-C6 alkyl group. In other embodiments, n is 1 and R 1 is a C3-C8 cycloalkyl group. In some embodiments, n is 1 and R 1 is C1-C6 haloalkyl. In certain embodiments, n is 1 and R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl. In some embodiments, n is 1 and R 1 In some embodiments, n is 1 and R 1 In some embodiments, n is 1 and R 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, n is 1 and R 1 In some embodiments of compounds of Formula (A), (I), (Id), (Ie), or (Ij), n is 1 and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring. In some embodiments, n is 1 and R 3 Together with R 1Together with the atoms to which they are attached, they form an unsubstituted 5-membered carbocyclic ring. In some embodiments, n is 1 and R 3 Together with R 1 Together with the atoms to which they are attached, they form an unsubstituted 6-membered carbocyclic ring. In some embodiments, n is 1 and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbocyclic ring substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, n is 1 and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 6-membered carbocyclic ring substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, n is 1 and R 3 Together with R 1 and the atoms to which they are attached form a 5- or 6-membered heterocyclic ring, wherein the 5- or 6-membered heterocyclic ring is unsubstituted or substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments of compounds of Formula (A), (I), (Id), (Ie), (Ii), (Ij), or (Ik), n is 0.
[0159] In some embodiments of compounds of Formula (A), (I), (Id), or (Ie), L is absent. In other embodiments, L is -CH2-. In some embodiments, n is 1, L is absent, and R 1 is H. In some embodiments, n is 1, L is absent, and R 1 is a C1-C6 alkyl group. In other embodiments, n is 1, L is absent, and R 1 is a C3-C8 cycloalkyl group. In some embodiments, n is 1, L is absent, and R 1 is a C1-C6 haloalkyl group. In certain embodiments, n is 1, L is absent, and R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl. In some embodiments, n is 1, L is absent, and R 1 In some embodiments, n is 1, L is absent, and R 1 In some embodiments, n is 1, L is absent, and R 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, n is 1, L is absent, and R 1 It is cyclopropyl.
[0160] In some embodiments of compounds of Formula (A), (I), (Id), or (Ie), n is 1, L is absent, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring. In some embodiments, n is 1, L is absent, and R 3 Together with R 1 Together with the atoms to which they are attached, they form an unsubstituted 5-membered carbocyclic ring. In some embodiments, n is 1, L is absent, and R 3 Together with R 1 Together with the atoms to which they are attached, they form an unsubstituted 6-membered carbocyclic ring. In some embodiments, n is 1, L is absent, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbocyclic ring substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, n is 1, L is absent, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 6-membered carbocyclic ring substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, n is 1, L is absent, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered heterocyclic ring, wherein the 5- or 6-membered heterocyclic ring is unsubstituted or substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, n is 1, L is absent, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbocyclic ring, wherein the 5-membered carbocyclic ring is unsubstituted or substituted with halogen, CN, -OH, C1-C6 alkyl or C1-C6 haloalkyl and R 2 、R 4 、R 5 and R 6 In certain embodiments, n is 1, L is absent, and R 3 Together with R 1 Together with the atoms to which they are attached, they form an unsubstituted 5-membered carbon ring, and R 2 、R 4 、R 5 and R 6 Each is H. In one variation, when carrying R 1 When the carbon of the molecule is in the "S" configuration, n is 1, L does not exist, and R 3Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbocyclic ring. In another variation, when R 1 When the carbon of the molecule is in the "R" configuration, n is 1, L does not exist, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbon ring.
[0161] In some embodiments of compounds of Formula (A), (I), (Id), or (Ie), n is 0 and L is absent.
[0162] In some embodiments of compounds of Formula (A), (I), (Id), or (Ie), n is 1, L is -CH2-, and R 1 is H. In some embodiments, n is 1, L is -CH2-, and R 1 is a C1-C6 alkyl group. In other embodiments, n is 1, L is -CH2-, and R 1 In some embodiments, n is 1, L is -CH2-, and R 1 is C1-C6 haloalkyl. In certain embodiments, n is 1, L is -CH2-, and R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl. In some embodiments, n is 1, L is -CH2-, and R 1 In some embodiments, n is 1, L is -CH2-, and R 1 In some embodiments, n is 1, L is -CH2-, and R 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, n is 1, L is -CH2-, and R 1 In some embodiments of compounds of Formula (A), (I), (Id), or (Ie), n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring. In some embodiments, n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form an unsubstituted 5-membered carbocyclic ring. In some embodiments, n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form an unsubstituted 6-membered carbon ring. In some embodiments, n is 1, L is -CH2-, and R 3 Together with R 1Together with the atoms to which they are attached, they form a 5-membered carbocyclic ring substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 6-membered carbocyclic ring substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered heterocyclic ring, wherein the 5- or 6-membered heterocyclic ring is unsubstituted or substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbocyclic ring, wherein the 5-membered carbocyclic ring is unsubstituted or substituted with halogen, CN, -OH, C1-C6 alkyl or C1-C6 haloalkyl and R 2 、R 4 、R 5 and R 6 In certain embodiments, n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form an unsubstituted 5-membered carbon ring, and R 2 、R 4 、R 5 and R 6 Each is H. In one variation, when carrying R 1 When the carbon of the molecule is in the "S" configuration, n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbocyclic ring. In another variation, when R 1 When the carbon of the molecule is in the "R" configuration, n is 1, L is -CH2-, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbon ring.
[0163] In some embodiments of compounds of Formula (A), (I), (Id), or (Ie), n is 0 and L is -CH2-.
[0164] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), G1 is N and G2 is CR d In some embodiments, G1 is N and G2 is CH. In some embodiments, G1 is N and G2 is C1-C6 alkyl. In some embodiments, G1 is N and G2 is CCH3. In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), G1 is CR d and G2 is N. In some embodiments, G1 is CH and G2 is N. In some embodiments, G1 is C1-C6 alkyl and G2 is N. In some embodiments, G1 is CCH3 and G2 is N.
[0165] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (Ii), (Ij), or (Ik), R 1 is H. In some embodiments, R 1 is a C1-C6 alkyl group. In other embodiments, R 1 In some embodiments, R 1 is C1-C6 haloalkyl. 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl. 1 In some embodiments, R 1 In some embodiments, R 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, R 1 In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (Ih), or (Ij), R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring. 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbocyclic ring. 3 Together with R 1 Together with the atoms to which they are attached, they form a 5-membered carbon ring, and R 2 、R 4 、R 5 and R 6 Each is H.
[0166] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), R 2 、R 3 、R 4 、R 5 and R 6 Each is independently H, halo, CN, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments, R 2 、R 3 、R 4 、R 5 and R 6 Each independently represents H, Cl, CN or CF3. In some embodiments, R 4 and R 5 Each is independently Cl, Br, I, CN, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments, R 2 、R 3 、R 4 、R 5 and R 6 is not H. In some embodiments, R 2 、R 3 、R 4 、R 5 and R 6 In some embodiments, two of R 2 、R 3 、R 4 、R 5 and R 6 At least two of are not H. In some embodiments, R 2 、R 3 、R 4 、R 5 and R 6 In some embodiments, R 6 In some embodiments, R 2 、R 3 、R 4 、R 5 and R 6 In some embodiments, R 2 、R 3 、R 4 、R 5 and R 6 In some embodiments, two of R 2 and R 6 Each is CF3, or R 4 and R 5 Each is CF3, or R3 and R 6 Each is CF3. In some embodiments, R 2 、R 3 、R 4 、R 5 and R 6 In some embodiments, one or two of R 4 and R 5 In some embodiments, R 2 、R 4 、R 5 and R 6 Each is H.
[0167] In some embodiments of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), for where R 2 and R 6 Each is a C1-C6 haloalkyl group. In some embodiments, for where R 2 and R 6 Each is independently selected from the group consisting of halo, C1-C6 alkyl and C1-C6 haloalkyl. for where R 2 and R 6 Each is independently selected from the group consisting of Cl, C1-C6 alkyl and C1-C6 haloalkyl. In some embodiments, for where R 2 and R 3 In some embodiments, for where R 5 and R 6 Each is independently selected from the group consisting of Cl, Br, I, CN, C1-C6 alkyl and C1-C6 haloalkyl. In some embodiments, for
[0168] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), R a 、R b and R cEach is independently a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein the 6-membered aryl or the 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. a 、R b and R c Each is independently a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein the 6-membered aryl or the 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from OH, halo, and C1-C6 alkyl. a 、R b and R c Each is independently a 5- or 6-membered heteroaryl, wherein the 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. a 、R b and R c Each is independently a 5- or 6-membered heteroaryl, wherein the 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from OH, halo and C1-C6 alkyl.
[0169] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), R a and R b Each independently selected from H, C1-C6 alkyl, In some embodiments, R a and R b Each independently selected from H, C1-C6 alkyl, In some embodiments, R a and R b Each independently selected from H, Groups composed of.
[0170] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), R c Selected from C1-C6 alkyl, In some embodiments, R c Choose Free
[0171] Groups composed of.
[0172] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0173] In some embodiments, A is And R a is a 5- or 6-membered heteroaryl group which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is a 5- or 6-membered heteroaryl group which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R a is pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl, or tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is pyridyl, wherein the pyridyl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is furanyl, wherein the furanyl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is a thienyl group, wherein the thienyl group is unsubstituted or substituted with one to four groups selected from the group consisting of OH, a halo group and a C1-C6 alkyl group.
[0174] In some embodiments, A is And R a Selected from H, C1-C6 alkyl, In some embodiments, A is And R a Choose from H, In some embodiments, A is And R a Choose from H,
[0175] Groups composed of.
[0176] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R b is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R b is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R bEach C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R b is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R b Each 6-membered aryl and 5 or 6-membered heteroaryl of is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R b is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R b Each 6-membered aryl and 5- or 6-membered heteroaryl of is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R b selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl.
[0177] In some embodiments, A is And R b Selected from H, C1-C6 alkyl, In some embodiments, A is And R b Choose from H,
[0178] In some embodiments, A is And R b for
[0179] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R cis selected from the group consisting of C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R c Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R c is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R c The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R c selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl.
[0180] In some embodiments, A is And R c Selected from C1-C6 alkyl, In some embodiments, A is And R c Choose Free
[0181] In some embodiments, A is And R c Choose Free Groups composed of.
[0182] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R aEach C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0183] In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R a selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0184] In some embodiments, A is And R a Selected from C1-C6 alkyl, In some embodiments, A is And R a Choose from H,
[0185] Groups composed of.
[0186] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0187] In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R a selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0188] In some embodiments, A is And R a Selected from C1-C6 alkyl, In some embodiments, A is And R a Choose from H,
[0189] Groups composed of.
[0190] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R b is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R b is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0191] In some embodiments, A is And R b is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R b The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R b is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R b The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R bselected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0192] In some embodiments, A is And R b Selected from C1-C6 alkyl, In some embodiments, A is And R b Choose from H,
[0193] Groups composed of.
[0194] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R b is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R b is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0195] In some embodiments, A is And R b is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R bThe 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R b is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R b The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R b selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0196] In some embodiments, A is And R b Selected from C1-C6 alkyl, In some embodiments, A is And R b Choose from H,
[0197] Groups composed of.
[0198] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein Ra Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0199] In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R a selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0200] In some embodiments, A is And R a Selected from C1-C6 alkyl, In some embodiments, A is And R a Choose from H,
[0201] Groups composed of.
[0202] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R ais selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0203] In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R a selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0204] In some embodiments, A is And R a Selected from C1-C6 alkyl, In some embodiments, A is And R a Choose from H,
[0205] Groups composed of.
[0206] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0207] In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R a selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0208] In some embodiments, A is And R a Selected from C1-C6 alkyl, In some embodiments, A is And R a Choose from H,
[0209] Groups composed of.
[0210] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0211] In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R a selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0212] In some embodiments, A is And R a Selected from C1-C6 alkyl, In some embodiments, A is And R a Choose from H,
[0213] Groups composed of.
[0214] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R a is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R a Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0215] In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R aThe 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R a is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R a selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0216] In some embodiments, A is And R a Selected from C1-C6 alkyl, In some embodiments, A is And R a Choose from H,
[0217] Groups composed of.
[0218] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R b is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl in is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl. In some embodiments, A is And R b is selected from the group consisting of H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein Rb Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy.
[0219] In some embodiments, A is And R b is a 6-membered aryl group or a 5- or 6-membered heteroaryl group, wherein the 6-membered aryl group and the 5- or 6-membered heteroaryl group R b is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R b is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R a The 6-membered aryl and 5- or 6-membered heteroaryl groups are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl, and C1-C6 alkoxy. In some embodiments, A is And R b selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, C1-C6 alkyl and C1-C6 alkoxy.
[0220] In some embodiments, A is And R b Selected from C1-C6 alkyl, In some embodiments, A is And R b Choose from H,
[0221] Groups composed of.
[0222] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is And R cis selected from the group consisting of C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl and 5- or 6-membered heteroaryl, wherein R c Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl, or 5- or 6-membered heteroaryl is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo, and C1-C6 alkyl.
[0223] In some embodiments, A is And R c is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein R c The 6-membered aryl and 5 or 6-membered heteroaryl are unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl. In some embodiments, A is And R c selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazinyl and tetrazinyl, each of which is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl.
[0224] In some embodiments, A is And R c Selected from C1-C6 alkyl, In some embodiments, A is And R c Choose Free Groups composed of.
[0225] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is
[0226] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is In some embodiments, A is in In other embodiments, A is in are connected in a Z configuration. For example, in some embodiments, A is In other embodiments, A is
[0227] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), A is In some embodiments, A is in In other embodiments, A is in are connected in a Z configuration. For example, in some embodiments, A is In other embodiments, A is
[0228] It should be understood that each description for A can be combined with the description for R 2 、R 3 、R 4 、R 5 and / or R 6 For example, in one aspect, it should be understood that in one aspect, each description of A can be combined with R 2 and R 6 Each is CF3 and R 3 、R 4 and R 5 Each of the descriptions for A can also be combined with the description for R 1 It will be appreciated that each description of A can be combined with each description of G1, G2, and R7, as if each combination were specifically and individually listed.
[0229] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), R 7 is H. In some embodiments, R 7 is H. In some embodiments, R 7 is a C1-C6 alkyl group. In some embodiments, R 7 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl. 7 It is a methyl group.
[0230] In some embodiments of compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), R 7 and R d In some embodiments, R d is a C1-C6 alkyl group and R 7 is H. In other embodiments, R d H and R 7 is a C1-C6 alkyl group. d is methyl and R 7 is H. In other embodiments, R d H and R 7 It is a methyl group.
[0231] In some embodiments, A is R a is furanyl, wherein R a The furanyl group is unsubstituted or substituted with OH, halo or C1-C6 alkyl. In some embodiments, A is R a is furanyl, wherein R a The furyl group is unsubstituted or substituted with OH, halogen or C1-C6 alkyl, R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R a for R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R a for R 2 is CF3, and R 6 In some embodiments, A is R a for R 2 Halogen, and R 3 In certain embodiments, A is R a for R 2 is Cl, and R 3 In certain embodiments, A is R a for And R 3 Together with R 1Together with the atoms to which they are attached, they form a 5- or 6-membered carbocyclic ring. R a for And R 6 In some embodiments, A is R a for R 6 is CN, and R 4 In certain embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 1 is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 7 or R d It is a C1-C6 alkyl group.
[0232] In some embodiments, A is R a is a thienyl group, wherein R a The thienyl group is unsubstituted or substituted with OH, halo or C1-C6 alkyl. In some embodiments, A is R a is a thienyl group, wherein R a The thienyl group is unsubstituted or substituted with OH, halogen or C1-C6 alkyl, R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R a for R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R a for R 2 CF3, and R 6 In certain embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 1is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 7 or R d It is a C1-C6 alkyl group.
[0233] In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted with OH, halo or C1-C6 alkyl. In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted with OH, halogen or C1-C6 alkyl, R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 1 is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 7 or R d It is a C1-C6 alkyl group.
[0234] In some embodiments, A is R a is phenyl, where R a The phenyl group is unsubstituted or substituted with OH, halo or C1-C6 alkyl. In some embodiments, A is R a is phenyl, where R a The phenyl group is unsubstituted or substituted by OH, halogen or C1-C6 alkyl, R 2 is a C1-C6 haloalkyl group, and R 6In some embodiments, A is R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 1 is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 7 or R d It is a C1-C6 alkyl group.
[0235] In some embodiments, A is R a for R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 1 is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R a for R 2 CF3, R 6 is CF3, and R 7 or R d It is a C1-C6 alkyl group.
[0236] In some embodiments, A is R b is phenyl, where R b The phenyl group is unsubstituted or substituted with OH, halo or C1-C6 alkyl. In some embodiments, A is R b is phenyl, where Rb The phenyl group is unsubstituted or substituted by OH, halogen or C1-C6 alkyl, R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R b for R 2 is CF3, and R 6 In certain embodiments, A is R b for R 2 CF3, R 6 is CF3, and R 1 is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R b for R 2 CF3, R 6 is CF3, and R 7 or R d It is a C1-C6 alkyl group.
[0237] In some embodiments, A is R c is furanyl, wherein R c The furanyl group is unsubstituted or substituted with OH, halo or C1-C6 alkyl. In some embodiments, A is R c is furanyl, wherein R c The furyl group is unsubstituted or substituted with OH, halogen or C1-C6 alkyl, R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R c is 2-furyl, R 2 is CF3, and R 6 In certain embodiments, A is R c is 2-furyl, R 2 CF3, R 6 is CF3, and R 1 is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R c is 2-furyl, R 2 CF3, R 6 is CF3, and R 7 or R dIt is a C1-C6 alkyl group.
[0238] In some embodiments, A is R c is pyridyl or phenyl, wherein R c The pyridyl or phenyl group is unsubstituted or substituted with OH, halo or C1-C6 alkyl. In some embodiments, A is R c is pyridyl or phenyl, wherein R c The pyridyl or phenyl group is unsubstituted or substituted with OH, halogen or C1-C6 alkyl, R 2 C1-C6 haloalkyl, and R 6 In some embodiments, A is R c for R 2 is CF3, and R 6 In certain embodiments, A is R c for R 2 CF3, R 6 is CF3, and R 1 is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R c for R 2 CF3, R 6 is CF3, and R 7 or R d It is a C1-C6 alkyl group.
[0239] In some embodiments, A is R 2 is a C1-C6 haloalkyl group, and R 6 In some embodiments, A is R 2 is CF3, and R 6 In certain embodiments, A is R 2 CF3, R 6 is CF3, and R 1 is C1-C6 alkyl or C1-C6 cycloalkyl. In some embodiments, A is R 2 CF3, R 6 is CF3, and R 7 or R d It is a C1-C6 alkyl group.
[0240] In some embodiments, A is R a is furanyl, wherein R a The furanyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R a is furanyl, wherein R a The furyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 is a C1-C6 haloalkyl group, and R 6 is a C1-C6 haloalkyl group. R a for R 2 CF3, and R 6 In certain embodiments, A is R a for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0241] In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 C1-C6 haloalkyl, and R 6 is a C1-C6 haloalkyl group. R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0242] In some embodiments, A is R a is furanyl, wherein R aThe furanyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R a is furanyl, wherein R a The furyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 is a C1-C6 haloalkyl group, and R 6 is a C1-C6 haloalkyl group. R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0243] In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 is a C1-C6 haloalkyl group, and R 6 is a C1-C6 haloalkyl group. R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0244] In some embodiments, A is R b is furanyl, wherein R bThe furanyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R b is furanyl, wherein R b The furyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 is a C1-C6 haloalkyl group, and R 6 is a C1-C6 haloalkyl group. R b for R 2 is CF3, and R 6 In certain embodiments, A is R b for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0245] In some embodiments, A is R b is a pyridyl group, wherein R b The pyridyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R b is a pyridyl group, wherein R b The pyridyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 C1-C6 haloalkyl, and R 6 is a C1-C6 haloalkyl group. R b for R 2 is CF3, and R 6 In certain embodiments, A is R b for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0246] In some embodiments, A is R b is furanyl, wherein R b The furanyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R b is furanyl, wherein R b The furyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 C1-C6 haloalkyl, and R 6 is a C1-C6 haloalkyl group. R b for R 2 is CF3, and R 6 In certain embodiments, A is R b for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0247] In some embodiments, A is R b is a pyridyl group, wherein R b The pyridyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R b is a pyridyl group, wherein R b The pyridyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 is a C1-C6 haloalkyl group, and R 6 is a C1-C6 haloalkyl group. Rb a for R 2 is CF3, and R 6 In certain embodiments, A is R b for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0248] In some embodiments, A is R a is furanyl, wherein R a The furanyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R a is furanyl, wherein R aThe furyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 is a C1-C6 haloalkyl group, and R 6 is a C1-C6 haloalkyl group. R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0249] In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 is a C1-C6 haloalkyl group, and R 6 is a C1-C6 haloalkyl group. R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0250] In some embodiments, A is R a is furanyl, wherein R a The furanyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R a is furanyl, wherein R a The furyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R2 is a C1-C6 haloalkyl group, and R 6 is a C1-C6 haloalkyl group. R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0251] In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted with OH, halo, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments, A is R a is a pyridyl group, wherein R a The pyridyl group is unsubstituted or substituted by OH, halo, C1-C6 alkyl or C1-C6 alkoxy, R 2 C1-C6 haloalkyl, and R 6 is a C1-C6 haloalkyl group. R a for R 2 is CF3, and R 6 In certain embodiments, A is R a for And R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered carbon ring.
[0252] In some embodiments of compounds of Formula (A), (I), (Id), (Ie), (Ii), (Ij), or (Ik), R e is a C1-C6 alkyl group. In some embodiments, R e In some embodiments, R e is a C1-C6 haloalkyl group. In some embodiments, R e For H.
[0253] In certain variations, the compound of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik) has one or more of the following structural features: (A) A is And R a Choose from H, A is a group consisting of And R b for Or A is And R c Choose Free A is a group consisting of and (B) for
[0254] In certain variations, the compound of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik) has one or more of the following structural features: (A) A is
[0255] R a 、R b and R c Each independently chooses freedom when it exists The group is composed of e When present, H or methyl; (B) for (C) n is 1; and (D) R 1 is H or methyl.
[0256] In certain variations, the compound of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik) has one or more of the following structural features: (A) A is
[0257] R a 、R b and R c Each independently chooses freedom when it exists The group is composed of eWhen present, it is H or methyl; (B) n is 1 and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring.
[0258] In some embodiments of any of the formulas provided herein, A is R a is 2-furyl, G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 3 H, R 4 H, R 5 H, R 7 is H, and R 6 In some embodiments, A is R a is methyl, G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 3 H, R 4 H, R 5 H, R 7 is H, and R 6 In some embodiments, A is R a is phenyl, G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 3 H, R 4 H, R 5 H, R 7 is H, and R 6 In some embodiments, A is R a is 2-furyl, G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 H, R 3 H, R 4 H, R 5 H, R 7 is H, and R 6 Not for H.
[0259] In some embodiments, A is G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 and R 6 Each is Br, R 3 H, R 4H, R 5 H, R 7 is H, and R a In some embodiments, A is G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 and R 6 Each is CF3, R 3 H, R 4 H, R 5 H, R 7 is H, and R a In some embodiments, A is G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 H, R 3 H, R 4 H, R 5 H, R 6 CF3, R 7 is H, and R a In some embodiments, A is G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 CF3, R 3 H, R 4 H, R 5 H, R 6 H, R 7 is H, and R a Not 2-furyl.
[0260] In some embodiments of any of the formulas provided herein, A is G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 3 H, R 4 H, R 5 H, R 6 F, R 7 is H, and R a In some embodiments, A is R a is phenyl, G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 3 H, R 4 H, R 5 H, R7 is H, and R 6 is not F. In some embodiments, A is G1 is N, G2 is CH, n is 0, L does not exist, R 2 CH3, R 3 H, R 4 H, R 5 H, R 6 CH3, R 7 is H, and R a is not H. In some embodiments, A is R a is H, G1 is N, G2 is CH, n is 0, L does not exist, R 2 CH3, R 3 H, R 4 H, R 5 H, R 7 is H, and R 6 Not CH3.
[0261] In some embodiments of any of the formulas provided herein, A is G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 3 H, R 4 H, R 5 H, R 6 Cl, R 7 is H, and R a is not n-propyl, isopropyl, isobutyl, 2-furyl, methyl, ethyl, 4-fluorophenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, phenyl or 2-thiofuryl. In some embodiments, A is R a is n-propyl, isopropyl, isobutyl, 2-furyl, methyl, ethyl, 4-fluorophenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, phenyl or 2-thiofuryl, G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 3 H, R 4 H, R 5 H, R 7 is H, and R 6 Not Cl.
[0262] In some embodiments of any of the formulas provided herein, A is G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 F, R3 F, R 4 F, R 5 F, R 6 Cl, R 7 is H, and R a In some embodiments, A is G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 3 F, R 4 H, R 5 H, R 6 H, R 7 is H, and R a In some embodiments, A is R a Not phenyl, G1 is N, G2 is CH, n is 1, R 1 H, L does not exist, R 2 Cl, R 4 H, R 5 H, R 6 H, R 7 is H, and R 3 Not F.
[0263] In some embodiments of any of the formulas provided herein, A is G1 is N, G2 is CR d , and n is 1, R 1 is not H. In some embodiments, A is G1 is N, G2 is CR d , n is 0, and L does not exist, then R a is not H. In some embodiments, A is G1 is N, G2 is CR d , and R e is a methyl group, then R a is not unsubstituted phenyl. In some embodiments, G1 is N, G2 is CR d , n is 1 and L does not exist, then R 1 Not for H.
[0264] Representative compounds are listed in Table 1.
[0265] Table 1
[0266]
[0267]
[0268]
[0269]
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294] In some embodiments, provided herein are compounds described in Table 1 or pharmaceutically acceptable salts thereof, and uses thereof.
[0295] Where appropriate, the embodiments and variations described herein are applicable to compounds of any formula detailed herein.
[0296] Provided herein are compounds selected from the group consisting of:
[0297] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0298] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(2-hydroxypropan-2-yl)isoxazole-3-carboxamide;
[0299] 5-Acetyl-N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)isoxazole-3-carboxamide
[0300] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxamide;
[0301] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0302] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0303] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0304] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyridin-4-yl)isoxazole-3-carboxamide;
[0305] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0306] N-(1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0307] N-{1-[2,4-bis(trifluoromethyl)benzyl]-1H-pyrazol-4-yl}-5-tert-butyl-1,2-oxazole-3-carboxamide;
[0308] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(thiophen-2-yl)isoxazole-3-carboxamide;
[0309] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-[3,3'-bipyridine]-5-carboxamide;
[0310] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(2,4-difluorophenyl)isoxazole-3-carboxamide;
[0311] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-imidazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0312] N-(1-(2,3-dihydro-1H-inden-2-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0313] N-(1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0314] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(4-fluorophenyl)nicotinamide;
[0315] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-phenylnicotinamide;
[0316] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(5-methylfuran-2-yl)isoxazole-3-carboxamide;
[0317] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)isoxazole-3-carboxamide;
[0318] N-(1-(2,6-dichlorobenzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0319] N-(1-(4-cyanobenzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0320] N-(1-(4-cyano-3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0321] N-(1-(2,4-bis(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0322] N-(1-(3,5-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0323] N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0324] N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0325] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide;
[0326] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide;
[0327] N-(1-((2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0328] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide;
[0329] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-3-yl)isoxazole-3-carboxamide;
[0330] N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0331] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-5-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0332] N-(1-(2,4-bis(trifluoromethyl)phenyl)-5-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0333] N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0334] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-3-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0335] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0336] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0337] N-(1-(2,4-bis(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0338] N-(1-(2,4-bis(trifluoromethyl)phenyl)-5-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0339] N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0340] N-(1-(2,4-bis(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0341] N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0342] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-5-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0343] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-3-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0344] N-(1-(2,4-bis(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)nicotinamide;
[0345] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0346] N-(1-(2,4-bis(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0347] N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0348] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-5-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0349] N-(1-(2,4-bis(trifluoromethyl)phenyl)-5-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0350] N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0351] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-3-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide
[0352] N-(1-(2,4-bis(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0353] N-(1-(2,4-bis(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0354] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-5-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0355] N-(1-(2,4-bis(trifluoromethyl)phenyl)-5-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0356] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0357] N-(1-(2,4-bis(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0358] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-[2,3'-bipyridine]-5'-carboxamide;
[0359] N-(1-(2,4-bis(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-[2,3'-bipyridine]-5'-carboxamide;
[0360] N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-[2,3'-bipyridine]-5'-carboxamide;
[0361] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-5-methyl-1H-pyrazol-4-yl)-[2,3'-bipyridine]-5'-carboxamide;
[0362] N-(1-(2,4-bis(trifluoromethyl)phenyl)-5-methyl-1H-pyrazol-4-yl)-[2,3'-bipyridine]-5'-carboxamide;
[0363] N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-[2,3'-bipyridine]-5'-carboxamide;
[0364] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-3-methyl-1H-pyrazol-4-yl)-[2,3'-bipyridine]-5'-carboxamide;
[0365] N-(1-(2,4-bis(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-4-yl)-[2,3'-bipyridine]-5'-carboxamide;
[0366] N-(1-(2,4-bis(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-5-(thiophen-2-yl)isoxazole-3-carboxamide;
[0367] N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-5-(thiophen-2-yl)isoxazole-3-carboxamide;
[0368] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)isoxazole-5-carboxamide;
[0369] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)thiazole-5-carboxamide;
[0370] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)thiazole-4-carboxamide;
[0371] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(furan-2-yl)thiazole-5-carboxamide;
[0372] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-[2,4'-bipyridine]-2'-carboxamide;
[0373] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-[2,3'-bipyridine]-6'-carboxamide;
[0374] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)acrylamide;
[0375] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0376] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0377] N-(1-(2,4-bis(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0378] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(2-methoxyphenyl)isoxazole-3-carboxamide;
[0379] N-(1-(2,4-bis(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0380] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(2-methoxyphenyl)isoxazole-3-carboxamide;
[0381] N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0382] N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0383] N-(1-(2,4-bis(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0384] N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0385] N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-3-(furan-2-yl)acrylamide;
[0386] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-5-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0387] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0388] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyrimidin-2-yl)isoxazole-3-carboxamide;
[0389] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-N-methyl-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0390] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)thiazole-5-carboxamide;
[0391] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-4-methyl-2-(pyridin-2-yl)thiazole-5-carboxamide;
[0392] N-(1-(1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0393] N-(1-(1-(4-fluoro-2-(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0394] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-1-methyl-3-(pyridin-2-yl)-1H-pyrazole-5-carboxamide;
[0395] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-1-methyl-5-(pyridin-2-yl)-1H-pyrazole-3-carboxamide;
[0396] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyrazin-2-yl)isoxazole-3-carboxamide;
[0397] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(6-methylpyridin-2-yl)isoxazole-3-carboxamide;
[0398] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(6-methylpyridin-2-yl)isoxazole-3-carboxamide;
[0399] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)thiazole-5-carboxamide;
[0400] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)-1H-pyrazole-3-carboxamide;
[0401] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-1-(pyridin-2-yl)-1H-1,2,3-triazole-4-carboxamide;
[0402] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)-1,3,4-thiadiazole-2-carboxamide;
[0403] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)oxazole-4-carboxamide;
[0404] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)oxazole-5-carboxamide;
[0405] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyrimidin-2-yl)isoxazole-3-carboxamide;
[0406] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-2-(pyridin-2-ylamino)thiazole-5-carboxamide;
[0407] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyrazin-2-yl)isoxazole-3-carboxamide;
[0408] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole-2-carboxamide;
[0409] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-4-methyl-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0410] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyrazin-2-yl)-1,3,4-thiadiazole-2-carboxamide;
[0411] N-(1-(1-(4-fluoro-2-(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)-1,3,4-thiadiazole-2-carboxamide;
[0412] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)-1,3,4-thiadiazole-2-carboxamide;
[0413] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)picolinamide;
[0414] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)pyrazine-2-carboxamide;
[0415] N-(1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0416] N-(1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)-1,3,4-thiadiazole-2-carboxamide;
[0417] N-(1-(2,6-dichlorobenzyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)-1,3,4-thiadiazole-2-carboxamide;
[0418] N-(1-(2,6-dichlorobenzyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0419] N-(1-(2,6-dichlorobenzyl)-1H-pyrazol-4-yl)-2-(furan-2-yl)thiazole-5-carboxamide;
[0420] N-(1-(2,6-dichlorobenzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)-1,3,4-thiadiazole-2-carboxamide;
[0421] N-(1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide;
[0422] N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole-2-carboxamide;
[0423] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyrazin-2-yl)-1,3,4-thiadiazole-2-carboxamide;
[0424] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-4-methyl-5-(pyridin-2-yl)isoxazole-3-carboxamide;
[0425] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyrimidin-4-yl)-1,3,4-thiadiazole-2-carboxamide;
[0426] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)-1,3,4-thiadiazole-2-carboxamide; and
[0427] N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)-1,3,4-thiadiazole-2-carboxamide,
[0428] Or a pharmaceutically acceptable salt thereof. Where applicable, also provided herein are any and all stereoisomers of the compounds depicted herein, including geometric isomers (e.g., cis / trans isomers or E / Z isomers), enantiomers, diastereomers, or mixtures thereof in any ratio, including racemic mixtures.
[0429] Representative examples of the compounds detailed herein are depicted herein, including intermediate compounds and final compounds according to the present disclosure. It should be understood that, in one aspect, any compound can be used in the methods detailed herein, including intermediate compounds that can be isolated and administered to an individual, where applicable.
[0430] Even if no salt is depicted, the compounds depicted herein may still exist in salt form, and it should be understood that the present disclosure encompasses all salts and solvates of the compounds depicted herein, as well as non-salt and non-solvate forms of the compounds, as are well understood by those skilled in the art. In some embodiments, the salts of the compounds provided herein are pharmaceutically acceptable salts. When one or more tertiary amine moieties are present in the compounds, N-oxides are also provided and described.
[0431] Where any compound described herein can exist in tautomeric forms, each tautomeric form is contemplated, even if only one or a few tautomeric forms are explicitly depicted. The specifically depicted tautomeric form may or may not be the predominant form in solution or when used according to the methods described herein.
[0432] The present disclosure also includes any or all stereochemical forms of the described compounds, including any enantiomeric or diastereomeric forms. The compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric or diastereomeric forms. All optical isomers and stereoisomers of the general formula compound and mixtures thereof in any ratio are considered to be within the scope of the formula. Therefore, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomer forms and mixtures thereof in any ratio. In the case where the compounds depicting Table 1 have a specific stereochemical configuration, any alternative stereochemical configuration of the compound is also provided herein, as well as mixtures of the stereoisomers of the compound in any ratio. For example, in the case where the compounds of Table 1 have a stereocenter in an "S" stereochemical configuration, enantiomers of compounds having a stereocenter in an "R" stereochemical configuration are also provided herein. Likewise, in the case where the compounds of Table 1 have stereocenters in the "R" configuration, enantiomers of compounds in the "S" stereochemical configuration are also provided herein. Mixtures of compounds with "S" and "R" stereochemical configurations are also provided. In addition, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers. For example, the compounds of any formula given herein may contain a bond with restricted rotation and therefore exist in different geometric configurations. In the case where the compounds of Table 1 are depicted as specific geometric isomers (e.g., E or Z isomers, or cis or trans isomers), any alternative geometric configurations of the compounds are also provided herein, as well as mixtures of the geometric isomers of the compounds in any ratio. For example, in the case where the compounds of Table 1 are depicted as "Z" isomers, "E" isomers of the compounds are also provided herein. Similarly, in the case where the compounds of Table 1 are depicted as "E" isomers, "Z" isomers of the compounds are also provided herein. Also provided are mixtures of compounds with "E" and "Z" stereochemical configurations, wherein the mixtures are in any ratio. Similarly, where the compounds of Table 1 are depicted as "cis" isomers, the "trans" isomers of the compounds are also provided herein; and where the compounds are depicted as "trans" isomers, the "cis" isomers of the compounds are also provided herein. Also provided are mixtures of compounds with "cis" and "trans" stereochemical configurations, wherein the mixtures are in any ratio. The present invention also encompasses all forms of the compounds, such as crystalline or non-crystalline forms of the compounds. Compositions comprising compounds of the present invention are also contemplated, such as compositions with substantially pure compounds (including their specific stereochemical forms), or compositions comprising mixtures of compounds of the present invention in any ratio, wherein the mixtures include two or more stereochemical forms, such as racemic or non-racemic mixtures.
[0433] The present invention also contemplates isotopically labeled and / or isotopically enriched forms of the compounds described herein. The compounds herein may contain unnatural proportions of atomic isotopes at one or more atoms comprising such compounds. In some embodiments, the compounds are isotopically labeled, such as isotopically labeled compounds of formula (I) described herein or variations thereof, wherein a portion of one or more atoms are replaced by isotopes of the same element. Exemplary isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C 13 N. 15 O. 17 O. 32 P. 35 S. 18 F. 36 Cl. Certain isotope-labeled compounds (e.g. 3 H and 14 C) can be used in compound or substrate tissue distribution studies. Incorporation of heavier isotopes, such as deuterium ( 2 H) may offer certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore, may be preferred in some circumstances.
[0434] Isotopically labeled compounds of the present invention can generally be prepared by standard methods and techniques known to those skilled in the art or by procedures analogous to those described in the accompanying Examples, by substituting an appropriate isotopically labeled reagent for the corresponding non-labeled reagent.
[0435] The present invention also includes any or all metabolites of any of the described compounds. Metabolites can include any chemical species produced by the biotransformation of any of the described compounds, such as metabolic intermediates and products of the compound, such as intermediates and products that would be produced in vivo following administration to a human.
[0436] Provided are articles of manufacture comprising a compound described herein, or a salt or solvate thereof, in a suitable container. The container can be a vial, jar, ampoule, pre-loaded syringe, intravenous bag, etc.
[0437] Preferably, the compounds detailed herein are orally bioavailable. However, the compounds may also be formulated for parenteral (eg, intravenous) administration.
[0438] One or more compounds described herein can be used to prepare a medicament by combining one or more compounds as active ingredients with a pharmacologically acceptable carrier known in the art. The carrier can take a variety of forms depending on the therapeutic form of the drug. In one variation, the medicament is manufactured for use in any of the methods disclosed herein, for example, for treating cancer.
[0439] General synthetic method
[0440] The compounds of the present invention can be prepared by a variety of methods generally described below and more specifically in the Examples below (e.g., the Schemes provided in the Examples below). In the following method descriptions, when symbols are used in the various formulas depicted, it should be understood that these symbols represent the groups described above with respect to these formulas herein.
[0441] When it is desired to obtain a specific enantiomer of a compound, this can be achieved by the corresponding enantiomeric mixture using a conventional procedure suitable for separating or splitting enantiomers. Thus, for example, diastereomeric derivatives can be prepared by reacting an enantiomeric mixture, such as a racemate, with an appropriate chiral compound. Subsequently, the diastereomers can be separated by any convenient means, such as by crystallization, and the desired enantiomer can be recovered. In another method of separation, chiral high performance liquid chromatography can be used to separate the racemate. Alternatively, when desired, a specific enantiomer can be obtained in a described method by using an appropriate chiral intermediate.
[0442] Where it is desired to obtain a specific isomer of a compound or to otherwise purify a reaction product, chromatography, recrystallization, and other conventional separation procedures may also be employed on intermediates or final products.
[0443] Also encompassed are solvates and / or polymorphs of the compounds provided herein, or pharmaceutically acceptable salts thereof. Solvates contain stoichiometric or non-stoichiometric amounts of a solvent and are typically formed during the crystallization process. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is an alcohol. Polymorphs include different crystal packing arrangements of compounds composed of the same elements. Polymorphs typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardnesses, crystal shapes, optical and electrical properties, stability, and / or solubility. A variety of factors may cause a single crystal form to dominate, such as the recrystallization solvent, crystallization rate, and storage temperature.
[0444] In some embodiments, compounds of formula (I) can be synthesized according to Scheme 1.
[0445] Solution 1
[0446]
[0447] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 , G1, G2 and A are as defined for Formula (A), (I) or any variation thereof as detailed herein.
[0448] An exemplary embodiment of the preparation method of Scheme 1 is shown in Scheme 1a.
[0449] Option 1a
[0450]
[0451] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 , G1, G2 and R a As defined for Formula (A), (I), or any variation thereof as detailed herein.
[0452] In some embodiments, compounds of formula (I) can be synthesized according to Scheme 2.
[0453] Option 2
[0454]
[0455] Among them, A, R 2 、R 3 、R 4 、R 5 、R 6 、R 7 , G1, G2 and n are as defined for Formula (A), (I) or any variation thereof detailed herein, and X is halogen.
[0456] An exemplary embodiment of the preparation method of Scheme 2 is shown in Scheme 2a.
[0457] Option 2a
[0458]
[0459] Among them, A, R 2 、R 3 、R 4 、R 5 、R 6 、R 7, G1, G2 and n are as defined for Formula (A), (I) or any variation thereof detailed herein, and X is halogen.
[0460] In some embodiments, compounds of formula (I) can be synthesized according to Scheme 3.
[0461] Option 3
[0462]
[0463] Among them, A, R 2 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as defined for Formula (A), (I) or any variation thereof as detailed herein.
[0464] An exemplary embodiment of the preparation method of Scheme 3 is shown in Scheme 3a.
[0465] Option 3a
[0466]
[0467] Among them, A, R 2 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as defined for Formula (A), (I) or any variation thereof as detailed herein.
[0468] In some embodiments, compounds of formula (I) can be synthesized according to Scheme 4.
[0469] Option 4
[0470]
[0471] Among them, A, R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 , G1 and G2 are as defined for Formula (A), (I) or any variation thereof as detailed herein, and X is halogen.
[0472] Specific examples are provided in the Examples section below. It will be appreciated that the above schemes can be modified to obtain various compounds of the present invention by selecting appropriate reagents and starting materials. For a general description of protecting groups and their use, see PGM Wuts and TW Greene, Greene's Protective Groups in Organic Synthesis, 4th edition, Wiley-Interscience, New York, 2006.
[0473] Pharmaceutical compositions and preparations
[0474] The present disclosure encompasses pharmaceutical compositions of any of the compounds detailed herein. Thus, the present disclosure includes pharmaceutical compositions comprising a compound as detailed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. In one aspect, a pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid. The pharmaceutical composition can be in a form suitable for oral, buccal, parenteral, nasal, topical, or rectal administration, or in a form suitable for administration by inhalation.
[0475] The compounds as described in detail herein may be in purified form, and compositions comprising the compounds in purified form are described in detail herein. Compositions comprising the compounds as described in detail herein, or salts thereof, are provided, such as compositions comprising substantially pure compounds. In some embodiments, compositions comprising the compounds as described in detail herein, or salts thereof, are in substantially pure form.
[0476] In one variation, the compounds herein are synthetic compounds prepared for administration to an individual. In another variation, compositions containing the compounds in substantially pure form are provided. In another variation, the present disclosure encompasses pharmaceutical compositions comprising the compounds detailed herein and a pharmaceutically acceptable carrier. In another variation, a method of administering the compounds is provided. The purified forms, pharmaceutical compositions, and methods of administering the compounds are suitable for any compound or form thereof described in detail herein.
[0477] The compounds or salts thereof described in detail herein can be formulated for any available route of delivery, including oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., intramuscular, subcutaneous, or intravenous), topical, or transdermal delivery forms. The compounds or salts thereof can be formulated with a suitable carrier to provide a delivery form including, but not limited to, tablets, caplets, capsules (e.g., hard gelatin capsules or soft elastic gelatin capsules), cachets, dragees, buccal tablets, jelly, dispersions, suppositories, ointments, poultices (catharsis), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal sprays or inhalants), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil emulsions), solutions, and elixirs.
[0478] One or more compounds described herein or their salts can be used to prepare preparations, such as pharmaceutical preparations, by combining one or more compounds or their salts as active ingredients with, for example, a pharmaceutically acceptable carrier as mentioned above. Depending on the treatment form of the system (e.g., transdermal patch versus oral tablet), the carrier can be in various forms. In addition, the pharmaceutical preparation may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts, buffers, coating agents, or antioxidants for adjusting osmotic pressure. Preparations comprising compounds may also contain other substances that have useful therapeutic properties. Pharmaceutical preparations can be prepared by known pharmaceutical methods. Suitable preparations can be found in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pennsylvania (Philadelphia, PA), 20th edition (2000), which is incorporated herein by reference.
[0479] The compounds as described herein may be administered to an individual in the form of recognized oral compositions such as tablets, coated tablets, and gel capsules in hard or soft shells, emulsions, or suspensions. Examples of carriers that can be used to prepare these compositions are lactose, corn starch or its derivatives, talc, stearates or their salts, and the like. Acceptable carriers for soft shell gel capsules are, for example, vegetable oils, waxes, greases, semisolid and liquid polyols, and the like. In addition, the pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, modifiers, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants.
[0480] Any compound described herein can be formulated as a tablet in any of the dosage forms described, for example, a compound as described herein or a pharmaceutically acceptable salt thereof can be formulated as a 10 mg tablet.
[0481] Also described are compositions comprising the compounds provided herein. In one variation, the compositions comprise a compound or a salt thereof and a pharmaceutically acceptable carrier or excipient. In another variation, compositions comprising substantially pure compounds are provided.
[0482] Usage and Application
[0483] The compounds and compositions described in detail herein, such as pharmaceutical compositions containing a compound of any formula provided herein or a salt thereof and a pharmaceutically acceptable carrier or excipient, can be used in methods of administration and treatment as provided herein. The compounds and compositions can also be used in in vitro methods, such as in vitro methods in which the compound or composition is administered to cells for screening purposes and / or for quality control assays.
[0484] In some embodiments, provided herein is a method for inhibiting the ATF6 pathway. In some embodiments, provided herein is a method for inhibiting ATF6. In some embodiments, ATF6 is ATF6α. It is believed that the compounds or salts thereof described herein and the compositions described herein can effectively inhibit the ATF6 pathway, ATF6, and / or ATF6α.
[0485] In some embodiments, the method of inhibiting the ATF6 pathway, ATF6 or ATF6α comprises administering or delivering a compound described herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition described herein to a cell comprising ATF6 or ATF6α. In some embodiments, the cell is a diseased cell, such as a cancer cell. In some embodiments, the cell has an activated ATF6 pathway. In some embodiments, the cell has been exposed to a situation that induces ER stress. Several situations that induce ER stress are known in the art, such as glucose deprivation, abnormal Ca 2+ regulation, viral infection, hypoxia, and exposure to ER stress-inducing molecules such as thapsigargin, ionomycin, or tunicamycin.
[0486] In some embodiments, the method of inhibiting the ATF6 pathway, ATF6, or ATF6α comprises administering or delivering a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein to a tumor.
[0487] In some embodiments, inhibition of the ATF6 pathway, ATF6, or ATF6α comprises inhibiting the expression of ATF6 and / or ATF6α target genes. In some embodiments, inhibition of the ATF6 pathway, ATF6, or ATF6α comprises inhibiting the expression of ATF6α target genes. In some embodiments, expression of ATF6 and / or ATF6α target genes is inhibited by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 98%.
[0488] In some embodiments, the ATF6 and / or ATF6α target gene comprises a promoter comprising an ER stress response element (ERSE). In some embodiments, the promoter comprises a sequence that shares at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with CCAATCGGCGGCGGCCACG (SEQ ID NO.1). In some embodiments, the promoter comprises SEQ ID NO.1. In some embodiments, the ATF6 and / or ATF6α target gene is GRP78, HERPUD1 or ERO1B. In some embodiments, the ATF6α target gene is GRP78. Inhibition of expression of the ATF6 and / or ATF6α target gene can be determined by methods known in the art, for example, by detecting the mRNA of the target gene using techniques such as PCR, qPCR or Northern blotting, or by detecting the polypeptide gene product, for example, by Western blotting or mass spectrometry.
[0489] In some embodiments, the compound, salt, or composition thereof has an IC of less than about 10 μM, such as less than about 5 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, or 600 nM. 50 Inhibits the ATF6 pathway, ATF6 or ATF6α. In some embodiments, the compound, its salt or composition has an IC between about 10 nM and 5 μM, such as between about 50 nM and 2 μM, 100 nM and 1 μM or 20 nM and 1 μM. 50 Inhibits the ATF6 pathway, ATF6 or ATF6α. The half-maximal inhibitory concentration (IC 50 ) is a measure of the effectiveness of a substance in inhibiting a specific biological or biochemical function. 50 It is a quantitative measure of the amount of inhibitor required to inhibit a given biological process or a component of a process such as an enzyme, cell, cell receptor, or microorganism by half. IC is determined in vitro and in vivo. 50 Methods are known in the art.
[0490] In some embodiments, the compounds described herein, or salts thereof, and compositions described herein, are administered in an amount that does not inhibit ATF6β activity or inhibits ATF6β activity to a lesser extent. In some embodiments, the inhibition of ATF6α is at least or about 2-fold greater than the inhibition of ATF6β activity, for example, at least or about 3-fold, 4-fold, 5-fold, 8-fold, 10-fold, 15-fold, 30-fold, 50-fold, 60-fold, 75-fold, or 100-fold greater.
[0491] Provided herein is a method of treating a disease in a subject, comprising administering to the subject an effective amount of a compound of Formula (I), or any embodiment, variation, or aspect thereof, including but not limited to a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or any embodiment, variation, or aspect thereof (collectively referred to as a compound of Formula (I) or a compound of the invention or as detailed or described herein), or a pharmaceutically acceptable salt thereof.
[0492] In some embodiments, provided herein is a method of treating a disease in a subject mediated by the ATF6 pathway, the method comprising administering to the subject an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method of treating a disease in a subject mediated by ATF6 pathway activation, the method comprising administering to the subject an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method of treating a disease in a subject mediated by ATF6 activation, the method comprising administering to the subject an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method of treating a disease in a subject mediated by ATF6α activation, the method comprising administering to the subject an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof.
[0493] In some embodiments, provided herein is a method for treating a disease in an individual characterized by activation of the ATF6 pathway, the method comprising administering to the individual an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method for treating a disease in an individual characterized by activation of ATF6, the method comprising administering to the individual an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method for treating a disease in an individual characterized by activation of ATF6α, the method comprising administering to the individual an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method for treating a disease in an individual characterized by increased expression of an ATF6 target gene, the method comprising administering to the individual an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method for treating a disease in an individual characterized by increased expression of an ATF6α target gene, the method comprising administering to the individual an effective amount of a compound of Formula (A) or (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the increased expression is compared to tissue or cells that have not undergone the disease.
[0494] It is believed that the compounds of the present invention or its salt is effective in treating a variety of diseases and conditions, such as diseases in which the transcriptional targets activated by ATF6 play a role in the pathogenesis or development of the disease. For example, in some embodiments, the compounds of the present invention and compositions can be used to treat viral infections, cancer, neurodegenerative diseases or vascular diseases, such as cardiovascular disease. In certain embodiments, the disease is viral infection, hereditary cerebellar atrophy and ataxia or Alzheimer's disease. In certain embodiments, the disease is type 2 diabetes or diabetic nephropathy. In certain embodiments, the disease is myocardial atrophy, heart failure, atherosclerosis or ischemia, such as ischemic heart disease or cerebral ischemia.
[0495] It has been shown that the ATF6 branch of UPR is important for viral infection. For example, ATF6 is important for maintaining cell viability and regulating immune response during West Nile virus (West Nile virus) infection (Ambrose R " Journal of Virology (J.Virol.) " February 2013, Vol. 87, No. 4, 2206-2214). In addition, African swine fever virus activates ATF6 branch to prevent early apoptosis and ensure viral replication (Galindo I, " Cell Death and Disease (Cell Death Dis) " July 5, 2012; 3: e341.doi: 10.1038 / cddis.2012.81). Therefore, in some embodiments, compound as herein described or its salt or composition as herein described can be used for the method for treating or preventing viral infection. In certain embodiments, viral infection is African swine fever virus, dengue virus (dengue virus), enterovirus, hepatitis B virus, hepatitis C virus, influenza virus, tick-borne encephalitis virus or West Nile virus infection. In some embodiments, the viral infection is caused by a virus that activates ATF6 in infected cells.
[0496] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods for treating cancer, such as breast cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer, kidney cancer, lung cancer, melanoma, fibrosarcoma, osteosarcoma, connective tissue sarcoma, renal cell carcinoma, giant cell carcinoma, squamous cell carcinoma, leukemia, skin cancer, soft tissue cancer, liver cancer, gastrointestinal cancer, or adenocarcinoma. In some embodiments, the compounds, salts, or compositions can be used in methods for treating metastatic renal cancer, chronic lymphocytic leukemia, pancreatic adenocarcinoma, or non-small cell lung cancer.
[0497] ATF6α transcriptional targets are expressed at high levels in cancer cells. For example, there is a correlation between intracellular GRP78 levels and tumor size (Cai, JW et al., J Cell Physiol, 1993, 154(2):229-37). Furthermore, when GRP78 / BiP expression is experimentally suppressed in cancer cells that are then injected into mice, the cells are unable to form tumors due to increased sensitivity to cytotoxic T cell (CTL) responses and tumor necrosis factor (TNF) (Jamora, C. et al., Proc Natl Acad Sci USA, 1996, 93(15):7690-7694; Sugawara, S. et al., Cancer Res, 1993, 53(24):6001-6005).
[0498] Cancer cells in cellular dormancy lack proliferation markers and exist in a dormant state. Cells known to undergo cellular dormancy include disseminated tumor cells (DTCs) and tumor cells located in the circulation (referred to as circulating tumor cells (CTCs)) (Hensel, JA et al., "Nature Reviews: Clinical Oncology (Nat Rev Clin Oncol)", 2013, 10 (1): 41-51). Minimal residual disease caused by DTC alone is a well-known event associated with poor patient prognosis. DTCs, which are usually negative for proliferation markers (such as Ki67), may be the root cause of tumor recurrence that appears decades after treatment of the primary tumor (Meng, S. et al., "Clin Cancer Res (Clin Cancer Res)", 2004, 10 (24): 8152-8162). It has been reported that ATF6α is a transduction survival signal of dormant cancer cells through the ATF6α-Rheb-mTOR pathway (Schewe, DM et al., Proc Natl Acad Sci USA, 2008, 105(30): 10519-10524). ATF6α signaling is important for preventing ER and low glucose stress, and the interaction between ATF6α and mTOR signaling appears to confer resistance to doxorubicin and the mTOR inhibitor rapamycin in dormant cancer cells, revealing a possible mechanism of drug resistance (Schewe, DM et al., Proc Natl Acad Sci USA, 2008, 105(30): 10519-10524).
[0499] In addition, multiple cancer studies have shown that ATF6 expression is higher in cancer metastases than in primary lesions, and that colon cancer patients with increased ATF6α expression in primary tumors have a higher chance of recurrence (Ramaswamy, S. et al., Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(26):15149-15154).
[0500] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods of treating cancer in an individual, wherein one or more cancer cells in the individual are dormant cancer cells. In some embodiments, one or more of the dormant cancer cells are disseminated tumor cells or circulating tumor cells. In some embodiments, one or more of the dormant cancer cells are disseminated tumor cells.
[0501] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, may be used in methods for treating cancer in an individual, wherein the individual has undergone prior treatment. In some embodiments, the cancer is resistant to prior treatment or is refractory to prior treatment. In some embodiments, the cancer has progressed after prior treatment. In embodiments, the cancer is a recurrent cancer. In some embodiments, prior treatment is with a ubiquitin-proteasome pathway inhibitor (e.g., bortezomib), a taxane (e.g., paclitaxel or docetaxel), a Cox-2 inhibitor (e.g., celecoxib), a platinum anti-tumor drug (e.g., cisplatin or oxaliplatin), an anthracycline (e.g., doxorubicin), a pyrimidine analog (e.g., 5-fluorouracil or gemcitabine), a topoisomerase inhibitor (e.g., etoposide), an mTOR inhibitor (e.g., rapamycin), an immune checkpoint inhibitor, or an agent used in immuno-oncology. In some embodiments, the cancer is resistant to treatment with a ubiquitin-proteasome pathway inhibitor (e.g., bortezomib), a taxane (e.g., paclitaxel or docetaxel), a Cox-2 inhibitor (e.g., celecoxib), a platinum anti-tumor drug (e.g., cisplatin or oxaliplatin), an anthracycline (e.g., doxorubicin), a pyrimidine analog (e.g., 5-fluorouracil or gemcitabine), a topoisomerase inhibitor (e.g., etoposide), an mTOR inhibitor (e.g., rapamycin), an immune checkpoint inhibitor, or an agent used in immuno-oncology. In some embodiments, the cancer is resistant to treatment with doxorubicin and / or rapamycin.
[0502] In some embodiments, administration of the compound, salt, or composition reduces tumor growth, tumor proliferation, or tumor formation in an individual. In some embodiments, the compound, salt, or composition can be used in a method of reducing tumor growth, tumor proliferation, or tumor formation in an individual in need thereof. In some embodiments, tumor growth is slowed or arrested. In some embodiments, tumor growth is reduced by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In some embodiments, tumor size is reduced. In some embodiments, tumor size is reduced by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In some embodiments, tumor metastasis is prevented or slowed. In some embodiments, the tumor growth, tumor proliferation, or tumor formation is compared to the tumor growth, tumor proliferation, or tumor formation in the individual before administration of the compound, salt, or composition. In some embodiments, the tumor growth, tumor proliferation, or tumor formation is compared to the tumor growth, tumor proliferation, or tumor formation in a similar individual or a group of individuals. Methods for measuring tumor growth, tumor proliferation, and tumor formation are known in the art, for example, by repeatedly imaging an individual.
[0503] It is also believed that the compounds of the present invention or its salt effectively inhibit angiogenesis. The activation of ATF6 and PERK affects the survival effect of vascular endothelial growth factor (VEGF) on endothelial cells (EC) by positively regulating the AKT phosphorylation mediated by mTORC2 on Ser473 (this is required for the full activity of AKT). In mouse matrix gel plugs (standard angiogenesis analysis), the depletion of PLCγ, ATF6 or eIF2a significantly inhibits the angiogenesis induced by VEGF in vivo (Karali, E. et al., "Molecular Cell (Molecular Cell)", 2014, 54: 559-572). Therefore, it is believed that the compounds of the present invention or its salt effectively treats various diseases and disorders related to angiogenesis.
[0504] Angiogenesis has been implicated in the pathogenesis of a variety of disease conditions, including solid tumors and cancer metastasis, atherosclerosis, retrolental fibroplasia, hemangiomas, chronic inflammation, intraocular neovascular diseases (e.g., proliferative retinopathies such as diabetic retinopathy, age-related macular degeneration (AMD), neovascular glaucoma), immune rejection of transplanted corneal and other tissues, rheumatoid arthritis, and psoriasis. Thus, in some embodiments, the compounds and compositions of the present invention are used in methods of treating cancer, such as any of the cancers described herein, unwanted or abnormal hypertrophy, arthritis, rheumatoid arthritis (RA), psoriasis, psoriatic plaques, sarcoidosis, atherosclerosis, atherosclerotic plaques, diabetic and other proliferative retinopathy (including retinopathy of prematurity), retrolental fibrous membrane proliferation, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, corneal neovascularization, corneal transplant neovascularization, corneal transplant rejection, retinal / choroidal neovascularization, gonioangiogenesis (rubeosis iridis), ocular neovascular diseases, vascular restenosis, arteriovenous malformation (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasia (including Grave's disease), disease), corneal and other tissue transplants, chronic inflammation, lung inflammation, acute lung injury / ARDS, sepsis, primary pulmonary hypertension, malignant pulmonary effusions, cerebral edema (e.g., associated with acute stroke / closed head injury / trauma), synovitis, pannus formation in RA, myositis ossificans, hypertrophic bone formation, osteoarthritis (OA), refractory ascites, polycystic ovary disease, endometriosis, 3rd fluid compartment disease (pancreatitis, compartment syndrome, gluteal disease, enteropathy), uterine fibroids, premature birth, chronic inflammatory diseases such as IBD (Crohn's disease and ulcerative colitis), renal allograft rejection, inflammatory bowel disease, nephrotic syndrome, unwanted or abnormal tissue mass growth (non-cancerous), hemorrhagic joints, hypertrophic scarring, hair growth inhibition, Osler-Weber syndrome syndrome), pyogenic granuloma retrolental fibroplasia, scleroderma, trachoma, vascular adhesions, synovitis, dermatitis, preeclampsia, ascites, pericardial effusion (e.g., associated with pericarditis), and pleural effusion.
[0505] The collapse of intestinal barrier defenses in conjunction with microbial flora imbalance is becoming a key contributing factor to several conditions including inflammatory bowel disease, type 1 diabetes, Alzheimer's disease and cancer. Specifically, in colorectal cancer (CRC) patients, high expression levels of ATF6 in tumor tissue are associated with increased tumor size and reduced disease-free survival. On the other hand, altered microbial flora is associated with CRC. These data show the connection between UPR activation, microbial flora and colon tumor formation. A novel relationship between UPR activation and microbial flora-dependent colon tumor formation via ATF6 has been demonstrated. Goblet cell loss and bacterial infiltration into epithelial crypts occur before tumor formation, and antibiotic treatment of nATF6IEC mice significantly reduces tumor burden. In an inducible mouse model of ATF6 activation, the tumor incidence rate was 100% at 26 weeks. Four days after the activated ATF6 induction, bacterial access to colon epithelial cells increased significantly, and cell proliferation increased, suggesting that these changes are early events downstream of ATF6 activation. As assessed by 16S rRNA gene amplicon sequencing at 5 weeks of age, before tumor formation, some researchers have found that the cecal contents of nATF6IEC mice have a dysbiotic microbiome and reduced microbial diversity. This dysbiotic microbiome, when transferred into germ-free nATF6IEC mice, enhances tumor formation compared to control microbiome transferred into nATF6IEC mice. These data suggest that microbial dysbiosis and subsequent STAT3 signaling in epithelial cells significantly influence tumor formation in this model.
[0506] Therefore, in some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods for preventing or treating CRC by inhibiting ATF6, thereby preventing goblet cell loss and dysbiosis. In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods for blocking ATF6 signaling and reversing dysbiosis in a subset of CRC patients to combat tumor progression.
[0507] The ability of the UPR signaling arm to significantly affect ER protein homeostasis and function suggests that the selective activation of these pathways has great potential to alleviate the pathological imbalance of ER protein homeostasis associated with human diseases with diverse causes. Specifically, activation of the ATF6 signaling arm has been shown to be useful for improving the imbalance of ER protein homeostasis and function associated with the disease. Using a chemical genetic approach, stress-independent activation of the ATF6 transcription factor induces protective remodeling of the ER protein homeostasis pathway, thereby selectively reducing the secretion and extracellular aggregation of proteins associated with unstable amyloid disease such as transthyretin and immunoglobulin light chains, and does not significantly affect the secretion of the endogenous proteome (Shoulders et al., 2013; Chen et al., 2014; Cooley et al., 2014; Plate et al., 2016). Therefore, the compounds described herein or their salts or compositions described herein can be used in methods for correcting pathological imbalances in ER protein homeostasis in cells and animal models of protein misfolding and aggregation diseases.
[0508] One aspect of the present invention is based on the unexpected discovery that overexpression of ATF6 in cells prevents cell death, which would otherwise occur when the protein improperly accumulates in the cell. Thus, in some embodiments, the compounds or salts thereof, or compositions described herein, can be used in methods for treating conditions such as Parkinson's disease (PD), which are associated with the abnormal accumulation of molecules that interact with parkin and are not properly disposed of within the cell.
[0509] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods for preventing cell death. For example, the present invention encompasses preventing neuronal cell death, including preventing substantia nigra neuronal death in mammals, including humans.
[0510] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods for treating neurodegenerative diseases associated with abnormal protein precipitation and / or aggregation. For example, the brains of patients with Alzheimer's disease exhibit neurofibrillary tangles (NFTs), senile plaques, and cerebrovascular deposits of amyloid-β; the brains of patients with prion diseases exhibit plaques containing prion protein; the brains of patients with Huntington's disease exhibit huntingtin protein deposits; patients with dominantly inherited spinocerebellar ataxia exhibit deposits of the corresponding ataxia nuclear protein; patients with multiple system atrophy exhibit alpha-synuclein deposits; patients with progressive supranuclear palsy exhibit tau deposits; and patients with familial amyotrophic lateral sclerosis exhibit SOD1 deposits (Johnson, WG, J. Anat. 4:609-616 (2000)). Because so many diseases share common pathological mechanisms, they may share pathways that lead to abnormal protein aggregation and / or precipitation (Hardy, J. and Gwinn-Hardy, K., Science 282(5391): 1075-1079 (1998)).
[0511] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods as stand-alone therapies or as a combination therapy with other palliative agents (e.g., agents that alleviate the symptoms of the disorder to be treated) and / or agents that target the cause of the disorder. For example, administering to a subject a composition that increases ATF6 expression can be combined with administration of L-DOPA, a dopamine agonist, a monoamine oxidase B inhibitor, or any other composition useful for treating neurodegenerative diseases such as Parkinson's disease.
[0512] In a mouse model of ischemic heart disease, overexpression of the active ATF6 transcription factor in the heart was also shown to improve cardiac performance through a mechanism involving ATF6-dependent regulation of the antioxidant gene catalase (Jin et al., 2017). Similarly, overexpression of the active ATF6 transcription factor in the liver improved insulin sensitivity in obese mice (Ozcan et al., 2016). These results suggest that ATF6 activation offers a unique therapeutic opportunity to improve defects in ER proteostasis associated with a variety of diseases.
[0513] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods of enhancing myocardial recovery from I / R injury, particularly by activating the endogenous adaptive ATF6 gene program in the heart.
[0514] The ATF6α pathway also plays a role in stress-induced lipid accumulation. p50ATF6 interacts with the nuclear form of SREBP-2, thereby antagonizing the transcription of SREBP-2-regulated lipogenic genes and lipid accumulation in cultured hepatocytes and kidney cells. In addition, in response to pharmacological induction of ER stress, Atf6α-deficient mice exhibited much longer-lasting liver dysfunction and steatosis than wild-type mice. This could be explained by the long-term expression of CHOP and the sustained repression of C / EBPα and / or the failure of ATF6α-mediated induction, trafficking and ERAD function of genes encoding protein chaperones. When fed a HFD, Atf6α - / - Mice develop hepatic steatosis and glucose intolerance, as well as increased expression of SREBP-1c. On the other hand, overexpression of the functionally active nuclear fragment of ATF6 in zebrafish induces fatty liver, suggesting that fine-tuning of ATF6α may be important for preventing hepatic steatosis.
[0515] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods of treating metabolic disorders, such as obesity, type I and type II diabetes, pancreatitis, dyslipidemia, hyperlipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, renal disease, diabetic complications, neuropathy, gastroparesis, disorders associated with severe inactivating mutations in the insulin receptor, and other metabolic disorders.
[0516] In some embodiments, the compounds described herein, or salts thereof, or compositions described herein, can be used in methods of treating ischemic heart disease or myocardial recovery from ischemia / reperfusion (I / R).
[0517] According to the present disclosure, in some embodiments, the subject is a mammal. In some embodiments, the subject is a primate, bovine, ovine, porcine, equine, canine, feline, rabbit, or rodent. In some embodiments, the subject is a human. In some embodiments, the subject suffers from any of the diseases or conditions disclosed herein. In some embodiments, the subject is at risk of developing any of the diseases or conditions disclosed herein.
[0518] Also provided herein are uses of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein, in the manufacture of a medicament. In some embodiments, the medicament is used to treat a condition or disease described herein. In some embodiments, the medicament is used to prevent and / or treat a condition or disease mediated by the ATF6 pathway, ATF6, or ATF6α.
[0519] Combination therapy
[0520] As provided herein, the compounds described herein, or salts thereof, and compositions described herein can be administered with an agent to treat any of the diseases and conditions disclosed herein. In some embodiments, the agent modulates the unfolded protein response or the integrated stress response. In some embodiments, the agent is an anti-angiogenic agent. In some embodiments, the agent is an anticancer agent. In some embodiments, the agent targets an immune checkpoint protein.
[0521] In some embodiments, (a) a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein and (b) the agent are administered sequentially, concurrently, or simultaneously. In certain embodiments, (a) a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein and (b) the agent are administered at an interval of about 15 minutes or less, such as at an interval of about 10 minutes, 5 minutes, or 1 minute or less. In certain embodiments, (a) a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein and (b) the agent are administered at an interval of about 15 minutes or more, such as at an interval of about 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes, or more. (a) a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein and (b) the agent may be administered first. In certain embodiments, (a) a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein and (b) the agent are administered simultaneously.
[0522] In some embodiments, the agent regulates the unfolded protein response or the integrated stress response. In some embodiments, the agent inhibits the unfolded protein response or the integrated stress response. In some embodiments, the agent regulates the PERK pathway. In some embodiments, the agent inhibits the PERK pathway. In some embodiments, the agent inhibits PERK. It is known that ATF6 works in collaboration with IRE1 because one of the target genes of ATF6 is a key substrate of XBP1-IRE1 (Yoshida, H. et al., Cell, 2001, 107(7):881-891), so for example, ATF6 and IRE1 signaling are important for the survival of melanoma cells undergoing ER stress, which suggests the potential benefits of combining ATF6 inhibitors with IRE1 inhibitors (Tay, KH et al., Cell Signal, 2014, 26(2):287-294). Therefore, in some embodiments, the agent regulates the IRE1 / XBP1 pathway. In some embodiments, the agent inhibits the IRE1 / XBP1 pathway. In some embodiments, the agent inhibits IRE1 or XBP1.
[0523] In some embodiments, the agent is an anti-angiogenic agent. It is believed that the compounds of the present invention or their salts are effective in inhibiting angiogenesis and treating diseases and conditions related to angiogenesis. Therefore, provided herein is a method of inhibiting angiogenesis, the method comprising administering to an individual (a) a compound as described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein and (b) an anti-angiogenic agent. Also provided herein is a method of treating a disease or condition related to angiogenesis, such as any disease or condition related to angiogenesis disclosed herein, the method comprising administering to an individual (a) a compound as described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein and (b) an anti-angiogenic agent. In some embodiments, the anti-angiogenic agent is a VEGF antagonist. In some embodiments, the anti-angiogenic agent is bevacizumab or ranibizumab.
[0524] The role of angiogenesis as a mediator of immune regulation within the tumor microenvironment has recently become increasingly clear. Furthermore, emerging evidence suggests that immunotherapy can induce immune-mediated vasculopathy in tumors, suggesting that tumor vasculature may be an important interface between the tumor-directed immune response and the cancer itself. The introduction of immune checkpoint inhibition as an effective immunotherapy strategy for many cancers has led to a better understanding of this interface. Initial studies of the complex relationship between angiogenesis, VEGF signaling, and the immune system suggest that the combination of immune checkpoint blockade and angiogenesis inhibition has the potential to enhance the efficacy of immunotherapy and will broadly impact the future of oncology. The role of ATF6 beyond VEGF signaling strengthens the idea of combining ATF6 inhibitors with immune checkpoint inhibitors (Ott, PA, FS Hodi, and EI Buchbinder, Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol, 2015. 5: p. 202).
[0525] Thus, in some embodiments, the agent targets an immune checkpoint protein. In some embodiments, the agent is an antibody targeting an immune checkpoint protein. In some embodiments, the agent targets PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, CCR4, OX40, OX40L, IDO, and A2AR. In some embodiments, the agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[0526] Provided herein is a method for enhancing an immune response in an individual, comprising administering to the individual (a) a compound as described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein and (b) an agent targeting an immune checkpoint protein. In some embodiments, the individual has cancer. In some embodiments, the enhanced immune response is directed against a tumor or cancer cell.
[0527] Also provided herein are methods of treating cancer in an individual in need thereof, comprising administering to the individual (a) a compound described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein and (b) an agent that targets an immune checkpoint protein, wherein the individual has an increased immune response.
[0528] In some embodiments, the agent is an anticancer agent. In some embodiments, the anticancer agent is an ubiquitin-proteasome pathway inhibitor (e.g., bortezomib), a taxane (e.g., paclitaxel or docetaxel), a Cox-2 inhibitor (e.g., celecoxib), a platinum anti-tumor drug (e.g., cisplatin or oxaliplatin), an anthracycline (e.g., doxorubicin), a pyrimidine analog (e.g., 5-fluorouracil or gemcitabine), a topoisomerase inhibitor (e.g., etoposide), or an agent that regulates an unfolded protein response or an integrated stress response (e.g., an IRE1 / XBP1 inhibitor or a PERK inhibitor). In some embodiments, the anticancer agent is oxaliplatin, 5-fluorouracil, or gemcitabine. In some embodiments, the anticancer agent is an immune checkpoint inhibitor or an agent used in immuno-oncology.
[0529] In some embodiments, an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein, is administered to an individual having cancer to increase sensitivity to one or more anti-cancer therapies.
[0530] Therapeutic resistance is a major barrier to improved outcomes in cancer patients. Radiation induces ER stress and its downstream signaling and appears to be associated with changes in the ROS balance secondary to irradiation. Previously, blocking ATF6 gene expression was sufficient to enhance radioactively induced cell death (Dadey, DY et al., Oncotarget, 2016, 7(2): 2080-2092). This suggests that ATF6 has become a potential therapeutic target to enhance the efficacy of radiotherapy.
[0531] In some embodiments, an effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein is administered to an individual with cancer to increase sensitivity to radiation. In some embodiments, provided herein are methods of treating cancer in an individual in need thereof, comprising administering to the individual (a) a compound as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein and (b) radiation.
[0532] In some embodiments, an effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein, is administered to an individual suffering from cancer to increase sensitivity to one or more anticancer agents. In some embodiments, the anticancer agent is an ubiquitin-proteasome pathway inhibitor (e.g., bortezomib), a taxane (e.g., paclitaxel or docetaxel), a Cox-2 inhibitor (e.g., celecoxib), a platinum anti-tumor drug (e.g., cisplatin or oxaliplatin), an anthracycline (e.g., doxorubicin), a pyrimidine analog (e.g., 5-fluorouracil or gemcitabine), a topoisomerase inhibitor (e.g., etoposide), or an agent (e.g., IRE1 / XBP1 inhibitor or PERK inhibitor) that regulates an unfolded protein response or an integrated stress response. In some embodiments, the anticancer agent is oxaliplatin, 5-fluorouracil or gemcitabine. In some embodiments, the anticancer agent is an immune checkpoint inhibitor or an agent used in immuno-oncology.
[0533] Provided herein is a method for treating a metabolic and / or fibrotic disease in an individual, the method comprising administering to the individual (a) a compound as described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein and (b) a medicament. In some embodiments, the medicament is a proteasome inhibitor, such as bortezomib, carfilzomib, and ixazomib. In some embodiments, the medicament is a monoclonal antibody, such as daratumumab and elotuzumab. In some embodiments, the medicament is a histone deacetylase (HDAC) protein inhibitor, such as panobinostat, romidepsin, and vorinostat. In some embodiments, the medicament is an immunomodulatory drug (IMiD), such as thalidomide, lenalidomide, and pomalidomide. In some embodiments, the agent is an adrenocortical steroid, such as dexamethasone, prednisone, prednisolone, and methylprednisolone. In some embodiments, the agent is a therapy targeting IRE1-XBP1.
[0534] Dosage and administration method
[0535] The dosage of a compound administered to an individual (e.g., a human) may vary depending on the specific compound or salt thereof, the method of administration, and the specific disease being treated, such as the type and stage of cancer. In some embodiments, the amount of the compound or salt thereof is a therapeutically effective amount.
[0536] On the one hand, the effective amount of compound can be the dosage between about 0.01 and about 100mg / kg.The effective amount of the compounds of this invention or dosage can be by conventional methods, such as simulation, dose escalation or clinical trial, considering the following factors to determine: the mode or approach of administration or drug delivery, the pharmacokinetics of medicament, the severity of disease to be treated and the course of disease, the health status, condition and weight of experimenter.Exemplary dosage is about in the range of about 0.1mg to 10g every day.
[0537] In one aspect, any of the methods provided herein can comprise administering to a subject a pharmaceutical composition containing an effective amount of a compound provided herein or a salt thereof and a pharmaceutically acceptable excipient.
[0538] The compound or composition of the present invention can be administered to an individual according to an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, and in some variations, the duration of a sustainable individual's life is administered. In one variation, the compound is administered according to a daily or intermittent schedule. The compound can be administered to an individual continuously (e.g., at least once a day) over a period of time. The frequency of administration can also be less than once a day, such as approximately once a week. The frequency of administration can exceed once a day, such as twice or three times a day. The frequency of administration can also be intermittent, including 'drug holiday' (e.g., once a day, for 7 days, followed by 7 days of drug withdrawal, repeating any 14-day period, such as approximately 2 months, approximately 4 months, approximately 6 months, or longer). Any frequency of administration can be used with any compound described herein and any dosage described herein.
[0539] The compounds or salts thereof provided herein can be administered to an individual via various routes, including, for example, intravenous, intramuscular, subcutaneous, oral, and transdermal administration. In some embodiments, the compound or composition is administered orally. The compounds provided herein can be frequently administered at low doses, referred to as 'metronomic therapy', or administered as part of a maintenance therapy using a compound alone or in combination with one or more other drugs. Metronomic therapy or maintenance therapy may include cyclic administration of the compounds provided herein. Metronomic therapy or maintenance therapy may include intratumoral administration of the compounds provided herein.
[0540] The present invention also provides compositions (including pharmaceutical compositions) for treating, preventing and / or delaying the onset and / or development of the diseases described herein, as described herein, and other methods described herein.In certain embodiments, the composition comprises a pharmaceutical formulation in unit dosage form.
[0541] Products and kits
[0542] The present disclosure further provides an article of manufacture comprising a compound disclosed herein or a salt thereof, a composition described herein, or a unit dose described herein in suitable packaging. In certain embodiments, the article of manufacture is used in any of the methods described herein. Suitable packaging is known in the art and includes, for example, vials, containers, ampoules, bottles, jars, flexible packaging, and the like. The article of manufacture may further be sterilized and / or sealed.
[0543] The present disclosure further provides kits for performing the disclosed methods, the kits comprising one or more compounds described herein or compositions comprising compounds described herein. The kits may employ any of the compounds disclosed herein. In one variation, the kits employ a compound described herein or a pharmaceutically acceptable salt thereof. The kits may be used for any one or more of the uses described herein and, therefore, may contain instructions for treating a disease described herein, such as cancer.
[0544] The kit generally comprises suitable packaging. The kit may include one or more containers containing any of the compounds described herein. Each component (if more than one component is present) may be packaged in a separate container, or, where cross-reactivity and shelf life permit, some components may be combined in one container.
[0545] The kit may be in unit dosage form, in bulk (e.g., multi-dose packaging), or in subunit dosage form. For example, a kit may be provided that contains a sufficient dose of a compound as disclosed herein and / or a second pharmaceutically active compound useful for a disease described in detail herein (e.g., hypertension) to provide effective treatment to an individual for an extended period of time, such as one week, two weeks, three weeks, four weeks, six weeks, eight weeks, three months, four months, five months, seven months, eight months, nine months, or more. The kit may also include multiple doses of the compound and instructions for use, and may be packaged in an amount sufficient to store and use in a pharmacy (e.g., a hospital pharmacy or a compounding pharmacy).
[0546] The kit may optionally include a set of instructions, generally written instructions, although electronic storage media (e.g., magnetic or optical disks) containing instructions for use of the components of the method of the invention are also acceptable. The instructions included in the kit generally include information about each component and its administration to a subject.
[0547] The present invention may be further understood with reference to the following examples, which are provided for purposes of illustration and are not intended to be limiting.
[0548] Examples
[0549] Synthesis Example
[0550] The following examples are provided to illustrate, but not to limit, the present disclosure. One skilled in the art will recognize that the following synthetic reactions and schemes can be modified by selecting appropriate starting materials and reagents to obtain other compounds of Formula (A), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), or (Ik), or salts thereof. The compounds are prepared using the general methods described above.
[0551] The following abbreviations are used throughout the Examples: DCM (dichloromethane), DIAD (diisopropyl azodicarboxylate), DIPEA or DIEA (N,N-diisopropylethylamine), DMF (N,N-dimethylformamide), DMSO (dimethyl sulfoxide), HATU ((1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate), HPLC (high pressure liquid chromatography), IPA (isopropyl alcohol), LCMS (liquid chromatography mass spectrometry), NMR (nuclear magnetic resonance), PPh3 (triphenylphosphine), RT (room temperature), TEA (triethylamine), THF (tetrahydrofuran), and TLC (thin layer chromatography).
[0552] Example S1. Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (Compound 1)
[0553]
[0554] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)phenyl)ethan-1-ol. To a stirred solution of 2,4-bis(trifluoromethyl)benzaldehyde (500 mg, 2.06 mmol, 1 eq) in THF (5 mL) was added ethylmagnesium bromide (412 mg (3 ml), 3.09 mmol, 1.5 eq) portionwise at room temperature and the reaction was stirred for 10 minutes. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and NMR. After the reaction was complete, the reaction mixture was quenched with water and extracted with ethyl acetate (50 mL x 3). The combined organic extracts were washed with water (50 mL x 2), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)phenyl)ethan-1-ol (110 gm, 19% as a colorless liquid). 1 H NMR (400MHz, DMSO-d6) δ = 8.13-8.06 (m, 1H), 8.05-7.99 (m, 1H), 7.94 (s, 1H), 4.80 (br.s., 1H), 1.65-1.52 (m, 2H), 0.92 (t, J = 7.2Hz, 3H).
[0555] Step 2: Synthesis of 1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-4-nitro-1H-pyrazole. To a stirred solution of PPh3 (196 mg, 0.73 mmol, 1.0 equiv) and DIAD (148 mg, 0.73 mmol, 1.0 equiv) in THF (2 mL) was added 1-(2,4-bis(trifluoromethyl)phenyl)ethan-1-ol (200 mg, 0.73 mmol, 1.0 equiv). After 4-nitro-1H-pyrazole (66 mg, 0.58 mmol, 0.8 equiv) was added dropwise, the reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and LCMS. After the reaction was complete, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 3). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product 1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-4-nitro-1H-pyrazole (200 mg, 76%, as a brown liquid). LCMS: 368 [M+H] + .
[0556] Step 3: Synthesis of 1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-4-nitro-1H-pyrazole (200 mg, 0.54 mmol, 1.0 equiv) in methanol (10 mL) was added palladium on carbon [Pd / C] (46 mg, 10% w / w) under nitrogen, and the reaction mixture was purged with H gas for 2 hours. The product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to give 1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-1H-pyrazol-4-amine (200 mg, 100% as a brown liquid). LCMS: 338 [M+H]. + .
[0557]
[0266] Step 4: Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide. To a solution of 5-(pyridin-2-yl)isoxazole-3-carboxylic acid (60 mg, 0.31 mmol, 1 eq) in DMF (1 mL) was added HATU (132 mg, 0.31 mmol, 1.1 eq). The mixture was treated dropwise with DIPEA (130 mg, 1.01 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-1H-pyrazol-4-amine (106 mg, 0.31 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The product formation was confirmed by TLC and LCMS, and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL x 2). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)propyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (10 mg, 6.2% as a white solid). 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.75(d,J=5.1Hz,1H),8.19(s,1H),8.06(dp,J=15.2,8.1Hz,5H),7.77(s,1H),7.56(t,J=6.0 Hz,1H),7.46(s,1H),5.62(dd,J=9.1,5.8Hz,1H),2.44(dd,J=15.2,7.9Hz,0H),2.12(dp,J=13.6,6.7Hz,1H),0.86(t,J=7.4Hz,3H). LCMS:510[M+H] +
[0558] Example S2. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(2-hydroxypropan-2-yl)isoxazole-3-carboxamide (Compound 2)
[0559]
[0560] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. 4-Nitro-1H-pyrazole (0.73 g, 0.006 mol, 1 eq) was dissolved in DMF (20 mL). The reaction mixture was cooled to 0°C with ice water, and KCO (1.34 g, 0.009 mol, 1.5 eq) was added portionwise to the stirred reaction mixture over 10 minutes and then 1-(bromomethyl)-2,4-bis(trifluoromethyl)benzene (2.0 g, 0.006 mol, 1 eq) was added dropwise. The above reaction mixture was stirred for 1 hour (the reaction was monitored by TLC and LCMS). After the reaction was complete, the reaction mixture was diluted with ethyl acetate (50 mL) and extracted with water (50 mL). The organic layer was collected and concentrated to obtain the product, which was further purified by flash chromatography to obtain a white product. LCMS: 339 [M+H] + .
[0561] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (2 gm, 1 equivalent) in methanol (20 mL) was added palladium on carbon [Pd / C] (10 wt %) under nitrogen and the reaction mixture was purged with hydrogen for 2 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated to obtain the product, which was purified by flash chromatography to give a brown viscous liquid. LCMS: 309 [M+H] + .
[0562] Step 3: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine hydrochloride. 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine (1 gm) was dissolved in ethanol. 20 ml of HCl in ethanol (15 ml) was added at 0°C and stirred at room temperature for half an hour. The resulting suspension was filtered. The residue was triturated with diethyl ether to obtain the product, 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine hydrochloride. LCMS: 309 [M+H]. + .
[0563] Step 4: Synthesis of 5-acetyl-N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)isoxazole-3-carboxamide. 5-Acetylisoxazole-3-carboxylic acid (500.0 mg, 1 eq., 3.22 mmol) was dissolved in 5 ml of DMF. HATU (1.22 gm, 1 eq., 3.22 mmol) was added. DIPEA (832.25 mg, 2 eq., 6.45 mmol) was added. The reaction mixture was stirred for 20 minutes. 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine hydrochloride (1.112 gm, 1 eq., 3.22 mmol) was added. The reaction mixture was stirred for 24 hours. The mixture was worked up by adding water and recovered with ethyl acetate. The crude material was purified by trituration with IPA. LCMS: 446 [M+H]. + .
[0564] Step 5: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(2-hydroxypropan-2-yl)isoxazole-3-carboxamide. 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine hydrochloride (200.0 mg, 1 equivalent, 0.447 mmol) was dissolved in THF at 0°C. A 3M solution of methylmagnesium bromide (70.99 mg, 4 equivalents, 1.789 mmol) in diethyl ether was added at 0°C. The reaction mixture was stirred at 0°C for half an hour. The reaction was quenched with ammonium chloride solution and recovered with ethyl acetate. The resulting residue was prepared for purification. 1 H NMR(400MHz,DMSO-d6)δ10.99(br.S.,1H),8.27(s,1H),7.99-8.13(m,2H),7.74(s,1H) ,7.04(d,J=8.33Hz,1H),6.67(s,1H),5.75(br.S.,1H),5.64(br.S.,2H),1.50(s,6H). LCMS:462[M+H] + .
[0565] Example S3. Synthesis of 5-acetyl-N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)isoxazole-3-carboxamide (Compound 3)
[0566]
[0567] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. 4-Nitro-1H-pyrazole (0.73 g, 0.006 mol, 1 eq) was dissolved in DMF (20 mL). The reaction mixture was cooled to 0°C with ice water, and KCO (1.34 g, 0.009 mol, 1.5 eq) was added portionwise. The reaction mixture was stirred for 10 minutes and then 1-(bromomethyl)-2,4-bis(trifluoromethyl)benzene (2.0 g, 0.006 mol, 1 eq) was added dropwise. The above reaction mixture was stirred for 1 hour (the reaction was monitored by TLC and LCMS). After the reaction was completed, the reaction mixture was diluted with ethyl acetate (50 mL) and extracted with water (50 mL). The organic layer was collected and concentrated to obtain the product, which was further purified by flash chromatography to obtain a white product. LCMS: 339 [M+H] + .
[0568] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (2 gm, 1 equivalent) in methanol (20 mL) was added palladium on carbon [Pd / C] (10 wt %) under nitrogen and the reaction mixture was purged with hydrogen for 2 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated to obtain the product, which was purified by flash chromatography to give a brown viscous liquid. LCMS: 309 [M+H] + .
[0569] Step 3: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine hydrochloride. 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine (1 gm) was dissolved in ethanol. 20 ml of HCl in ethanol (15 ml) was added at 0°C and stirred at room temperature for half an hour. The resulting suspension was filtered. The resulting residue was triturated with diethyl ether to obtain the product, 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine hydrochloride. LCMS: 309 [M+H]. + .
[0570] Step 4: Synthesis of 5-acetyl-N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)isoxazole-3-carboxamide. 5-Acetylisoxazole-3-carboxylic acid (200.0 mg, 1 equivalent, 1.29 mmol) was dissolved in 3 ml of DMF. HATU (491.4 mg, 1 equivalent, 1.29 mmol) was added. DIPEA (332.8 mg, 2 equivalents, and 2.58 mmol) was added. The reaction mixture was stirred for 20 minutes. 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine hydrochloride (445.1 mg, 1 equivalent, 1.29 mmol) was added. The resulting reaction mixture was stirred for 24 hours. The mixture was worked up by adding water and recovered with ethyl acetate, and the resulting crude material was purified by trituration with IPA. 1 H NMR(400MHz,DMSO-d6)δ11.23(br.s.,1H),8.32(s,1H),7.96-8.16(m,2H),7.78( s,1H),7.72(s,1H),7.06(d,J=7.89Hz,1H),5.67(br.s.,2H),2.57-2.67(m,3H). LCMS:446[M+H] + .
[0571] Example S4. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxamide formate (Compound 4 formate)
[0572]
[0573] Step 1: Synthesis of (Z)-3-fluoro-N'-hydroxybenzimidamide. 3-Fluorobenzonitrile (3.0 gm, 1 eq., 0.024 mol) was dissolved in nTHF:MeOH (1:1). NH2OH.HCl (1.5 eq., 2.60 gm, and 0.037 mol) was added. TEA (3.5 eq., 12.08 ml, and 0.086 mol) was added. The reaction mixture was kept at room temperature for 24 hours. The reaction mixture was worked up by evaporating to dryness. 20% MeOH / DCM was then added and the resulting suspension was filtered. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give the product, (Z)-3-fluoro-N'-hydroxybenzimidamide (2.5 g), as a white solid. LCMS: 154 [M+H]+.
[0574] Step 2: Synthesis of ethyl 3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxylate. (Z)-3-Fluoro-N'-hydroxybenzimidamide (2.0 gm, 1 eq., 0.0129 mol) was dissolved in 15 ml of THF. Ethyl 2-chloro-2-oxoacetate (3.5 gm, 2 eq., 0.0259 mol) was added thereto at 0°C and the reaction mixture was stirred at room temperature for 15 minutes. Thereafter, the reaction was stirred at 70°C for 30 hours. The mixture was quenched with water and recovered with ethyl acetate. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give the product, ethyl 3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxylate (2.1 g), as a yellow liquid. LCMS: 236 [M+H] + .
[0575] Step 3: Synthesis of sodium 3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxylate (5). Ethyl 3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxylate (1 equivalent, 1 gm, 0.004 mol) was dissolved in 5 ml of methanol. NaOH (1 equivalent, 169 mg, and 0.004 mol) was added thereto and kept at room temperature for 2 hours. The reaction was worked up by evaporating MeOH. The crude material obtained was triturated with ether to obtain the product, sodium 3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxylate (600 mg) as a white crystalline solid.
[0576] Step 4: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxamide formate. Sodium 3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxylate (100 mg, 1 equivalent, 0.434 mmol) was dissolved in DCM (2 ml). Oxalyl chloride (164.3 mg, 3 equivalents, 1.30 mmol) was added at 0°C. One drop of DMF was added. After 15 minutes, the reaction mixture was stirred for 1 hour at room temperature. The reaction mixture was dried under vacuum to obtain 3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carbonyl chloride. Separately, 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine (147.7 mg, 1.1 equivalents, 0.478 mmol) was dissolved in DCM (2 ml). TEA (6 equivalents, 0.36 ml, and 2.604 mmol) was added, and the mixture was stirred at room temperature for half an hour. This reaction mixture was added to 3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carbonyl chloride. The reaction mixture was stirred at room temperature for 24 hours. The reaction was worked up by adding water and recovered with ethyl acetate. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified. The product, N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3-(3-fluorophenyl)-1,2,4-oxadiazole-5-carboxamide formate (12 mg), was obtained. 1 H NMR (400MHz, DMSO-d6) δ8.45(s,1H),8.40(s,1H),8.08(d,J=7.6Hz,2H),7.96(d,J=7. 7Hz,1H),7.86(d,J=9.1Hz,2H),7.75-7.65(m,1H),7.53(td,J=8.7,2.9Hz,1H),7.06( d,J=8.2Hz,1H),6.90(s,1H),5.69(s,2H),2.39(s,0H),1.52(d,J=19.7Hz,1H),1.23( s, 6H), 1.04 (d, J = 5.0Hz, 0H), 0.84 (q, J = 10.8, 8.5Hz, 1H), 0.07 (s, 0H), -0.07 (s, 1H). LCMS:499[M+H] + .
[0577] Example S5. Synthesis of (S)- and (R)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (Compounds 5 and 6)
[0578]
[0579] Step 1: Synthesis of 1-[2,4-bis(trifluoromethyl)phenyl]ethanol. To a stirred solution of 1-[2,4-bis(trifluoromethyl)phenyl]ethanone (1 gm, 0.003 mol, 1.0 equiv) in methanol (5 mL) was added portionwise NaBH4 (0.216 gm, 0.005 mol, 1.2 equiv) at 0°C and stirred for 10 minutes. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and LCMS. After completion of the reaction, the reaction mixture was quenched with water and extracted with ethyl acetate (50 mL x 3). The combined organic extracts were washed with water (50 mL x 2), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-[2,4-bis(trifluoromethyl)phenyl]ethanol (1 gm, 100% (crude) as a colorless liquid). 1 H NMR (400MHz, DMSO-d6) δ 8.04-8.15 (m, 2H), 7.93 (s, 1H), 5.70 (d, J = 3.95Hz, 1H), 5.09 (br.s., 1H), 1.34 (d, J = 6.14Hz, 3H).
[0580] Step 2: Synthesis of 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-4-nitro-1H-pyrazole. To a stirred solution of PPh3 (517 mg, 1.93 mmol, 1.0 equiv) and DIAD (319 mg, 1.93 mmol, 1.0 equiv) in THF (2 mL) was added 4-nitro-1H-pyrazole (175 mg, 1.55 mmol, 0.8 equiv), and then 1-[2,4-bis(trifluoromethyl)phenyl]ethanol (500 mg, 1.93 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and LCMS. After the reaction was complete, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 3). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-4-nitro-1H-pyrazole (550 mg, 84%, as a brown liquid). LCMS: 354 [M+H] + .
[0581] Step 3: Synthesis of 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (500 mg, 1.41 mmol, 1.0 equiv) in methanol (10 mL) was added palladium on carbon [Pd / C] (75 mg, 10% w / w) under nitrogen, and the reaction mixture was purged with H gas for 2 hours. The product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to obtain 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine (450 mg, 100% (crude) as a brown liquid). LCMS: 324 [M+H]. + .
[0582]
[0266] Step 4: Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide. To a solution of 5-(pyridin-2-yl)isoxazole-3-carboxylic acid (200 mg, 1.11 mmol, 1 eq) in DMF (1 mL) was added HATU (467 mg, 1.22 mmol, 1.1 eq). The mixture was treated dropwise with DIPEA (461 mg, 3.57 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-{1[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine (360 mg, 1.11 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The product was confirmed to be formed by TLC and LCMS and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (70 mg, 26% as an off-white solid). LCMS: 496 [M+H] + .
[0583] Step 5: A racemic mixture of (S) and (R)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide. N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (70 mg) was purified by chiral HPLC to obtain single enantiomers as Enantiomer A (18 mg) and Enantiomer B (20 mg). (Enantiomer A): 1 H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.76 (d, J = 4.7 Hz, 1H), 8.20 (s, 1H), 8.12-7.99 (m, 4H), 7.74 (d, J = 8.6 Hz, 1H), 7.56 (dd, J = 7.5, 4.8 Hz, 1H), 7.47 (s, 1H), 5.94 (q, J = 6.8 Hz, 1H), 1.88 (d, J = 6.9 Hz, 3H). (Enantiomer B): 1 H NMR (400MHz, DMSO-d6) δ11.09 (s, 1H), 8.76 (d, J = 4.6Hz, 1H), 8.20 (s, 1H), 8.12-7.96 (m, 4H), 7.7 4(d,J=8.9Hz,1H),7.60-7.52(m,1H),7.47(s,1H),5.94(q,J=6.9Hz,1H),1.88(d,J=6.8Hz,3H).
[0584] Example S6. Synthesis of (S)- and (R)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compounds 7 and 8)
[0585]
[0586] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)phenyl)ethan-1-ol. To a stirred solution of 1-(2,4-bis(trifluoromethyl)phenyl)ethan-1-one (1 gm, 0.003 mol, 1.0 equiv) in methanol (5 mL) was added portionwise NaBH4 (0.216 gm, 0.005 mol, 1.2 equiv) at 0°C and stirred for 10 minutes. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and NMR. After completion of the reaction, the reaction mixture was quenched with water and extracted with ethyl acetate (50 mL x 3). The combined organic extracts were washed with water (50 mL x 2), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)phenyl)ethan-1-ol (1 gm, 100% as a colorless liquid). 1 H NMR (400MHz, DMSO-d6) δ 8.04-8.15 (m, 2H), 7.93 (s, 1H), 5.70 (d, J = 3.95Hz, 1H), 5.09 (br.s., 1H), 1.34 (d, J = 6.14Hz, 3H).
[0587] Step 2: Synthesis of 1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-4-nitro-1H-pyrazole. To a stirred solution of PPh3 (517 mg, 1.93 mmol, 1.0 equiv) and DIAD (319 mg, 1.93 mmol, 1.0 equiv) in THF (2 mL) was added 1-(2,4-bis(trifluoromethyl)phenyl)ethan-1-ol (500 mg, 1.93 mmol, 1.0 equiv). 4-nitro-1H-pyrazole (175 mg, 1.55 mmol, 0.8 equiv) was then added dropwise, and the reaction mixture was stirred at room temperature overnight. Product formation was confirmed by TLC and LCMS. After completion of the reaction, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL×3). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product 1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-4-nitro-1H-pyrazole (550 mg, 84%, as a brown liquid). LCMS: 353 [M+H] + .
[0588] Step 3: Synthesis of 1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (500 mg, 1.41 mmol, 1.0 equiv) in methanol (10 mL) was added palladium on carbon [Pd / C] (75 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. The formation of the product was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to afford 1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-amine (450 mg, 100% as a brown liquid). LCMS: 323 [M+H]. + .
[0589]
[0266] Step 4: Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. To a solution of 5-(furan-2-yl)isoxazole-3-carboxylic acid (200 mg, 1.11 mmol, 1 eq) in DMF (1 mL) was added HATU (467 mg, 1.22 mmol, 1.1 eq). The mixture was treated dropwise with DIPEA (461 mg, 3.57 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-{1[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine (360 mg, 1.11 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The product formation was confirmed by TLC and LCMS, and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. (150 mg, 27%, as an off-white solid). LCMS: 484 [M+H] + .
[0590] Step 5: A racemic mixture of (S) and (R)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (mg,) was purified by chiral HPLC to obtain single enantiomers as Enantiomer A (45 mg) and Enantiomer B (40 mg). LCMS: 484 [M+H] + . (Enantiomer A): 1 H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 8.19 (s, 1H), 8.09 (d, J = 8.3 Hz, 1H), 8.05 (s, 1H), 8.00 (s, 1H), 7.73 (d, J = 6.9 Hz, 1H), 7.28 (d, J = 3.6 Hz, 1H), 7.14 (s, 1H), 6.80-6.74 (m, 1H), 5.93 (q, J = 6.9 Hz, 1H), 1.87 (d, J = 6.9 Hz, 3H). (Enantiomer B): 1 H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.18(s,1H),8.08(d,J=8.3Hz,1H),8.04(s,1H),8.00(d,J=1.9Hz,1H),7.73( d,J=7.5Hz,1H),7.28(d,J=3.6Hz,1H),7.14(s,1H),6.80-6.74(m,1H),5.93(q,J=6.9Hz,1H),1.87(d,J=6.9Hz,3H).
[0591] Example S7. Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(thiophen-2-yl)isoxazole-3-carboxamide (Compound 9)
[0592]
[0593] Step 1: Synthesis of 1-[2,4-bis(trifluoromethyl)phenyl]ethanol. To a stirred solution of 1-[2,4-bis(trifluoromethyl)phenyl]ethanone (1 gm, 0.003 mol, 1.0 equiv) in methanol (5 mL) was added portionwise NaBH4 (0.216 gm, 0.005 mol, 1.2 equiv) at 0°C and stirred for 10 minutes. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and LCMS. After completion of the reaction, the reaction mixture was quenched with water and extracted with ethyl acetate (50 mL x 3). The combined organic extracts were washed with water (50 mL x 2), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-[2,4-bis(trifluoromethyl)phenyl]ethanol (1 gm, 100% (crude) as a colorless liquid). 1 H NMR (400MHz, DMSO-d6) δ 8.04-8.15 (m, 2H), 7.93 (s, 1H), 5.70 (d, J = 3.95Hz, 1H), 5.09 (br.s., 1H), 1.34 (d, J = 6.14Hz, 3H).
[0594] Step 2: Synthesis of 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-4-nitro-1H-pyrazole. To a stirred solution of PPh3 (517 mg, 1.93 mmol, 1.0 equiv) and DIAD (319 mg, 1.93 mmol, 1.0 equiv) in THF (2 mL) was added 4-nitro-1H-pyrazole (175 mg, 1.55 mmol, 0.8 equiv), and then 1-[2,4-bis(trifluoromethyl)phenyl]ethanol (500 mg, 1.93 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and LCMS. After the reaction was complete, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 3). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-4-nitro-1H-pyrazole (550 mg, 84%, as a brown liquid). LCMS: 354 [M+H] + .
[0595] Step 3: Synthesis of 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (500 mg, 1.41 mmol, 1.0 equiv) in methanol (10 mL) was added palladium on carbon [Pd / C] (75 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. The formation of the product was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to afford 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine (450 mg, 100% (crude) as a brown liquid). LCMS: 324 [M+H]. + .
[0596]
[0266] Step 4: N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(thiophen-2-yl)isoxazole-3-carboxamide. To a solution of 5-furan-2-yl-isoxazole-3-carboxylic acid (200 mg, 1.11 mmol, 1 eq) in DMF (1 mL) was added HATU (467 mg, 1.22 mmol, 1.1 eq). The mixture was treated dropwise with DIPEA (461 mg, 3.57 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-{1[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine (360 mg, 1.11 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The product formation was confirmed by TLC and LCMS, and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(thiophen-2-yl)isoxazole-3-carboxamide. (70 mg, 28%, as an off-white solid). 1 H NMR (400MHz, DMSO-d6) δ11.04(s,1H),8.19(s,1H),8.09(d,J=8.3Hz,1H),8.05(s,1H),7.89(d,J=5.0Hz,1H), 7.84(d,J=3.7Hz,1H),7.73(d,J=7.6Hz,1H),7.32-7.21(m,1H),5.93(q,J=6.9Hz,1H),1.87(d,J=6.9Hz,3H). LCMS:501[M+H] + .
[0597] Example S8. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyridin-4-yl)isoxazole-3-carboxamide (Compound 10)
[0598]
[0599] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (1.83 g, 16.28 mmol, 1 eq) in DMF (10 ml) was added portionwise KCO (3.36 gm, 24.42 mmol, 1.5 eq) at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (5.0 gm, 16.28 mmol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (4.5 g, as a white solid). LCMS: 339 [M+H] + .
[0600] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (2.5 g, 1 eq) in methanol (40 mL) was added palladium on carbon [Pd / C] (250 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to afford 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (0.800 g as a brown liquid). LCMS: 309 [M+H] + .
[0601] Step 3: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyridin-4-yl)isoxazole-3-carboxamide. To a stirred solution of 5-(pyridin-4-yl)-1,2-oxazole-3-carboxylic acid (50 mg, 0.263 mmol, 1 eq) in DMF (5 mL) was added HATU (109 mg, 0.289 mmol, 1.1 eq) and the resulting reaction mixture was stirred for one hour. Then 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (81 mg, 0.263 mmol, 1 eq) and DIPEA (108 mg, 0.841 mmol, 3.2 eq) were added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (70 mL), and the organic layer was collected and dried over anhydrous sodium sulfate and concentrated on a rotary evaporator to give the crude product, which was further purified by reverse phase chromatography (10 mg). 1 H NMR(400MHz,DMSO-d6)δppm 5.66(br.s.,2H)7.04(d,J=7.02Hz,1H)7.77(d,J=8.33Hz,2H)7.93(d,J=5.70Hz,2H)8 .02-8.12(m,1H)8.32(s,1H)8.51(br.s.,1H)8.78(d,J=4.82Hz,2H)11.19(br.s.,1H). LCMS:481(M+H) + .
[0602] Example S9. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (Compound 11)
[0603]
[0604] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (1.83 g, 16.28 mmol, 1 eq) in DMF (10 ml) was added portionwise KCO (3.36 gm, 24.42 mmol, 1.5 eq) at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (5.0 gm, 16.28 mmol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (4.5 g, as a white solid). LCMS: 339 [M+H] + .
[0605] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (2.5 g, 1 eq.) in methanol (40 mL) was added palladium on carbon [Pd / C] (250 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to afford 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (0.800 g, as a brown liquid). LCMS: 309 [M+H] + .
[0606] Step 3: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide. To a stirred solution of 5-(pyridin-2-yl)-1,2-oxazole-3-carboxylic acid (50 mg, 0.263 mmol, 1 eq) in DMF (5 mL) was added HATU (109 mg, 0.289 mmol, 1.1 eq) and the resulting reaction mixture was stirred for one hour. 1-(2,4-Bis(trifluoromethyl)-1H-pyrazol-4-amine (81 mg, 0.263 mmol, 1 eq) and DIPEA (108 mg, 0.841 mmol, 3.2 eq) were then added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (70 mL), and the organic layer was collected and dried over anhydrous sodium sulfate and concentrated on a rotary evaporator to give the crude product, which was further purified by reverse phase chromatography (5 mg). 1H NMR(400MHz,DMSO-d6)δppm 5.67(br.s.,2H)7.07(d,J=8.77Hz,1H)7.50(s,3H)7.57(d,J=7.02Hz,1H )7.79(s,1H)7.99-8.11(m,2H)8.33(s,1H)8.76(br.s.,1H)11.15(s,1H). LCMS:481[M+H] + .
[0607] Example S10. Synthesis of N-(1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 12)
[0608]
[0609] Step 1: Synthesis of 1-[2,4-bis(trifluoromethyl)phenyl]ethanol. To a stirred solution of 1-[2,4-bis(trifluoromethyl)phenyl]ethanone (100 mg, 0.39 mmol, 1.0 equiv) in methanol (5 mL) was added portionwise NaBH4 (17 mg, 0.46 mmol, 1.2 equiv) at 0°C and stirred for 10 minutes. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and LCMS. After the reaction was complete, the reaction mixture was quenched with water and extracted with ethyl acetate (50 mL×3). The combined organic extracts were washed with water (50 mL×2), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-[2,4-bis(trifluoromethyl)phenyl]ethanol (100 mg, 100% (crude material) as a colorless liquid). 1 H NMR (400MHz, DMSO-d6) δ 8.04-8.15 (m, 2H), 7.93 (s, 1H), 5.70 (d, J = 3.95Hz, 1H), 5.09 (br.s., 1H), 1.34 (d, J = 6.14Hz, 3H).
[0610] Step 2: Synthesis of 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-4-nitro-1H-pyrazole. To a stirred solution of PPh3 (103 mg, 0.38 mmol, 1.0 equiv) and DIAD (78 mg, 0.38 mmol, 1.0 equiv) in THF (2 mL) was added 4-nitro-1H-pyrazole (35 mg, 0.31 mmol, 0.8 equiv), and then 1-[2,4-bis(trifluoromethyl)phenyl]ethanol (100 mg, 1.93 mmol, 1.0 equiv). The resulting reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and LCMS. After the reaction was complete, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 3). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-4-nitro-1H-pyrazole (75 mg, 55%, as a brown liquid). LCMS: 354 [M+H] + .
[0611] Step 3: Synthesis of 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (200 mg, 1.0 equiv) in methanol (10 mL) was added palladium on carbon [Pd / C] (20 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H2 gas for 2 hours. The formation of the product was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to obtain 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine (200 mg as a brown liquid). LCMS: 324 [M+H]. + .
[0612] Step 4: Synthesis of ethyl 4-(2-furyl)-2,4-dioxobutanoate. To a solution of 2-acetylfuran (5.0 g, 45.40 mmol, 1 eq) in THF was added portionwise 60% sodium hydride (3.63 g, 90.81 mmol, 2.0 eq) at 0 ° C. The resulting reaction mixture was stirred at room temperature for another 30 minutes, followed by the addition of diethyl oxalate (12.28 ml, 90.81 mmol, 2.0 eq) dropwise at 0 ° C. and the reaction mixture was stirred at room temperature for another 18 hours. Product formation was confirmed by TLC and LCMS. The reaction mixture was quenched with ice water and washed with diethyl ether (2×100 mL). The aqueous layer was separated and neutralized with 1N HCl and extracted with EtOAc (3×100 mL). The combined organic extracts were washed with water (2 x 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a crude material which was purified by combi-flash chromatography (15-20% ethyl acetate in hexanes) to afford ethyl 4-(2-furyl)-2,4-dioxobutanoate (3.6 g, 45% as a yellow solid). LCMS: 211 [M+H] + .
[0613] Step 5: Synthesis of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester. A suspension of 4-furan-2-yl-2,4-dioxo-butyric acid ethyl ester (1.6 g, 7.61 mmol, 1.0 equiv) and hydroxylamine hydrochloride (0.528 g, 7.61 mmol, 1.0 equiv) in EtOH was stirred at 85 ° C for 2 hours. The product formation was confirmed by TLC and LCMS. The resulting mixture was concentrated under reduced pressure, and the residue was dissolved in DCM and distilled water. The organic phase was separated, dried over anhydrous Na2SO4, filtered through a silica gel pad, and then concentrated under reduced pressure to give 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester. The crude product obtained was used in the next step without further purification (700 mg, 52% as a yellow solid). LCMS: 208 [M+H] + .
[0614] Step 6: Synthesis of 5-furan-2-yl-isoxazole-3-carboxylic acid. To a solution of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester (0.5 g, 2.41 mmol) in THF (30 mL) and methanol (6 mL) was slowly added aqueous lithium hydroxide solution (10 mL). The resulting mixture was stirred for 16 hours. THF was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with distilled water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 5-furan-2-yl-isoxazole-3-carboxylic acid (225 mg, 52% as a white solid). LCMS: 180 [M+H]+ .
[0615] Step 7: N-(1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. To a solution of 5-furan-2-yl-isoxazole-3-carboxylic acid (100 mg, 0.55 mmol, 1 eq) in DMF (1 mL) was added HATU (233 mg, 0.61 mmol, 1.1 eq). The mixture was treated dropwise with DIPEA (230 mg, 1.78 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine (180 mg, 0.55 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The reaction mixture was diluted with water (50 mL). The resulting precipitate was filtered and freeze-dried on a freeze dryer. The crude material obtained was purified by reverse-phase HPLC to yield N-(1-{1-[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (7 mg, 3% as a white solid). 1 H NMR: (400MHz, DMSO-d6) δ11.07(s,1H),8.18(d,J=6.4Hz,1H),8.05(s,1H),8.00(s,1H),7.73(t,J=4.2Hz,2H ),7.28(d,J=3.6Hz,1H),7.17-7.05(m,1H),6.80-6.67(m,1H),5.93(q,J=6.9Hz,1H),1.87(d,J=6.9Hz,3H). LCMS:485[M+H] + .
[0616] Example S11. Synthesis of N-{1-[2,4-bis(trifluoromethyl)benzyl]-1H-pyrazol-4-yl}-5-tert-butyl-1,2-oxazole-3-carboxamide (Compound 13)
[0617]
[0618] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (1.83 g, 16.28 mmol, 1 eq) in DMF (10 ml) was added portionwise KCO (3.36 gm, 24.42 mmol, 1.5 eq) at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (5.0 gm, 16.28 mmol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (4.5 g, as a white solid). LCMS: 339 [M+H] + .
[0619] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (2.5 g, 1 eq) in methanol (40 mL) was added palladium on carbon [Pd / C] (250 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to afford 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (0.800 g as a brown liquid). LCMS: 309 [M+H] + .
[0620] Step 3: Synthesis of N-{1-[2,4-bis(trifluoromethyl)benzyl]-1H-pyrazol-4-yl}-5-tert-butyl-1,2-oxazole-3-carboxamide. To a stirred solution of 5-tert-butyl-1,2-oxazole-3-carboxylic acid (100 mg, 0.588 mmol, 1 eq) in DMF (8 mL) was added HATU (246 mg, 0.646 mmol, 1.1 eq) and the reaction mixture was stirred for half an hour followed by the addition of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl}-5-tert-butyl-1,2-oxazole-3-carboxamide. To the mixture of bis(trifluoromethyl)-1H-pyrazol-4-amine (182 mg, 0.588 mmol, 1 equivalent) and DIPEA (242 mg, 1.881 mmol, 3.2 equivalents) was stirred overnight at room temperature. The reaction mixture was monitored by TLC and LCMS. The reaction mixture was diluted with ethyl acetate and washed with water, and the organic layer was collected, dried over sodium sulfate, and concentrated on a rotary evaporator to give a crude product which was further purified by reverse phase chromatography (15 mg). 1H NMR (400MHz, DMSO-d6) δppm 1.35 (s, 9H) 5.65 (s, 2H) 6.64 (s, 1H) 7.06 (d, J = 7.89Hz, 1H) 7.75 (s, 1H) 7.99-8.17 (m, 2H) 8.29 (s, 1H) 10.97 (s, 1H). LCMS:461(M+H) + .
[0621] Example S12. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(thiophen-2-yl)isoxazole-3-carboxamide (Compound 14)
[0622]
[0623] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (1.83 gm, 16.28 mmol, 1 eq) in DMF (10 ml) was added portionwise KCO (3.36 gm, 24.42 mmol, 1.5 eq) at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (5.0 gm, 16.28 mmol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (4.5 g, as a white solid). LCMS: 339 [M+H] + .
[0624] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (2.5 g, 1 eq) in methanol (40 mL) was added palladium on carbon [Pd / C] (250 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to afford 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (0.800 g as a brown liquid). LCMS: 309 [M+H] + .
[0625] Step 3: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(thiophen-2-yl)isoxazole-3-carboxamide. To a stirred solution of 5-(thiophen-2-yl)-1,2-oxazole-3-carboxylic acid (100 mg, 0.512 mmol, 1 eq) in DMF (5 mL) was added HATU (213 mg, 0.0.513 mmol, 1.1 eq) and the resulting reaction mixture was stirred for one hour. Then 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (158 mg, 0.0.512 mmol, 1 eq) and DIPEA (210 mg, 1.63 mmol, 3.2 eq) were added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (70 mL), and the organic layer was collected and dried over anhydrous sodium sulfate and concentrated on a rotary evaporator to give the crude product, which was further purified by reverse phase chromatography (7 mg white solid). 1 H NMR(400MHz, DMSO-d6)δppm5.67(br.s.,2H)7.05(d,J=7.45Hz,1H)7.29(br.s.,2H)7.78( s,1H)7.84(br.s.,1H)7.90(d,J=4.38Hz,2H)8.04-8.14(m,2H)8.32(s,1H)11.11(s,1H). LCMS:486(M+H) + .
[0626] Example S13. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-[3,3'-bipyridine]-5-carboxamide (Compound 15)
[0627]
[0628] To a stirred solution of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-bromonicotinamide (100 mg, 0.20 mmol, 1 eq) and pyridin-3-ylboronic acid (32 mg, 0.26 mmol, 1.3 eq) in DMF (7 mL) was added NaCO (53 mg, 0.50 mmol, 2.5 eq), water (1.5 mL) and Tetrakis (23 mg, 0.020 mmol, 0.1 eq). The resulting reaction mixture was heated at 100 ° C for 2 hours. The reaction was monitored by TLC and LCMS. After the reaction was complete, the reaction mixture was cooled to room temperature and water (20 mL) was added. The resulting solid was filtered off and washed with water and dried under vacuum to obtain a crude material. The crude product was purified by preparative purification to afford solid N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-[3,3'-bipyridine]-5-carboxamide (25 mg, 25%) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ10.89(s,1H),9.13(dd,J=4.7,2.2Hz,2H),9.06(d,J=2.5Hz,1H),8.68(d,J=4.6Hz,1H),8.64(s,1H),8.34(s,1H) ,8.27(d,J=8.0Hz,1H),8.08(d,J=5.4Hz,2H),7.77(s,1H),7.58(dd,J=7.9,4.8Hz,1H),7.10(d,J=8.2Hz,1H),5.68(s,2H),1.62(s,2H).
[0629] Example S14. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(2,4-difluorophenyl)isoxazole-3-carboxamide (Compound 16)
[0630]
[0631] To a solution of 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid (100 mg, 0.44 mmol, 1 equivalent) in DMF (1 mL) was added HATU (185 mg, 0.48 mmol, 1.1 equivalents). The mixture was treated dropwise with DIPEA (183 mg, 1.42 mmol, 3.2 equivalents). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazole-4-amine (137 mg, 0.44 mmol, 1 equivalent) in DMF (1 mL). The reaction mixture was kept stirred at room temperature for 24 hours. The product was confirmed to be formed with TLC and LCMS and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over NaSO and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(2,4-difluorophenyl)isoxazole-3-carboxamide (36 mg, 15.7%, as an off-white solid). 1 H NMR (400MHz, DMSO-d6) δ11.16(s,1H),8.33(s,1H),8.10(q,J=8.3Hz,3H),7.78(s,1H),7.61(t,J=1 0.9Hz, 1H), 7.35 (dd, J = 10.1, 7.7Hz, 1H), 7.26 (d, J = 2.9Hz, 1H), 7.06 (d, J = 8.1Hz, 1H), 5.67 (s, 2H).
[0632] Example S15. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-imidazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 17)
[0633]
[0634] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-imidazole. To a stirred solution of 4-nitro-1H-imidazole (0.368 g, 0.003 mol, 1 eq) in DMF (20 mL) was added. The reaction mixture was cooled to 0°C with ice water, and KCO (0.674 g, 0.004 mol, 1.5 eq) was added portionwise. The reaction mixture was stirred for 10 minutes, and then 1-(bromomethyl)-2,4-bis(trifluoromethyl)benzene (1.0 g, 0.003 mol, 1 eq) was added dropwise. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-imidazole (1.1 g, 100% crude) as an off-white solid. LCMS: 339 [M+H] + .
[0635] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-imidazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-imidazole (500 mg, 1 eq) in methanol (20 mL) was added palladium on carbon [Pd / C] (100 mg, 10% w / w) under nitrogen and the reaction mixture was purged with hydrogen for 2 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated to obtain the product, which was purified by flash chromatography to give 1-(2,4-bis(trifluoromethyl)benzyl)-1H-imidazol-4-amine (460 mg, 100% crude) as a brown viscous liquid. LCMS: 309 [M+H] + .
[0636] Step 3: Synthesis of ethyl 4-(2-furyl)-2,4-dioxobutanoate. To a solution of 2-acetylfuran (5.0 g, 45.40 mmol, 1 eq) in THF was added portionwise 60% sodium hydride (3.63 g, 90.81 mmol, 2 eq) at 0 ° C. The resulting reaction mixture was stirred at room temperature for another 30 minutes, followed by the addition of diethyl oxalate (12.28 ml, 90.81 mmol, 2 eq) dropwise at 0 ° C. and the reaction mixture was stirred at room temperature for another 18 hours. Product formation was confirmed by TLC and LCMS. The reaction mixture was quenched with ice water and washed with diethyl ether (2×100 mL). The aqueous layer was separated and neutralized with 1N HCl and extracted with EtOAc (3×100 mL). The combined organic extracts were washed with water (2 x 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give the crude material, which was purified by combi-flash chromatography (0-20% ethyl acetate in hexanes) to afford ethyl 4-(furan-2-yl)-2,4-dioxobutanoate (3.6 g, 45% as a yellow solid). LCMS: 210 [M+H] + .
[0637] Step 4: Synthesis of ethyl 5-(furan-2-yl)isoxazole-3-carboxylate. A suspension of ethyl 4-(furan-2-yl)-2,4-dioxobutanoate (1.6 g, 7.61 mmol, 1 eq) and hydroxylamine hydrochloride (0.528 g, 7.61 mmol, 1 eq) in EtOH was stirred at 85 ° C for 2 hours. Product formation was confirmed by TLC and LCMS. The resulting mixture was concentrated under reduced pressure, and the residue was dissolved in DCM and distilled water. The organic phase was separated, dried over anhydrous Na2SO4, filtered through a silica gel pad, and then concentrated under reduced pressure to give ethyl 5-(furan-2-yl)isoxazole-3-carboxylate. The crude product obtained was used in the next step without further purification (700 mg, 52% as a yellow solid). LCMS: 207 [M+H] + .
[0638] Step 5: Synthesis of 5-(furan-2-yl)isoxazole-3-carboxylic acid. To a solution of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester (0.5 g, 2.41 mmol) in THF (30 mL) and methanol (6 mL) was slowly added aqueous lithium hydroxide (10 mL). The resulting mixture was stirred for 16 hours. THF was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with distilled water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 5-furan-2-yl-isoxazole-3-carboxylic acid (225 mg, 52% as a white solid). LCMS: 179 [M+H] +.
[0639] Step 6: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-imidazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. To a stirred solution of 5-(furan-2-yl)isoxazole-3-carboxylic acid (200 mg, 0.647 mmol, 1 eq) in DMF (10 ml) was added HATU (270 mg, 0.711 mmol, 1.1 eq) and DIPEA (267 mg, 2.07 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, 1-(2,4-bis(trifluoromethyl)benzyl)-1H-imidazol-4-amine (115 mg, 0.647 mmol, 1 eq) was added. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by LCMS. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with water (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to give a crude product, which was purified by using column chromatography (100 mg, 32%, as a white solid). 1 H NMR(400MHz, DMSO-d6)=11.21(br.s.,1H),8.17-8.05(m,2H),8.00(s,1H),7. 74(s,1H),7.49(s,1H),7.24(br.s.,3H),6.76(br.s.,1H),5.57(br.s.,2H). LCMS:471[M+H] + .
[0640] Example S16. Synthesis of N-(1-(2,3-dihydro-1H-inden-2-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 18)
[0641]
[0642] Step 1: Synthesis of 1-(2,3-dihydro-1H-inden-2-yl)-4-nitro-1H-pyrazole. 2,3-Dihydro-1H-inden-2-ol (1) (1 gm, 0.007 mol, and 1 eq) and 4-nitro-1H-pyrazole (0.556 gm, 0.0049 mol, and 0.66 eq) were dissolved in 6 ml of THF. Triphenylphosphine (2.035 gm, 0.007 mol, and 1.041 eq) was added thereto. The reaction mixture was stirred at 0°C. DIAD (1.569 gm, 0.007 mol, 1.041 eq) diluted in 3 ml of THF was added dropwise thereto. The mixture was stirred at 0°C for 10 minutes. Thereafter, the reaction was kept in a microwave at 140°C for 15 minutes. The reaction mixture was concentrated to dryness and purified by column to give the product, 1-(2,3-dihydro-1H-inden-2-yl)-4-nitro-1H-pyrazole (3), as a yellow oil. LCMS: 229 [M+H] + .
[0643] Step 2: Synthesis of 1-(2,3-dihydro-1H-inden-2-yl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,3-dihydro-1H-inden-2-yl)-4-nitro-1H-pyrazole (250 mg) in MeOH (10 mL) was added and purged with nitrogen, followed by addition of Pd / C (10 wt %), 1-(2,3-dihydro-1H-inden-1-yl)-4-nitro-1H-pyrazole) and purged with nitrogen for another 5 minutes. The resulting reaction mixture was then purged with hydrogen for one hour. The reaction was monitored by TLC and LCMS. The reaction mixture was filtered through a bed of celite, washed with methanol, and concentrated under reduced pressure to give the crude product, 1-(2,3-dihydro-1H-inden-2-yl)-1H-pyrazol-4-amine, which was used directly in the next step. LCMS: 199 [M+H] + .
[0644] Step 3: Synthesis of N-(1-(2,3-dihydro-1H-inden-2-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. 5-(Furan-2-yl)isoxazole-3-carboxylic acid (200 mg, 1 eq, 1.117 mmol) was dissolved in 5 mL of DMF. HATU (424.5 mg, 1.117 mmol, and 1 eq) was added. DIPEA (0.288 mg, 2 eq, and 2.234 mmol) was added. The reaction mixture was stirred for 20 minutes. 1-(2,3-dihydro-1H-inden-2-yl)-1H-pyrazol-4-amine (222.3 mg, 1 eq, 1.117 mmol) was added. The resulting reaction mixture was stirred for 24 hours. The mixture was worked up by adding water and recovered with ethyl acetate. The crude material was triturated with IPA:hexanes (1:9), kept stirring overnight and filtered. The residue obtained was the product N-(1-(2,3-dihydro-1H-inden-2-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. 1 H NMR (400MHz, DMSO-d6) δ10.98 (s, 1H), 8.01 (d, J = 7.5Hz, 2H), 7.66 (s, 1H), 7.31-7.12 (m, 6H), 6.77 (d d,J=3.4,1.8Hz,1H),5.29-5.17(m,1H),3.43(dd,J=16.2,7.8Hz,2H),3.27(dd,J=16.1,5.9Hz,2H). LCMS:360[M+H] + .
[0645] Example S17. Synthesis of N-(1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 19)
[0646]
[0647] Step 1: Synthesis of 1-(2,3-dihydro-1H-inden-1-yl)-4-nitro-1H-pyrazole. 2,3-Dihydro-1H-inden-1-ol (1 gm, 0.007 mol, and 1 eq) and 4-nitro-1H-pyrazole (0.556 gm, 0.0049 mol, and 0.6 eq) were dissolved in 6 ml of THF. Triphenylphosphine (2.035 gm, 0.007 mol, and 1.041 eq) was added. The reaction mixture was stirred at 0°C. DIAD (1.56 gm, 0.007 mol, 1.041 eq) diluted in 3 ml of THF was added dropwise. The mixture was stirred at 0°C for 10 minutes. The reaction was then microwaved at 140°C for 15 minutes. The reaction mixture was concentrated to dryness and column purified to give the product, 1-(2,3-dihydro-1H-inden-1-yl)-4-nitro-1H-pyrazole, as a yellow oil.
[0648] Step 2: Synthesis of 1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,3-dihydro-1H-inden-1-yl)-4-nitro-1H-pyrazole (200 mg) in MeOH (10 mL) was added and purged with nitrogen. Pd / C (20 mg 10 wt %, 1-(2,3-dihydro-1H-inden-1-yl)-4-nitro-1H-pyrazole) was added and purged with nitrogen for another 5 minutes. The resulting reaction mixture was then purged with hydrogen for one hour. The reaction was monitored by TLC and LCMS. The reaction mixture was filtered through a bed of celite, washed with methanol, and concentrated under reduced pressure to give the crude product, 1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-amine, which was used directly in the next step. LCMS: 199 [M+H] + .
[0649] Step 3: Synthesis of N-(1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. 5-(Furan-2-yl)isoxazole-3-carboxylic acid (100 mg, 1 equivalent, 0.502 mmol) was dissolved in 5 ml of DMF. HATU (190.9 mg, 0.502 mmol, and 1 equivalent) was added. DIPEA (0.17 ml, 2 equivalents, and 1.005 mmol) was added. The reaction mixture was stirred for 20 minutes. 1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-amine (4) (89.9 mg, 1 equivalent, 0.502 mmol) was added. The resulting reaction mixture was stirred for 24 hours. Worked up by adding water and recovered with ethyl acetate. The crude material was triturated with IPA:hexanes (1:9), kept stirring overnight and filtered. The residue obtained was the product N-(1-(2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. 1 H NMR (400MHz, DMSO-d6) δ11.01(s,1H),8.01(d,J=4.3Hz,2H),7.67(s,1H),7.35(d,J=7 .6Hz,1H),7.32-7.24(m,2H),7.19(t,J=7.4Hz,1H),7.14(s,1H),7.07(d,J=7.5Hz,1H) ,6.80-6.74(m,1H),5.92(t,J=7.1Hz,1H),3.12(ddd,J=14.6,8.7,5.1Hz,1H),2.93(dt ,J=15.7,7.5Hz,1H),2.61(dtd,J=13.1,8.2,5.1Hz,1H),2.35(dq,J=13.4,6.6Hz,1H). LCMS:360[M+H] + .
[0650] Example S18. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(4-fluorophenyl)nicotinamide (Compound 20)
[0651]
[0652] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (1.83 g, 16.28 mmol, 1 eq) in DMF (10 ml) was added portionwise KCO (3.36 gm, 24.42 mmol, 1.5 eq) at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (5.0 gm, 16.28 mmol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (4.5 g, as a white solid). LCMS: 339 [M+H] + .
[0653] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (1.0 g, 1 eq.) in methanol (20 mL) was added palladium on carbon [Pd / C] (100 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to afford 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (0.800 g as a brown liquid). LCMS: 309 [M+H] + .
[0654] Step 3: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-bromonicotinamide. To a stirred solution of 5-bromonicotinic acid (200 mg, 1.01 mmol, 1 eq) in DMF (15 mL) was added HATU (422 mg, 1.11 mmol, 1.1 eq) and stirred for half an hour, followed by the addition of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine (300 mg, 1.01 mmol, 1 eq) and DIEA (0.550 mL, 3.23 mmol, 3.2 eq). The reaction mixture was stirred at room temperature overnight. The reaction was monitored by LCMS. The reaction mixture was diluted with ethyl acetate (150 mL) and washed with water (100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to give the product (450 mg, brown solid). LCMS: 492 [M+H] + .
[0655] Step 4: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(4-fluorophenyl)nicotinamide. To a solution of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-bromonicotinamide (150 mg, 0.30 mmol, 1.1 equiv) in dioxane (0.5 mL) was added (4-fluorophenyl)boronic acid (46 mg, 0.33 mmol, 1.1 equiv), Na2CO3 (60 mg, 0.60 mmol, 2.0 equiv), followed by Pd(PPh3)2Cl2 (10 mg, 0.015 mmol, 0.05 equiv). The resulting reaction mixture was heated at 100°C overnight. Product formation was confirmed by LCMS. After completion of the reaction, the mixture was filtered through a bed of celite and washed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure. The crude product obtained was triturated in isopropanol (5 mL) and concentrated under reduced pressure to give N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(4-fluorophenyl)nicotinamide (20 mg, brown solid). 1 H NMR(400MHz,DMSO-d6)δppm 5.67(s,2H)7.10(d,J=8.77Hz,1H)7.40(t,J=8.55Hz,2H)7.76(s,1H)7.89(dd,J=8.77, 5.26Hz,2H)8.09(br.s.,2H)8.34(s,1H)8.53(br.s.,1H)9.06(br.s.,2H)10.81(s,1H). LCMS:509[M+H] + .
[0656] Example S19. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-phenylnicotinamide (Compound 21)
[0657]
[0658] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (1.83 g, 16.28 mmol, 1 eq) in DMF (10 ml) was added portionwise KCO (3.36 gm, 24.42 mmol, 1.5 eq) at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (5.0 gm, 16.28 mmol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (4.5 g, as a white solid). LCMS: 339 [M+H] + .
[0659] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (1.0 g, 1 eq.) in methanol (20 mL) was added palladium on carbon [Pd / C] (100 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to afford 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (0.800 g as a brown liquid). LCMS: 309 [M+H] + .
[0660] Step 3: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-bromonicotinamide. To a stirred solution of 5-bromonicotinic acid (200 mg, 1.01 mmol, 1 eq) in DMF (15 ml) was added HATU (422 mg, 1.11 mmol, 1.1 eq) and stirred for half an hour. Then, 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine (300 mg, 1.01 mmol, 1 eq) and DIEA (0.550 mL, 3.23 mmol, 3.2 eq) were added. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by LCMS. The reaction mixture was diluted with ethyl acetate (150 mL) and washed with water (100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to give the product (450 mg, brown solid). LCMS: 492 [M+H] + .
[0661] Step 4: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-phenylnicotinamide. To a solution of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-bromonicotinamide (150 mg, 0.30 mmol, 1.1 equiv) in dioxane (0.5 mL) was added phenylboronic acid (39 mg, 0.33 mmol, 1.1 equiv), NaCO (60 mg, 0.60 mmol, 2.0 equiv), followed by Pd(PPh)Cl (10 mg, 0.015 mmol, 0.05 equiv). The resulting reaction mixture was heated at 100° C. overnight. Product formation was confirmed by LCMS. After completion of the reaction, the mixture was filtered through a bed of celite and washed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure. The crude product obtained was triturated with isopropanol (5 mL) and concentrated under reduced pressure to obtain N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-phenylnicotinamide (20 mg, brown solid). 1 H NMR(400MHz,DMSO-d6)δppm 5.67(br.s.,2H)7.10(d,J=7.02Hz,2H)7.48(br.s.,1H)7.56(t,J=7.24Hz,1H)7.76(s,1H)7.8 4(d,J=7.45Hz,3H)8.09(br.s.,1H)8.34(s,1H)8.55(br.s.,2H)9.08(br.s.,1H)10.81(s,1H). LCMS:491[M+H] + .
[0662] Example S20. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(5-methylfuran-2-yl)isoxazole-3-carboxamide (Compound 22)
[0663]
[0664] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (2.0 g, 6.51 mmol, 1 eq) in DMF (20 ml) was added portionwise KCO at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (0.73 gm, 6.51 mmol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous NaSO, and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (2.1 g as a white solid). LCMS: 339[M+H] + .
[0665] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (1.0 g, 1 eq.) in methanol (20 mL) was added palladium on carbon [Pd / C] (100 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to afford 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (0.800 g as a brown liquid). LCMS: 309 [M+H] + .
[0666] Step 3: Synthesis of ethyl 4-(5-methylfuran-2-yl)-2,4-dioxobutanoate. To a solution of 2-acetyl-5-methylfuran (1.0 g, 8.05 mmol, 1 eq) in THF was added 60% sodium hydride (0.386 g, 16.11 mmol, 2 eq) portionwise at 0 ° C. The resulting reaction mixture was stirred at room temperature for another 30 minutes, followed by the addition of diethyl oxalate (2.35 ml, 16.11 mmol, 2 eq) dropwise at 0 ° C. and the reaction mixture was stirred at room temperature for another 18 hours. Product formation was confirmed by TLC and LCMS. The reaction mixture was quenched with ice water and washed with diethyl ether (2×50 mL). The aqueous layer was separated and neutralized with 1N HCl and extracted with EtOAc (3×50 mL). The combined organic extracts were washed with water (2 x 50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a crude material which was purified by combi-flash chromatography (0-20% ethyl acetate in hexanes) to afford ethyl 4-(5-methylfuran-2-yl)-2,4-dioxobutanoate (1.0 g, 55% as a yellow solid). LCMS: 224 [M+H] + .
[0667] Step 4: Synthesis of ethyl 5-(5-methylfuran-2-yl)isoxazole-3-carboxylate. A suspension of ethyl 4-(5-methylfuran-2-yl)-2,4-dioxobutanoate (1.0 g, 4.46 mmol, 1 eq) and hydroxylamine hydrochloride (0.218 g, 4.46 mmol, 1 eq) in EtOH was stirred at 85 ° C for 2 hours. The product formation was confirmed by TLC and LCMS. The resulting mixture was concentrated under reduced pressure, and the residue was dissolved in DCM and distilled water. The organic phase was separated, dried over anhydrous Na2SO4, filtered through a silica gel pad, and then concentrated under reduced pressure to give ethyl 5-(5-methylfuran-2-yl)isoxazole-3-carboxylate. The crude product obtained was used in the next step without further purification (600 mg, 52% as a yellow solid). LCMS: 221 [M+H] + .
[0668] Step 5: Synthesis of 5-(5-methylfuran-2-yl)isoxazole-3-carboxylic acid. To a solution of ethyl 5-(5-methylfuran-2-yl)isoxazole-3-carboxylate (0.5 g, mmol) in THF (30 mL) and methanol (6 mL) was slowly added 1N aqueous lithium hydroxide solution (10 mL). The resulting mixture was stirred for 16 hours. THF was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with distilled water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 5-methylfuran-2-yl-isoxazole-3-carboxylic acid (180 mg, 52% as a white solid). LCMS: 193 [M+H] + .
[0669] Step 6: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(5-methylfuran-2-yl)isoxazole-3-carboxamide. To a solution of 5-methylfuran-2-yl-isoxazole-3-carboxylic acid (100 mg, 0.518 mmol, 1 eq) in DMF (1 mL) was added HATU (216 mg, 0.569 mmol, 1.1 eq). The mixture was treated dropwise with DIPEA (214 mg, 1.65 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine (176 mg, 0.569 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The reaction mixture was diluted with water (25 mL). The resulting precipitate was filtered and freeze-dried on a freeze dryer. The crude material obtained was purified by reverse-phase HPLC to yield N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(5-methylfuran-2-yl)isoxazole-3-carboxamide (55 mg, as a white solid). 1 H NMR(400MHz,DMSO-d6)δppm 1.22-1.23(m,1H)2.40(s,3H)5.66(s,2H)6.40(d,J=3.07Hz,1H)7.01-7.10(m,2 H)7.17(d,J=3.51Hz,1H)7.77(s,1H)8.05-8.11(m,1H)8.31(s,1H)11.10(s,1H). LCMS:484[M+H] + .
[0670] Example S21. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)isoxazole-3-carboxamide (Compound 23)
[0671]
[0672] To a solution of isoxazole-3-carboxylic acid (100 mg, 0.88 mmol, 1 equivalent) in DMF (1 mL) was added HATU (369 mg, 0.97 mmol, 1.1 equivalents). The mixture was treated dropwise with DIPEA (365 mg, 2.83 mmol, 3.2 equivalents). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazole-4-amine (273 mg, 0.884 mmol, 1 equivalent) in DMF (1 mL). The reaction mixture was kept stirred at room temperature for 24 hours. It was confirmed with TLC and LCMS that the product was formed and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over NaSO and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)isoxazole-3-carboxamide (40 mg, 11%) as an off-white solid. 1 H NMR(400MHz,DMSO-d6)δ11.06(s,1H),9.14(d,J=1.5Hz,1H),8.29(s,1H),8.06(d,J =8.3Hz, 2H), 7.76 (s, 1H), 7.05 (d, J = 8.1Hz, 1H), 6.99 (d, J = 1.7Hz, 1H), 5.66 (s, 2H).
[0673] Example S22. Synthesis of N-(1-(2,6-dichlorobenzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 24)
[0674]
[0675] Step 1: Synthesis of 1-(2,6-dichlorobenzyl)-4-nitro-1H-pyrazole. 4-Nitro-1H-pyrazole (1.177 gm, 1 eq., 0.0104 mol) was dissolved in 5 ml of DMF. KCO (2.15 gm, 0.015 mol, 1.5 eq.) was added at 0°C, and the reaction mixture was stirred for 30 minutes. 2-(Bromomethyl)-1,3-dichlorobenzene (2.5 gm, 0.0104 mol, 1 eq.) was added, and the reaction mixture was stirred for 1 hour. The reaction was worked up by adding water and recovered in ethyl acetate. The organic layer was concentrated under reduced pressure to yield the desired product, 1-(2,6-dichlorobenzyl)-4-nitro-1H-pyrazole. LCMS: 272 [M+H]. + .
[0676] Step 2: Synthesis of 1-(2,6-dichlorobenzyl)-1H-pyrazol-4-amine. 1-(2,6-dichlorobenzyl)-4-nitro-1H-pyrazole (3) (1 gm, 0.003 mol, 1 eq) was dissolved in methanol. Zinc (962 mg, 0.014 mol, 4 eq) was added thereto. Hydrazine monohydrate (6 ml) was added thereto. The reaction mixture was refluxed at 80°C for 24 hours. The reaction was monitored. The reaction mixture was treated by passing it through a bed of celite. The obtained organic layer was washed with water to extract the remaining hydrazine hydrate. The layers were then concentrated under reduced pressure to obtain the desired product, 1-(2,6-dichlorobenzyl)-1H-pyrazol-4-amine. LCMS: 241 [M+H]. + .
[0677] Step 3: Synthesis of 1-(2,6-dichlorobenzyl)-1H-pyrazol-4-amine hydrochloride. 1-(2,6-dichlorobenzyl)-1H-pyrazol-4-amine (0.8 gm) was dissolved in methanol. 5 ml of HCl in ether was added and stirred overnight. The resulting suspension was filtered. The residue was dried by washing with ether. The product, 1-(2,6-dichlorobenzyl)-1H-pyrazol-4-amine hydrochloride, was obtained. LCMS: 241 [M+H] + .
[0678] Step 4: Synthesis of N-(1-(2,6-dichlorobenzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. 5-(Furan-2-yl)isoxazole-3-carboxylic acid (100 mg, 1 equivalent, 0.558 mmol) was dissolved in 3 ml of DMF. HATU (212.8 mg, 0.558 mmol, and 1 equivalent) was added. DIPEA (144.13 mg, 2 equivalents, and 1.117 mmol) was added. The reaction mixture was stirred for 20 minutes. 1-(2,6-dichlorobenzyl)-1H-pyrazol-4-amine.HCl (186.3 mg, 1.2 equivalents, 0.670 mmol) was added. The resulting reaction mixture was stirred for 24 hours. The mixture was worked up by adding water and recovered with ethyl acetate. The crude material was purified by prep. The product obtained was N-(1-(2,6-dichlorobenzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. 1H NMR (400MHz, DMSO-d6) δ11.00(s,1H),8.06(s,1H),8.00(s,1H),7.63(s,1H),7.56(d,J=8.1Hz,2H),7.45(t,J=8.1Hz,1H),7.28( d,J=3.5Hz,1H),7.13(s,1H),6.77(dd,J=3.4,1.8Hz,1H),5.55(s,2H),5.32(s,0H),3.97(s,0H),1.23(s,1H),0.89-0.81(m,0H). LCMS:402[M+H] + .
[0679] Example S23. Synthesis of N-(1-(4-cyanobenzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 25)
[0680]
[0681] To a solution of 5-(furan-2-yl)isoxazole-3-carboxylic acid (100 mg, 0.55 mmol, 1 equivalent) in DMF (1 mL) was added HATU (233 mg, 0.61 mmol, 1.1 equivalents). The mixture was treated dropwise with DIPEA (230 mg, 1.78 mmol, 3.2 equivalents). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 4-((4-amino-1H-pyrazol-1-yl)methyl)benzonitrile (110 mg, 0.55 mmol, 1 equivalent) in DMF (1 mL). The reaction mixture was kept at room temperature and stirred for 24 hours. The product was confirmed to form with TLC and LCMS and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over NaSO and concentrated under reduced pressure to obtain a crude material. The crude product was purified by preparative purification to give solid N-(1-(4-cyanobenzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (30 mg, 18% as an off-white solid). 1 H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.25(s,1H),8.00(d,J=1.8Hz,1H),7.82(d,J=7.9Hz,1H),7.70(s,1H),7.36( d,J=8.0Hz,1H),7.29(d,J=3.5Hz,1H),7.16(s,1H),6.77(dd,J=3.4,1.8Hz,1H),5.46(s,2H),2.92(q,J=7.2Hz,1H).
[0682] Example S24. Synthesis of N-(1-(4-cyano-3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 26)
[0683]
[0684] Step 1: Synthesis of 4-((4-nitro-1H-pyrazol-1-yl)methyl)-2-(trifluoromethyl)benzonitrile. To a stirred solution of 4-nitro-1H-pyrazole (0.213 g, 1.893 mmol, 1 eq) in DMF (20 mL) was added. The reaction mixture was cooled to 0° C. with ice water, and KCO (0.39 g, 2.839 mmol, 1.5 eq) was added portionwise. The reaction mixture was stirred for 10 minutes and then 4-(bromomethyl)-2-(trifluoromethyl)benzonitrile (0.500 g, 1.893 mmol, 1 eq) was added dropwise. The above reaction mixture was stirred for 1 hour (the reaction was monitored by TLC and LCMS). After the reaction was completed, the reaction mixture was diluted with ethyl acetate (50 mL) and extracted with water (50 mL). The organic layer was collected and concentrated to obtain the product, which was further purified by flash chromatography to obtain a white product. LCMS: 297 [M+H] + .
[0685] Step 2: Synthesis of 4-((4-amino-1H-pyrazol-1-yl)methyl)-2-(trifluoromethyl)benzonitrile. To a stirred solution of 4-((4-nitro-1H-pyrazol-1-yl)methyl)-2-(trifluoromethyl)benzonitrile (500 mg, 1 eq) in methanol (20 mL) was added palladium on carbon [Pd / C] (10 wt %) under nitrogen and the reaction mixture was purged with hydrogen for 2 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated to obtain the product, which was purified by flash chromatography to give a brown viscous liquid. LCMS: 267 [M+H] + .
[0686] Step 3: Synthesis of ethyl 4-(2-furyl)-2,4-dioxobutanoate. To a solution of 2-acetylfuran (5.0 g, 45.40 mmol, 1 eq) in THF was added portionwise 60% sodium hydride (3.63 g, 90.81 mmol, 2 eq) at 0 ° C. The resulting reaction mixture was stirred at room temperature for another 30 minutes, followed by the addition of diethyl oxalate (12.28 ml, 90.81 mmol, 2 eq) dropwise at 0 ° C. and the reaction mixture was stirred at room temperature for another 18 hours. Product formation was confirmed by TLC and LCMS. The reaction mixture was quenched with ice water and washed with diethyl ether (2×100 mL). The aqueous layer was separated and neutralized with 1N HCl and extracted with EtOAc (3×100 mL). The combined organic extracts were washed with water (2 x 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a crude material which was purified by combi-flash chromatography (0-20% ethyl acetate in hexanes) to afford ethyl 4-(2-furyl)-2,4-dioxobutanoate (3.6 g, 45% as a yellow solid). LCMS: 210 [M+H] + .
[0687] Step 4: Synthesis of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester. A suspension of 4-furan-2-yl-2,4-dioxo-butyric acid ethyl ester (1.6 g, 7.61 mmol, 1 eq) and hydroxylamine hydrochloride (0.528 g, 7.61 mmol, 1 eq) in EtOH was stirred at 85 ° C for 2 hours. The product formation was confirmed by TLC and LCMS. The resulting mixture was concentrated under reduced pressure, and the residue was dissolved in DCM and distilled water. The organic phase was separated, dried over anhydrous Na2SO4, filtered through a silica gel pad, and then concentrated under reduced pressure to give 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester. The crude product obtained was used in the next step without further purification (700 mg, 52% as a yellow solid). LCMS: 207 [M+H] + .
[0688] Step 5: Synthesis of 5-furan-2-yl-isoxazole-3-carboxylic acid. To a solution of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester (0.5 g, 2.41 mmol) in THF (30 mL) and methanol (6 mL) was slowly added aqueous lithium hydroxide solution (10 mL). The resulting mixture was stirred for 16 hours. THF was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with distilled water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 5-furan-2-yl-isoxazole-3-carboxylic acid (225 mg, 52% as a white solid). LCMS: 179 [M+H] + .
[0689] Step 6: Synthesis of N-(1-(4-cyano-3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. To a stirred solution of 5-(furan-2-yl)isoxazole-3-carboxylic acid (100 mg, 0.563 mmol, 1 eq) in DMF (10 ml) was added HATU (235 mg, 0.619 mmol, 1.1 eq) and stirred for half an hour. 4-((4-amino-1H-pyrazol-1-yl)methyl)-2-(trifluoromethyl)benzonitrile (150 mg, 0.563 mmol, 1 eq) and DIEA were then added. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by LCMS. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with water (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to give the product, which was further purified by reverse phase chromatography. (10 mg white solid). 1 H NMR(400MHz,DMSO-d6)δppm 5.57(s,2H)6.78(br.s.,1H)7.17(s,1H)7.29(d,J=3.51Hz,2H)7.73(s,1H )7.88(s,1H)8.01(s,1H)8.16(d,J=7.45Hz,1H)8.31(s,1H)11.09(s,1H). LCMS:428[M+H] + .
[0690] Example S25. Synthesis of N-(1-(2,4-bis(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 27)
[0691]
[0692] Step 1: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (2.0 g, 6.51 mmol, 1 eq) in DMF (20 ml) was added portionwise KCO at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (0.73 gm, 6.51 mmol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous NaSO, and concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (2.1 g as a white solid). LCMS: 326[M+H] + .
[0693] Step 2: Synthesis of 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (1.0 g, 1 eq) in methanol (20 mL) was added palladium on carbon [Pd / C] (100 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H2 gas for 2 h. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to afford 1-(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (0.800 g as a brown liquid). LCMS: 296 [M+H] + .
[0694] Step 3: Synthesis of ethyl 4-(2-furyl)-2,4-dioxobutanoate. To a solution of 2-acetylfuran (5.0 g, 45.40 mmol, 1 eq) in THF was added portionwise 60% sodium hydride (3.63 g, 90.81 mmol, 2 eq) at 0 ° C. The resulting reaction mixture was stirred at room temperature for another 30 minutes, followed by the addition of diethyl oxalate (12.28 ml, 90.81 mmol, 2 eq) dropwise at 0 ° C. and the reaction mixture was stirred at room temperature for another 18 hours. Product formation was confirmed by TLC and LCMS. The reaction mixture was quenched with ice water and washed with diethyl ether (2×100 mL). The aqueous layer was separated and neutralized with 1N HCl and extracted with EtOAc (3×100 mL). The combined organic extracts were washed with water (2 x 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a crude material which was purified by combi-flash chromatography (0-20% ethyl acetate in hexanes) to afford ethyl 4-(2-furyl)-2,4-dioxobutanoate (3.6 g, 45% as a yellow solid). LCMS: 210 [M+H] + .
[0695] Step 4: Synthesis of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester. A suspension of 4-furan-2-yl-2,4-dioxo-butyric acid ethyl ester (1.6 g, 7.61 mmol, 1 eq) and hydroxylamine hydrochloride (0.528 g, 7.61 mmol, 1 eq) in EtOH was stirred at 85 ° C for 2 hours. The product formation was confirmed by TLC and LCMS. The resulting mixture was concentrated under reduced pressure, and the residue was dissolved in DCM and distilled water. The organic phase was separated, dried over anhydrous Na2SO4, filtered through a silica gel pad, and then concentrated under reduced pressure to give 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester. The crude product obtained was used in the next step without further purification (700 mg, 52% as a yellow solid). LCMS: 207 [M+H] + .
[0696] Step 5: Synthesis of 5-furan-2-yl-isoxazole-3-carboxylic acid. To a solution of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester (0.5 g, 2.41 mmol) in THF (30 mL) and methanol (6 mL) was slowly added aqueous lithium hydroxide solution (10 mL). The resulting mixture was stirred for 16 hours. THF was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with distilled water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 5-furan-2-yl-isoxazole-3-carboxylic acid (225 mg, 52% as a white solid). LCMS: 179 [M+H] + .
[0697] Step 6: Synthesis of N-(1-(2,4-bis(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. To a stirred solution of 5-(furan-2-yl)isoxazole-3-carboxylic acid (60 mg, 0.338 mmol, 1 eq) in DMF (10 ml) was added HATU (141 mg, 0.0.372 mmol, 1.1 eq) and stirred for half an hour, followed by the addition of 1 -(2,4-bis(trifluoromethyl)-1H-pyrazol-4-amine (100 mg, 0.338 mmol, 1 eq) and DIEA (0.18 mL, 1.081 mmol, 3.2 eq) were added thereto. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by LCMS. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with water (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to give the product (12 mg). 1 H NMR(400MHz, DMSO-d6)δppm 6.79(br.s.,2H)7.21(s,2H)7.31(br.s.,1H)8.06(s,1H)8.02(s,1H)8.27(br.s.,1H)8.49(br.s.,1H)11.30(br.s.,1H). LCMS:457[M+H] + .
[0698] Example S26. Synthesis of N-(1-(3,5-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide (Compound 28)
[0699]
[0700] Step 1: Synthesis of 1-(3,5-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole. To a stirred solution of 4-nitro-1H-pyrazole (0.55 g, 4.88 mmol, 1 eq) in DMF (20 mL) was added. The reaction mixture was cooled to 0°C with ice water, K2CO3 (1.01 g, 7.32 mmol, 1.5 eq) was added portionwise, the reaction mixture was stirred for 10 minutes, and then 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene (1.5 g, 4.88 mmol, 1 eq) was added dropwise. The above reaction mixture was stirred for 1 hour (the reaction was monitored by TLC and LCMS). After the reaction was completed, the reaction mixture was diluted with ethyl acetate (50 mL) and extracted with water (50 mL). The organic layer was collected and concentrated to obtain the product, which was further purified by flash chromatography to obtain a white product. LCMS: 339 [M+H] + .
[0701] Step 2: Synthesis of 1-(3,5-bis(trifluoromethyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(3,5-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (500 mg, 1 eq.) in methanol (20 mL) was added palladium / carbon [Pd / C] (10 wt %) under nitrogen and the reaction mixture was purged with hydrogen for 2 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was filtered through a celite bed and the filtrate was concentrated to obtain the product, which was purified by flash chromatography to give a brown viscous liquid. LCMS: 309 [M+H] + .
[0702] Step 3: Synthesis of ethyl 4-(2-furyl)-2,4-dioxobutanoate. To a solution of 2-acetylfuran (5.0 g, 45.40 mmol, 1 eq) in THF was added portionwise 60% sodium hydride (3.63 g, 90.81 mmol, 2 eq) at 0 ° C. The resulting reaction mixture was stirred at room temperature for another 30 minutes, followed by the addition of diethyl oxalate (12.28 ml, 90.81 mmol, 2 eq) dropwise at 0 ° C. and the reaction mixture was stirred at room temperature for another 18 hours. Product formation was confirmed by TLC and LCMS. The reaction mixture was quenched with ice water and washed with diethyl ether (2×100 mL). The aqueous layer was separated and neutralized with 1N HCl and extracted with EtOAc (3×100 mL). The combined organic extracts were washed with water (2 x 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a crude material which was purified by combi-flash chromatography (0-20% ethyl acetate in hexanes) to afford ethyl 4-(2-furyl)-2,4-dioxobutanoate (3.6 g, 45% as a yellow solid). LCMS: 210 [M+H] + .
[0703] Step 4: Synthesis of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester. A suspension of 4-furan-2-yl-2,4-dioxo-butyric acid ethyl ester (1.6 g, 7.61 mmol, 1 eq) and hydroxylamine hydrochloride (0.528 g, 7.61 mmol, 1 eq) in EtOH was stirred at 85 ° C for 2 hours. The product formation was confirmed by TLC and LCMS. The resulting mixture was concentrated under reduced pressure, and the residue was dissolved in DCM and distilled water. The organic phase was separated, dried over anhydrous Na2SO4, filtered through a silica gel pad, and then concentrated under reduced pressure to give 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester. The crude product obtained was used in the next step without further purification (700 mg, 52% as a yellow solid). LCMS: 207 [M+H] + .
[0704] Step 5: Synthesis of 5-furan-2-yl-isoxazole-3-carboxylic acid. To a solution of 5-furan-2-yl-isoxazole-3-carboxylic acid ethyl ester (0.5 g, 2.41 mmol) in THF (30 mL) and methanol (6 mL) was slowly added aqueous lithium hydroxide solution (10 mL). The resulting mixture was stirred for 16 hours. THF was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with distilled water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 5-furan-2-yl-isoxazole-3-carboxylic acid (225 mg, 52% as a white solid). LCMS: 179 [M+H] + .
[0705] Step 6: Synthesis of N-(1-(3,5-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. To a stirred solution of 5-(furan-2-yl)isoxazole-3-carboxylic acid (100 mg, 0.558 mmol, 1 eq) in DMF (10 ml) was added HATU (233 mg, 0.613 mmol, 1.1 eq) and stirred for half an hour, followed by the addition of 1-(3,5-bis(trifluoromethyl)-1H-pyrazol-4-amine (172 mg, 0.558 mmol, 1 eq) and DIEA. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by LCMS. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with water (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to give the crude product, which was purified by trituration with isopropanol (12 mg of white solid). 1 H NMR(400MHz,DMSO-d6)δppm 5.56(s,2H)7.16(s,1H)7.29(d,J=3.51Hz,1H)7.72(s,2H)7.95(s,2H)8.01(s,1H)8.08(br.s.,1H)8.33(s,1H)11.06(s,1H). LCMS:471[M+H] + .
[0706] Example S27. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide and N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (Compounds 29 and 30)
[0707]
[0708] Step 1: Synthesis of ethyl 2,4-dioxo-4-(pyridin-2-yl)butanoate. To a solution of 1-(pyridin-2-yl)ethan-1-one (5.0 g, 0.04 mol, 1 eq) in THF was added portionwise 60% sodium hydride (3.3 g, 0.08 mol, 2.0 eq) at 0°C. The resulting reaction mixture was stirred at room temperature for an additional 30 minutes, followed by the addition of diethyl oxalate (11.2 ml, 0.08 mol, 2.0 eq) dropwise at 0°C and the reaction mixture was stirred at room temperature for an additional 18 hours. Product formation was confirmed by TLC and LCMS. The aqueous layer was separated and neutralized with 1N HCl and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with water (2 x 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a crude material which was purified by combi-flash chromatography (0-20% ethyl acetate in hexanes) to afford ethyl 2,4-dioxo-4-(pyridin-2-yl)butanoate (3 g, yellow solid). LCMS: 221 [M+H] + .
[0709] Step 2: Synthesis of ethyl 5-(pyridin-2-yl)isoxazole-3-carboxylate. A suspension of ethyl 2,4-dioxo-4-(pyridin-2-yl)butanoate (1.6 g, 7.61 mmol, 1.0 equiv) and hydroxylamine hydrochloride (0.528 g, 7.61 mmol, 1.0 equiv) in EtOH was stirred at 85 ° C for 48 hours. Product formation was confirmed by TLC and LCMS. The resulting mixture was concentrated under reduced pressure, and the residue was dissolved in DCM and distilled water. The organic phase was separated, dried over anhydrous Na2SO4, filtered through a silica gel pad, and then concentrated under reduced pressure to give ethyl 5-(pyridin-2-yl)isoxazole-3-carboxylate. The crude material was obtained and purified by combi-flash chromatography (0-20% ethyl acetate in hexane). LCMS: 218 [M+H] + .
[0710] Step 3: Synthesis of 5-(pyridin-2-yl)isoxazole-3-carboxylic acid. To a solution of ethyl 5-(pyridin-2-yl)isoxazole-3-carboxylate (0.5 g, 2.41 mmol) in THF (30 mL) and methanol (6 mL) was slowly added aqueous lithium hydroxide (10 mL). The resulting mixture was stirred for 16 hours. THF was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with distilled water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 5-(pyridin-2-yl)isoxazole-3-carboxylic acid (225 mg, 52% as a white solid). LCMS: 190 [M+H] + .
[0711] Step 4: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-4-nitro-1H-pyrazole (peak 1) and 1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-4-nitro-1H-pyrazole (peak 2). To a stirred solution of 3-methyl-4-nitro-1H-pyrazole (1.24 g, 0.009 mol, 1 eq) in DMF (20 mL) was added portionwise K2CO3 (1.86 g, 0.013 mol, 1 eq) at 0°C and stirred for 10 minutes. 1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene (3 gm, 0.009 mol, 1 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water (100 mL x 4), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a mixture of 1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-4-nitro-1H-pyrazole (peak 1) and 1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-4-nitro-1H-pyrazole (peak 2). The crude material obtained was ready for separation. LCMS: 353 [M+H] + .
[0712] Step 5: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-amine (peak 1). To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-4-nitro-1H-pyrazole (peak 1) (150 mg, 1 equivalent) in methanol (10 mL) was added palladium / carbon [Pd / C] (10% w / w) under nitrogen. The reaction mixture was purged with H2 gas for 6 hours. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-amine (peak 1). LCMS: 323 [M+H] + .
[0713] Step 6: Synthesis of 1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-amine (peak 2). To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-4-nitro-1H-pyrazole (peak 2) (500 mg, 1 equivalent) in methanol (10 mL) was added palladium / carbon [Pd / C] (10% w / w) under nitrogen. The reaction mixture was purged with H2 gas for 6 hours. Product formation was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to obtain 1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-amine (peak 2). LCMS: 323 [M+H] + .
[0714] Step 7: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (Compound 29). To a solution of 5-(pyridin-2-yl)isoxazole-3-carboxylic acid (50 mg, 0.263 mmol, 1 eq) in DMF (1 mL) was added HATU (100 mg, 0.263 mmol, 1 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with DIPEA (0.13 ml, 0.775 mmol, 2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-(2,4-bis(trifluoromethyl)benzyl)-3-methyl-1H-pyrazol-4-amine (Peak 1) (85 mg, 0.263 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The reaction mixture was diluted with water (50 mL). The resulting precipitate was filtered off. The crude material obtained was purified by trituration with hexane. 1 H NMR (400MHz, DMSO-d6) δ10.40 (s, 1H), 8.77 (d, J = 4.82Hz, 1H), 8.02-8.11 (m, 4H), 7.76 (s ,1H),7.54-7.58(m,1H),7.50(s,1H),6.85(d,J=7.89Hz,2H),5.59(s,2H),2.19(s,3H). LCMS:495[M+H] + .
[0715] Step 8: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (Compound 30). To a solution of 5-(pyridin-2-yl)isoxazole-3-carboxylic acid (100 mg, 0.52 mmol, 1 eq) in DMF (1 mL) was added HATU (200 mg, 0.52 mmol, 1 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with DIPEA (135.7 mg, 1.05 mmol, 2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-(2,4-bis(trifluoromethyl)benzyl)-5-methyl-1H-pyrazol-4-amine (Peak 2) (170 mg, 0.52 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The reaction mixture was added with water (50 mL) for 1 h. The resulting precipitate was filtered off. The crude material obtained was purified by trituration with IPA. 1 H NMR(400MHz,DMSO-d6)δ10.39(s,1H),8.76(br.s.,1H),8.23(s,1H),8.00-8.12(m,4 H),7.55-7.58(m,1H),7.51(s,1H),7.12(d,J=8.33Hz,1H),5.58(s,2H),2.21(s,3H). LCMS:495[M+H] + .
[0716] Example S28. Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide (Compound 31)
[0717]
[0718] Step 1: Synthesis of ethyl 5-(tributylstannyl)isoxazole-3-carboxylate. To a solution of ethyl (Z)-2-chloro-2-(hydroxyimino)acetate (2.0 gm, 0.013 mol, 1 eq) in DCM (20 ml) was added KCO (2.01 gm, 0.014 mol, 2 eq) at room temperature. The resulting reaction mixture was stirred at room temperature for an additional 30 minutes, followed by the addition of tributyl(ethynyl)stannane (4.01 gm, 0.013 mol, 1 eq) dropwise at room temperature and the reaction mixture was stirred at room temperature for an additional 18 hours. The formation of the product was confirmed by TLC and LCMS. The reaction mixture was quenched with ice water and extracted with DCM (2×100 mL). The combined organic extracts were washed with water (2 x 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give the crude material, which was further purified by combi-flash chromatography (5-10% ethyl acetate in hexanes) to give ethyl 5-(tributylstannyl)isoxazole-3-carboxylate (2.1 gm, 35% as a brown liquid). LCMS: 432 [M+H] + .
[0719] Step 2: Synthesis of ethyl 5-(3-chloropyridin-2-yl)isoxazole-3-carboxylate. A suspension of ethyl 5-(tributylstannyl)isoxazole-3-carboxylate (600 mg, 1.39 mmol, 1.0 equiv) and 2-bromo-3-chloropyridine (267 mg, 1.39 mmol, 1.0 equiv) in toluene (2 ml) was degassed using nitrogen for 5 minutes. Tetrakis (161 mg, 0.13 mmol, 1.0 equiv) was added to the reaction mixture. The resulting reaction mixture was heated at 100 ° C for 16 hours. Product formation was confirmed by TLC and LCMS. The resulting mixture was diluted with water and extracted with ethyl acetate (2×100 mL). The organic phase was separated, dried over anhydrous Na2SO4, and concentrated under reduced pressure to give the crude material, which was further purified by combi-flash chromatography (10-15% ethyl acetate in hexanes) to give ethyl 5-(3-chloropyridin-2-yl)isoxazole-3-carboxylate (200 mg, 56%, as an off-white solid). LCMS: 253 [M+H] + .
[0720] Step 3: Synthesis of 5-(3-chloropyridin-2-yl)isoxazole-3-carboxylic acid. To a solution of ethyl 5-(3-chloropyridin-2-yl)isoxazole-3-carboxylate (200 mg, 0.79 mmol, 1.0 equiv) in THF (5 mL), methanol (3 mL) and water (2 mL) was added lithium hydroxide (66 mg, 1.58 mmol, 2.0 equiv). The resulting mixture was stirred for 16 hours. The THF was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with distilled water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 5-(3-chloropyridin-2-yl)isoxazole-3-carboxylic acid (200 mg, 88% as a white solid). LCMS: 225 [M+H] + .
[0721] Step 4: Synthesis of N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide. To a solution of 5-(3-chloropyridin-2-yl)isoxazole-3-carboxylic acid (50 mg, 0.22 mmol, 1 eq) in DMF (1 mL) was added HATU (93 mg, 0.24 mmol, 1.1 eq). The mixture was treated dropwise with DIPEA (92 mg, 0.71 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-amine hydrochloride (68 mg, 0.22 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The product formation was confirmed by TLC and LCMS, and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(2,4-bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide. (8 mg, 7%, as an off-white solid). 1 H NMR (400MHz, DMSO-d6) δ11.20(s,1H),8.76(d,J=4.5Hz,1H),8.33(s,1H),8.21(d,J=8.3Hz,1H),8.07(d, J=7.2Hz,2H),7.79(s,1H),7.64(dd,J=8.2,4.6Hz,1H),7.57(s,1H),7.07(d,J=8.1Hz,1H),5.67(s,2H). LCMS:516[M+H] + .
[0722] Example S29. Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide (Compound 32)
[0723]
[0724] To 5- (pyridin-2-yl) isoxazole -3- carboxylic acid (50mg, 0.22mmol, 1 equivalent) and HATU (72mg, 0.22mmol, 1 equivalent) in DMF (1mL) solution. The mixture was stirred for 30 minutes, followed by the addition of DIPEA (92mg, 0.71mmol, 3.2 equivalents) and a solution of 1- { 1 [2,4-bis (trifluoromethyl) phenyl] ethyl} -1H- pyrazole -4- amine hydrochloride (72mg, 0.22mmol, 1 equivalent) in DMF (1mL). The reaction mixture remained at room temperature and stirred for 24 hours. It was confirmed with TLC and LCMS that the product was formed and the reaction mixture was diluted with EtOAc (50mL) and washed with water (50mL × 2). The organic layer was dried over NaSO and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide (20 mg, 17% as an off-white solid). 1 H NMR (400MHz, DMSO-d6) δ11.14(s,1H),8.76(d,J=4.6Hz,1H),8.21(d,J=8.7Hz,2H),8.13-8.03(m,2H),7.7 4(d,J=7.5Hz,2H),7.64(dd,J=8.3,4.6Hz,1H),7.54(s,1H),5.94(q,J=6.5Hz,1H),1.88(d,J=6.9Hz,3H). LCMS:522[M+H] + .
[0725] Example S30. Synthesis of N-(1-((2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide (Compound 33)
[0726]
[0727] Step 1: Synthesis of (2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methanol. To a stirred solution of 2,4-bis(trifluoromethyl)benzaldehyde (300 mg, 1.23 mmol, 1.0 eq) in THF (5 mL) was added cyclopropylmagnesium bromide (0.269 gm, 1.85 mol, 1.5 eq) portionwise at room temperature and stirred for 10 minutes. The reaction mixture was stirred at room temperature for 1 hour. The formation of the product was confirmed by TLC and NMR. After completion of the reaction, the reaction mixture was quenched with water and extracted with ethyl acetate (50 mL×3). The combined organic extracts were washed with water (50 mL×2), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain (2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methanol (350 gm, 100% crude material as a colorless liquid). 1 H NMR(400MHz,DMSO-d6)δ8.15-8.02(m,2H),7.94(s,1H),5.67(d,J=4.8Hz,1H ),4.61(br.s.,1H),1.14-1.06(m,1H),0.58-0.49(m,1H),0.46-0.28(m,3H).
[0728] Step 2: Synthesis of 1-((2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methyl)-4-nitro-1H-pyrazole. To a stirred solution of PPh3 (329 mg, 1.23 mmol, 1.0 equiv) and DIAD (248 mg, 1.23 mmol, 1.0 equiv) in THF (2 mL) was added (2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methanol (350 mg, 1.23 mmol, 1.0 equiv). 4-nitro-1H-pyrazole (111 mg, 0.98 mmol, 0.8 equiv) was then added dropwise and the reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by TLC and LCMS. After completion of the reaction, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL×3). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain the crude material, which was further purified by flash column chromatography to obtain the pure product 1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-4-nitro-1H-pyrazole (130 mg, 30%, as a brown liquid). 1 H NMR (400MHz, DMSO-d6) δ9.21 (s, 1H), 8.29-8.20 (m, 2H), 8.17 (d, J = 8.3Hz, 1H), 8.05 (s, 1H), 5 .03(d,J=10.1Hz,1H),1.22(br.s.,1H),0.76(br.s.,2H),0.69(br.s.,1H),0.37(br.s.,1H).
[0729] Step 3: Synthesis of 1-((2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methyl)-1H-pyrazol-4-amine. To a stirred solution of 1-(2,4-bis(trifluoromethyl)benzyl)-4-nitro-1H-pyrazole (220 mg, 0.58 mmol, 1.0 equiv) in methanol (10 mL) was added palladium on carbon [Pd / C] (49 mg, 10% w / w) under nitrogen. The reaction mixture was purged with H gas for 2 h. The formation of the product was confirmed by LCMS. After completion of the reaction, the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure to afford 1-((2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methyl)-1H-pyrazol-4-amine (120 mg, 58% crude material as a brown liquid). LCMS: 350 [M+H]. + .
[0730]
[0266] Step 4: Synthesis of N-(1-((2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methyl)-1H-pyrazol-4-yl)-5-(pyridin-2-yl)isoxazole-3-carboxamide. To a solution of 5-(pyridin-2-yl)isoxazole-3-carboxylic acid (60 mg, 0.31 mmol, 1 eq) in DMF (1 mL) was added HATU (132 mg, 0.34 mmol, 1.1 eq). The mixture was treated dropwise with DIPEA (130 mg, 1.01 mmol, 3.2 eq). After stirring at room temperature for 15 minutes, the mixture was treated dropwise with a solution of 1-((2,4-bis(trifluoromethyl)phenyl)(cyclopropyl)methyl)-1H-pyrazol-4-amine (110 mg, 0.31 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred for 24 hours. The product was confirmed to be formed by TLC and LCMS, and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide. (65 mg, 40%, as an off-white solid). 1H NMR (400MHz, DMSO-d6) δ11.06 (s, 1H), 8.76 (d, J = 4.7Hz, 1H), 8.36 (s, 1H), 8.20 ( d,J=8.5Hz,1H),8.14(d,J=8.5Hz,1H),8.12-7.98(m,3H),7.70(s,1H),7.56(t, J=6.1Hz,1H),7.47(s,1H),4.96(d,J=9.6Hz,1H),1.94(qd,J=9.0,8.6,4.3Hz,1 H), 0.70 (dddd, J=28.2, 18.9, 9.1, 4.8Hz, 3H), 0.35 (dq, J=10.4, 5.4, 4.9Hz, 1H). LCMS: 530 [M+H] + .
[0731] Example S31. Synthesis of (R)- and (S)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide (Compounds 34 and 35)
[0732]
[0733]
[0266] Step 1: Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide. To a solution of 5-(pyridin-2-yl)isoxazole-3-carboxylic acid (95 mg, 0.42 mmol, 1 eq) and HATU (177 mg, 0.46 mmol, 1 eq) in DMF (1 mL) was added. The mixture was stirred for 30 minutes, followed by the addition of DIPEA (175 mg, 1.35 mmol, 3.2 eq) and a solution of 1-{1[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine hydrochloride (131 mg, 0.42 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred at room temperature for 24 hours. Confirm product formation with TLC and LCMS and reactant mixture is diluted with EtOAc (50mL) and washed with water (50mL×2).Organic layer is through NaSODry and concentrate under reduced pressure, obtain crude material, it is further purified by flash column chromatography, obtain pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazole-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide (95mg, 42%, as off-white solid). 1H NMR (400MHz, DMSO-d6) δ11.14(s,1H),8.76(d,J=4.6Hz,1H),8.21(d,J=8.7Hz,2H),8.13-8.03(m,2H),7.7 4(d,J=7.5Hz,2H),7.64(dd,J=8.3,4.6Hz,1H),7.54(s,1H),5.94(q,J=6.5Hz,1H),1.88(d,J=6.9Hz,3H). LCMS:522[M+H] + .
[0734] Step 2: A racemic mixture of (R) and (S)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide. N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(3-chloropyridin-2-yl)isoxazole-3-carboxamide (90 mg) was purified by chiral HPLC to obtain single enantiomers as Enantiomer A (12 mg) and Enantiomer B (11 mg). (Enantiomer A): 1 HNMR (400 MHz, DMSO-d6) δ 11.14 (s, 1H), 8.76 (d, J = 4.6 Hz, 1H), 8.21 (d, J = 8.7 Hz, 2H), 8.13-8.03 (m, 2H), 7.74 (d, J = 7.5 Hz, 2H), 7.64 (dd, J = 8.3, 4.6 Hz, 1H), 7.54 (s, 1H), 5.94 (q, J = 6.5 Hz, 1H), 1.88 (d, J = 6.9 Hz, 3H). (Enantiomer B): 1 H NMR (400MHz, DMSO-d6) δ11.14(s,1H),8.76(d,J=4.6Hz,1H),8.21(d,J=8.7Hz,2H),8.13-8.03(m,2H),7.7 4(d,J=7.5Hz,2H),7.64(dd,J=8.3,4.6Hz,1H),7.54(s,1H),5.94(q,J=6.5Hz,1H),1.88(d,J=6.9Hz,3H).
[0735] Example S32. Synthesis of (R)- and (S)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-3-yl)isoxazole-3-carboxamide (Compounds 36 and 37)
[0736]
[0737]
[0266] Step 1: Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-3-yl)isoxazole-3-carboxamide. To a solution of 5-(pyridin-3-yl)isoxazole-3-carboxylic acid (50 mg, 0.263 mmol, 1 eq) and HATU (100.2 mg, 0.263 mmol, 1 eq) in DMF (1 mL) was added. The mixture was stirred for 30 minutes, followed by the addition of DIPEA (101.8 mg, 0.789 mmol, 3 eq) and a solution of 1-{1[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine hydrochloride (94.73 mg, 0.263 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred at room temperature for 24 hours. The product formation was confirmed by TLC and LCMS, and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL × 2). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-3-yl)isoxazole-3-carboxamide. LCMS: 495 [M+H] + .
[0738] Step 2: A racemic mixture of (R) and (S)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-3-yl)isoxazole-3-carboxamide. N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-5-(pyridin-3-yl)isoxazole-3-carboxamide (60 mg) was purified by chiral HPLC to obtain single enantiomers as Enantiomer A (12 mg) and Enantiomer B (15 mg). (Enantiomer A): 1 H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 9.20 (s, 1H), 8.74 (d, J = 3.51 Hz, 1H), 8.38 (d, J = 7.89 Hz, 1H), 8.20 (s, 1H), 8.02-8.14 (m, 2H), 7.70-7.80 (m, 2H), 7.57-7.65 (m, 2H), 5.94 (d, J = 6.58 Hz, 1H), 1.88 (d, J = 6.58 Hz, 3H). (Enantiomer B): 1H NMR (400MHz, DMSO-d6) δ11.09(s,1H),9.20(s,1H),8.74(d,J=3.51Hz,1H),8.38(d,J=8.33Hz,1H),8.20(s,1 H),8.04-8.11(m,2H),7.70-7.77(m,2H),7.59-7.63(m,2H),5.94(d,J=6.58Hz,1H),1.88(d,J=6.58Hz,3H).
[0739] Example S34. Synthesis of (R) and (S) N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)isoxazole-5-carboxamide (Compounds 76 and 77)
[0740]
[0741]
[0266] Step 1: Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)isoxazole-5-carboxamide. To a solution of 3-(pyridin-2-yl)isoxazole-5-carboxylic acid (100 mg, 0.44 mmol, 1 eq) and HATU (168 mg, 0.44 mmol, 1 eq) in DMF (1 mL) was added. The mixture was stirred for 30 minutes, followed by the addition of DIPEA (185 mg, 1.41 mmol, 3.2 eq) and a solution of 1-{1[2,4-bis(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-amine hydrochloride (142 mg, 0.44 mmol, 1 eq) in DMF (1 mL). The reaction mixture was stirred at room temperature for 24 hours. The product was confirmed to be formed by TLC and LCMS and the reaction mixture was diluted with EtOAc (50 mL) and washed with water (2 × 50 mL). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain a crude material, which was further purified by flash column chromatography to obtain the pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)isoxazole-5-carboxamide (150 mg, in a pale solid state). LCMS: 496 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ11.18(s,1H),8.76(d,J=4.8Hz,1H),8.21(s,1H),8.10(dd,J=8.5,4.2Hz,2H),8.05(s,1H),8.01(td, J=7.7,1.8Hz,1H),7.79-7.69(m,2H),7.68(s,1H),7.58(dd,J=7.5,4.8Hz,1H),5.95(q,J=7.0Hz,1H),1.88(d,J=6.9Hz,3H).
[0742] Step 2: Synthesis of (R) and (S)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)isoxazole-5-carboxamide. Tautomers of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)isoxazole-5-carboxamide (90 mg, elution time: 3.69 min and 4.78 min) were prepared by chiral SFC (Daicel OD-H, 250×20 mm, 5 μm). An isocratic procedure was performed using analytical grade liquid carbon dioxide and HPLC grade isopropanol at a total flow rate of 51 g / min and a co-solvent percentage of 20% to obtain compound 40 (R)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)isoxazole-5-carboxamide (22 mg) and compound 41 (S)-N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-3-(pyridin-2-yl)isoxazole-5-carboxamide (23 mg). (Compound 76) LCMS: 496 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 11.18 (s, 1H), 8.76 (d, J = 4.8 Hz, 1H), 8.21 (s, 1H), 8.10 (dd, J = 8.5, 4.2 Hz, 2H), 8.05 (s, 1H), 8.01 (td, J = 7.7, 1.8 Hz, 1H), 7.79-7.69 (m, 2H), 7.68 (s, 1H), 7.58 (dd, J = 7.5, 4.8 Hz, 1H), 5.95 (q, J = 7.0 Hz, 1H), 1.88 (d, J = 6.9 Hz, 3H). (Compound 77) LCMS: 496 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ11.18(s,1H),8.76(d,J=4.8Hz,1H),8.21(s,1H),8.10(dd,J=8.5,4.2Hz,2H),8.05(s,1H),8.01(td, J=7.7,1.8Hz,1H),7.79-7.69(m,2H),7.68(s,1H),7.58(dd,J=7.5,4.8Hz,1H),5.95(q,J=7.0Hz,1H),1.88(d,J=6.9Hz,3H).
[0743] Example S35. Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)thiazole-5-carboxamide (Compound 78)
[0744]
[0745] Step 1: Synthesis of 2-(trimethylstannyl)pyridine. To a solution of 2-bromopyridine (100 mg, 0.63 mmol, 1 eq) in anhydrous toluene (30 mL) was added 1,1,1,2,2,2-hexamethyldistanane (227.0 mg, 0.69 mmol, 1.1 eq) and the mixture was degassed for 10 minutes. To this mixture was added Pd(PPh3)4 (73 mg, 0.063 mmol, 0.1 eq) and the mixture was degassed again for 5 minutes. The reaction mixture was stirred at 150 ° C under microwave for 20 minutes, after which TLC indicated complete consumption of the starting material. The mixture was concentrated in vacuo to give the crude product 2-(trimethylstannyl)pyridine (150 mg, crude), which was carried to the next step without further purification. LCMS: 244 [M+H] + .
[0746] Step 2: Synthesis of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)thiazole-5-carboxamide. To a solution of N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-bromothiazole-5-carboxamide (50 mg, 0.20 mmol, 1 eq) in anhydrous toluene (30 mL) was added 2-(trimethylstannyl)pyridine (105 mg, 0.206 mmol, 1 eq), and the mixture was degassed for 10 minutes. To this mixture was added Pd(PPh3)4 (23 mg, 0.20 mmol, 1 eq), and the mixture was degassed again for 5 minutes. The reaction mixture was stirred at 80°C for 8 hours, after which TLC indicated complete consumption of the starting material. The mixture was quenched with H2O, extracted with EtOAc, dried over anhydrous Na2SO4, and concentrated under reduced pressure to give the product, which was further purified by flash column chromatography and reverse phase HPLC to obtain pure product N-(1-(1-(2,4-bis(trifluoromethyl)phenyl)ethyl)-1H-pyrazol-4-yl)-2-(pyridin-2-yl)thiazole-5-carboxamide (5 mg, as an off-white solid). LCMS: 512 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.64(d,J=4.8Hz,1H),8.33(s,1H),8.20(d,J=8.0Hz,1H),8.15(s,1H),7.92(s,1H),7.89-7.81(m,1H),7 .79(s,1H),7.75(d,J=8.3Hz,1H),7.65-7...
Claims
1. A compound of formula (A), or a pharmaceutically acceptable salt thereof, wherein: One of G1 and G2 is N and one of G1 and G2 is CR d , Where R d is H or C1-C6 alkyl; R 1 is H, C1-C6 alkyl or C3-C8 cycloalkyl; or R 1 is H, C1-C6 alkyl, C3-C8 cycloalkyl or C1-C6 haloalkyl; R 8 is H or C1-C6 alkyl, n is 0 or 1; L is -CH2- or absent; R 2 , R 3 , R 4 , R 5 and R 6 Each is independently H, halo, CN, C1-C6 alkyl or C1-C6 haloalkyl; or R 2 , R 4 , R 5 and R 6 are each independently H, halo, CN, C1-C6 alkyl or C1-C6 haloalkyl and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring, wherein the 5- or 6-membered ring is unsubstituted or substituted with one to three groups selected from the group consisting of halo, CN, -OH, C1-C6 alkyl and C1-C6 haloalkyl; The conditions are: R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring; or R 2 , R 3 , R 4 , R 5 and R 6 At least two of are not H; or R 2 , R 3 , R 4 , R 5 and R 6 One of them is cyano; A is Among them --- instructions Connected in E or Z configuration; R a and R b Each is independently H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl, wherein R a and R b each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl of is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl, or is unsubstituted or substituted with one to four groups selected from OH, halo, C1-C6 alkyl and C1-C6 alkoxy; R c is C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl, wherein R c Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl of is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl; R e is H or C1-C6 alkyl; The condition is that when A is And R a When it is H, methyl, ethyl, n-Pr, i-Pr, i-Bu, 2-thiofuranyl, 2-furanyl, unsubstituted phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3,4-dimethoxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-fluorophenyl or 2,4-dichlorophenyl, at least one of (i.) to (ix.) applies: (i.) G2 is N; (ii.) n is 1, L does not exist, and R 1 is a C1-C6 alkyl group; (iii.) n is 0, L does not exist, and R 2 , R 3 , R 4 , R 5 and R 6 At least one of them is halo, CN or C1-C6 haloalkyl; (iv.) n is 1, and R 3 Together with R 1 Together with the atoms to which they are attached, they form a 5- or 6-membered ring; (v.) R 2 , R 3 , R 4 , R 5 and R 6 one of is CN; and (vi.) R 4 and R 5 Each is independently Cl, Br, I, CN, C1-C6 alkyl or C1-C6 haloalkyl; (vii.) R d and R 7 One of them is C1-C6 alkyl; (viii.) R 2 and R 3 Each is Cl; (ix.) R 2 , R 3 , R 4 , R 5 and R 6 At least one of is F, Br, I, CN or C1-C6 haloalkyl and R a is H or 2-thiofuranyl; The condition is that when A is When n is 1, R 1 Not for H; The condition is that when A is When n is 0 and L does not exist, R a Not for H; The condition is that when A is And R e When it is methyl, R a is not an unsubstituted phenyl group; The condition is that when A is When n is 1 and L does not exist, R 1 Not for H; and R 7 is H, C1-C6 alkyl or C1-C6 haloalkyl, The condition is that when R d is C1-C6 alkyl, R 7 When H, and when R 7 When it is C1-C6 alkyl, R d For H.
2. The compound according to claim 1, wherein: R 1 is H, C1-C6 alkyl or C3-C8 cycloalkyl; R 8 is H; A is Among them --- instructions Connected in E or Z configuration; R a and R b Each is independently H, C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl, wherein R a and R b Each C1-C6 alkyl, -C(O)C1-C6 alkyl, 6-membered aryl or 5- or 6-membered heteroaryl of is unsubstituted or substituted with one to four groups selected from the group consisting of OH, halo and C1-C6 alkyl; And represented by formula (I):
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein G1 is N and G2 is CR d .
4. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein G1 is CR d And G2 is N.
5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R d For H.
6. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R d It is a C1-C6 alkyl group.
7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein n is 1.
8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 1 For H.
9. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 1 It is a C1-C6 alkyl group.
10. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 1 It is methyl or ethyl.
